Biodegradation of the steroid progesterone in surface waters by Ojoghoro, Jasper Oreva
  
 
Biodegradation of the Steroid Progesterone in 
Surface Waters 
 
A Thesis Submitted for the Degree of  






Jasper Oreva Ojoghoro 
 
 
Institute of the Environment, Health and Societies 
 




Many studies measuring the occurrence of pharmaceuticals, understanding their 
environmental fate and the risk they pose to surface water resources have been published. 
However, very little is known about the relevant transformation products which result from the 
wide range of biotic and abiotic degradation processes that these compounds undergo in 
sewers, storage tanks, during engineered treatment and in the environment.  Thus, the present 
study primarily investigated the degradation of the steroid progesterone (P4) in natural 
systems (rivers), with a focus on the identification and characterisation of transformation 
products.  
Initial work focussed on assessing the removal of selected compounds (Diclofenac, 
Fluoxetine, Propranolol and P4) from reed beds, with identification of transformation products 
in a field site being attempted. However, it was determined that concentrations of parent 
compounds and products would be too low to work with in the field, and a laboratory study 
was designed which focussed on P4. Focus on P4 was based on literature evidence of its 
rapid biodegradability relative to the other model compounds and its usage patterns globally. 
River water sampling for the laboratory-based degradation study was carried out at 1 km 
downstream of four south east England sewage works (Blackbirds, Chesham, High Wycombe 
and Maple Lodge) effluent discharge points. Suspected P4 transformation products were 
initially identified from predictions by the EAWAG Biocatalysis Biodegradation Database 
(EAWAG BBD) and from a literature review. At a later stage of the present work, a replacement 
model for EAWAG BBD (enviPath) which became available, was used to predict P4 
degradation and results were compared. Samples were analysed using low resolution and 
accurate-mass time-of-flight mass spectrometers. Three degradation studies were conducted. 
Sampling for all studies was carried out at the same time in the year to minimize temporal 
variability in conditions and allow for effective comparison of results. Androgenic and 




Overall, the present study indicates that P4 degradation is relatively rapid in surface waters. 
Degradation followed the first order degradation kinetic and spiked P4 concentration (1,000 
µg/L) was degraded below instrument detection limit (0.32 µg/L) in 72 h (3 days) in all locations 
except High Wycombe where 90% degradation occurred. Degradation half-life (t½) was 
approximately 7 hours in all sites except High Wycombe (29 hours) where some residual P4 
(100 μg/L) was present after 72 hours. Overall, degradation rate was faster (0.1 hours) in the 
present study than those reported for algae (0.02-0.04 hours), thus, indicating that a more 
diverse microbial community was responsible for the breakdown of P4 observed in the present 
study. A number of putative degradation products were identified, including boldenone and 
(with less certainty) testosterone. The results highlighted that the transformation of 
progesterone can potentially create other classes of steroids, some of which may still be 
potent, and possess other types of biological activity. Although progesterone degraded to an 
androgen (boldenone) as shown by chemical analysis, the concentrations in the environment 
are unlikely to represent any immediate threat to aquatic resources, as results of the androgen 
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Globally, there is an increasing demand for clean water supply. Water is a significant natural 
resource and an essential component of biological tissues, providing a medium for vital 
metabolic reactions. Surface and ground waters represent not only important potable supply 
sources worldwide, but also ecologically, surface waters that are fit for purpose, are major 
drivers for the efficient functioning of aquatic ecosystems. Thus, the emerging evidence of the 
presence of pharmacologically active compounds in the aquatic environment is a serious 
concern (López-Sernaet al. 2012). 
The term ‘pharmaceuticals’ as used in environmental science, refers to a group of biologically 
active chemical compounds representing a broad range of therapeutic classes of drugs and 
that are designed to interact with specific organ sites (receptors) to elicit a desired therapeutic 
response in the target organism (Guo et al. 2014; Boxall et al. 2012; Pérez & Barceló 2007). 
Worldwide, over 4,000 different pharmaceuticals are used in human medicine (Guo et al. 
2014; Boxall et al. 2012), and additionally, some specialised products are used in veterinary 
practice (Liu et al., 2015a; Liu et al., 2015b). Globally, annual average consumption of 
pharmaceuticals varies from 15 g per capita in less industrialised countries to 50-150 g per 
capita in industrialised countries (López-Serna et al. 2010). In the European Union alone, 
about 3,000 different substances are approved for use as pharmaceuticals (Al Aukidy et al. 
2012; Sándor et al. 2012). Reports of a recently completed UK Water Industry chemical 
investigation program shows that over 1,754,488 kg/yr of common analgesics (paracetamol, 
ibuprofen, naproxen and aspirin) were prescribed in primary health care in Britain (Guo et al. 
2014). The annual consumption of progesterone and its derivatives, progestins, by a 60 million 
population each in France and the United Kingdom was estimated to be 12,800 and 1,700 kg 
respectively, while in the Czech Republic, 2,400 kg/yr for a 10 million population (Table 1.1) 
(Besse & Garric, 2009; Kumar et al., 2015). These represent an approximately 213.3, 28.3, 
and 240 mg/yr per individual for progesterone alone in France, United Kingdom and the Czech 
Republic respectively. In the United Kingdom, progesterone use represents a higher usage 
relative to the combined use (706 kg/yr) of androgens and estrogens (Fayad et al. 2013; 
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Runnalls et al. 2010).  In Hungary, 7,746 kg of diclofenac was sold in 2004 (Sándor et al.  
2012). With human population predicted to increase into the future (Liu et al., 2015c) and the 
increased emphasis on improving the quality of human and animal life, pharmaceutical usage 
is expected to increase consistently into the future as new and more effective drugs are 
discovered and produced (Petrović et al. 2014). 
Table 1.1: Annual Consumption of Progesterone and its Derivatives, Progestins 
Country Population (million) Consumption (kg/yr) Per capita use (mg/yr) 
Czech 
Republic 
10 2,400 240 
France 60 12,800 213 
United 
Kingdom 
60 1,700 28.3 
 
The use of pharmaceuticals has benefited society greatly as they are taken to protect, 
preserve and improve the quality of human health. However, these compounds have become 
emerging contaminants of scientific and public concern largely due to their widespread 
detection in the water cycle - especially in surface water.  The first report of the presence of 
pharmaceuticals in the water environment was in 1965 by Stumm-Zollinger & Fair who showed 
that human steroids were not completely degraded during wastewater treatment (Stumm-
Zollinger and Fair, 1965). Although further reports in the 1980s demonstrated the presence of 
these compounds in surface waters (Tabak et al. 1981; Aherne et al. 1985; Aherne and Briggs, 
1989), very little interest was focused on them, perhaps because of their trace environmental 
levels. It was not until the 1990s when biological screening methods were developed and the 
toxicity of environmentally relevant concentrations of hormones on fish was demonstrated 
(Desbrow et al. 1998; Routledge et al. 1998; Jobling et al. 1998, 2002, 2006) that the interest 
of the scientific community was focussed on the significance of these microcontaminants. The 
first evidence of the presence of other pharmaceuticals in surface and wastewater were 
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published in the 1970s (Garrison et al., 1976; Hignite & Azarnoff 1977). Subsequently, studies 
in the 20th and the 21st century have measured a wide range of pharmaceuticals residues 
including their human metabolites in a range of environmental compartments , including water, 
sediment and soil (Haddad & Kümmerer, 2014; J. Liu et al., 2015; Peng et al., 2014; Runnalls 
et al., 2010; Ternes & Joss, 2006; Ying et al. 2002).  
Concentrations of pharmaceutical compounds vary widely for different compounds and 
between different water types; wastewater, surface and groundwater, with hospital, 
pharmaceutical manufacturers and municipal wastewater having the highest recorded 
concentrations of all types of pharmaceuticals (Al Aukidy et al. 2012; Verlicchi et al. 2012; 
2014). Taking diclofenac as an example, concentrations of 6.9 to 2,031 µg/L were reported by 
Sim et al. (2011), for hospital and pharmaceutical wastewater in South Korea. In municipal 
wastewater, Vieno & Sillanpää 2014 reported concentrations of 7.1 µg/L.  Generally, reported 
concentrations of diclofenac in rivers have been generally <100 ng/L. However, concentrations 
of 1,200 and 8,500 ng/L were separately reported in Germany and Pakistan (Vieno, 2007; 
Scheurell et al., 2009; Ternes, 1998). High concentrations of diclofenac in drinking water were 
reported in some parts of Europe. For example, in Spain and Germany, 380 ng/L 
concentrations were reported (Heberer 2002; López-Serna et al. 2010; 2012). For other 
compounds, concentrations of 15.4 to 384.5 ng/L were reported by Liu et al., 2015 for 
antibiotics, Nonsteroidal anti-inflammatory drug (NSAIDs), β – blockers, antiepileptic and 
steroid hormones in surface waters that were downstream of sewage works in China. 
Reported groundwater concentrations of steroid hormones ranged from 9 to 115 ng/L for 
steroids in groundwater (Lopez, et al. 2015), with P4 and androstenedione ranking highest. 
Concentrations of other pharmaceuticals in Lopez et al. (2015) study ranged from 3 to 360 
ng/L with non-prescription drugs recording highest. Concentrations of the common analgesics, 
ibuprofen, diclofenac and acetaminophen ranged from 19 - 34 ng/L. More information on the 
published environmental concentration of compounds selected for the present study are 




1.1 Sources of Pharmaceuticals in the Water Environment  
The ubiquity of pharmaceuticals in the water environment is related to their constant excretion 
with urine and faeces following therapeutic use. Pereira et al. 2015 noted that human excretion 
represented the largest single pathway of pharmaceutical contamination of the water cycle. 
Pharmaceutical compounds are applied topically as gels, inhaled, ingested as 
tablets/capsules or as injections. Gels are absorbed up to 6 to 7% (Davies & Anderson, 1997) 
and the remaining residues are directly washed off, passing to wastewater treatment plants 
(WwTPs). Whatever the mode of administration, upon achieving systemic circulation, drugs 
undergo a set of biochemical reactions (metabolism) in the liver, transforming them to different 
extents depending on the individual drug (Pérez & Barceló 2007; 2008; Cwiertny et al. 2014). 
They are however not completely destroyed in the body, but are excreted as a mixture of 
metabolites, conjugates and unchanged parent compound with urine and faeces (Sammartino 
et al, 2008; Heberer 2002). Hepatic metabolism of drugs occurs in two main phases, phase I 
and II. The first phase involves oxidation/reduction and hydrolytic cleavage, leading to more 
polar molecules than the parent compounds (López-Serna et al. 2012). Depending on the 
pharmaceutical compound, the second phase (aka conjugation phase) consist of the process 
of glucuronidation, acetylation and sulphation, that allow metabolites to become hydrophobic 
and water soluble enough to be eliminated through urine and/or faeces (López-Serna et al. 
2012). Thus, human metabolites of drugs can be phase I or phase II metabolites depending 
on the biochemical reaction resulting in their formation (Evgenidou et al. 2015). Phase I 
metabolites result from the oxidation, reduction and hydrolysis that some parent compounds, 
e.g. ibuprofen, diclofenac, propranolol, etc., undergo in vivo to increase their aqueous 
solubility, a process that aids their rapid elimination from the body (Pérez & Barceló, 2007). 
Phase II metabolites, also referred to as conjugated metabolites, are mostly products of 
glucuronidation and less often sulfation, acetylation and methylation depending on the parent 
compound (Pérez & Barceló 2007). Phase II reactions add a polar molecule e.g. glucuronic 
acid, sulfate, acetyl or methyl functional group to a parent compound or to a phase I product  
(Evgenidou et al., 2015; Liu et al. 2011). Like phase I reactions, glucuronidation increases the 
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polarity of parent compounds, thus facilitating their rapid elimination with urine. To illustrate, 
conjugation of steroids (e.g. natural estrogen) adds a glucuronide functional group to the 
molecule, a process that makes natural estrogen conjugates more polar and less estrogenic 
than their natural parent compounds (Liu et al. 2015d). The latter points thus suggest that 
conjugation is a detoxification reaction that helps protect cells from the toxic effects of parent 
compounds. Phase II metabolites can be deconjugated back to their respective parent 
compound by the enzymes β-glucuronidase (in the case of glucuronidation) or arylsufatase 
for sulfation,  both secreted by microorganisms or specific organs in higher organisms 
(Evgenidou et al., 2015; Liu et al., 2015d; Gomez et al. 2009). For example, Gomez et al. 
(2009) reported the preferential deconjugation of glucuronides conjugates of estrogens 
relative to sulfate conjugates in crude sewage. The authors work, demonstrated that 
deconjugation is a biotic rather than abiotic process, requiring the metabolic activities of 
microorganisms in cleaving associated conjugate moiety. Furthermore, there are literature 
evidence of the ready deconjugation of glucuronated estrogens in sewer, due to the large 
amounts of the β-glucuronidase enzyme produced by faecal bacteria (Escherichia coli) 
(D'ascenzo et al. 2003; Heberer, 2002; Baronti et al. 2000). Based on the daily human 
excretion of conjugated estrogens, Baronti et al. (2000) noted that deconjugation of estrogens 
preferentially occurs in sewers. Additionally, two glucuronides of 17β-estradiol (17β-estradiol-
17-glucuronide and 17β-estradiol-3-glucuronide) were reported to be cleaved when in contact 
with the diluted activated sludge solution resulting in release of 17β-estradiol (Ternes et al. 
1999a; b). Ternes et al. (1999a; b) noted that depending on the processing time conjugates 
like glucuronides, are cleaved during WwTPs.  It is logical therefore to assume that the 
deconjugation reaction occurring in sewer, wastewater treatment (activated sludge process) 
and in the environment, may account for some of the parent pharmaceuticals regularly 
detected in wastewater and surface waters (Ferrer and Thurman, 2010; D’Ascenzo et al., 
2003). 
Following excretion, parent compounds, their metabolites including conjugates enter sewers 
en-route to wastewater treatment facilities. Conventional wastewater treatment processes 
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(WwTPs) do not completely eliminate these compounds (Haddad et al., 2015; Verlicchi et al., 
2012; Verlicchi & Zambello, 2014). Some compounds undergo structural reorganisation or 
transformation in sewers (Jelic et al. 2015), during wastewater treatment (Evgenidou et al., 
2015) and in the environment (Pico et al. 2015)  by a variety of biotic degradation (by bacteria 
and fungi) and  abiotic processes (hydrolysis and photolysis) occurring in such systems. 
Incomplete breakdown by WwTPs and transformation reactions, thus results in the constant 
input of pharmaceutical residues with effluents into surface waters (Fig.1.1). Since there is a 
growing emphasis on water reuse, some of the fresh water bodies that receive effluents from 
WwTPs effluent are also sources of water used for irrigation purposes, fish farming and 
provision of municipal drinking water. Thus, constant ingestion of these micropollutants with 
drinking water is possible, although potable water treatment is likely to further remove these 





Figure 1.1: Pathways of environmental occurrence of pharmaceuticals (Evgenidou et al., 
2015; Liu et al. 2011 Pérez & Barceló 2007) 
 
Many studies measuring pharmaceuticals occurrence, understanding their environmental fate 
and the risk they pose to environmental resources have been published  (Haman et al. 2015; 
Pereira et al. 2015; Altenburger et al. 2015; Escher et al. 2014; Li et al. 2016; Zhang et al. 
2014; Agunbiade & Moodley 2014; Al Aukidy et al. 2012; Tölgyesi et al. 2010; Besse & Garric 
2008). Substantial amounts of information are now available on the occurrence of parent drugs 
in the  environment (Boxall et al., 2012; López-Serna et al., 2012), their physicochemical and 
toxicological properties (Kosma et al. 2014; 2015) as well as their behaviour and 
environmental fate (Evgenidou et al., 2015). However, less is known about the relevant 
transformation products (TPs) that result from the wide range of biotic and abiotic degradation 
processes that these compounds undergo in sewers, storage tanks, during engineered 
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treatment and in the environment (Evgenidou et al., 2015; Jelic et al., 2015; Johnson & 
Williams, 2004; López-Serna et al., 2012).  
Since pharmaceuticals are contaminants of environmental concern, it is important to 
understand their transformation pathways in the environment and during wastewater 
treatment. To illustrate, TPs of some commonly used drugs (e.g. antibiotics, analgesics and 
steroids), have been reported to retain the structural backbone of the biologically active parent 
compounds and have exhibited equal or enhanced biological activity relative to the parent 
compound (Diniz et al. 2015; Haddad & Kümmerer 2014; Cwiertny et al. 2014). Furthermore, 
a reflection on lessons learnt from the adverse environmental impacts of organochlorine 
pesticides due to the prioritization of their economic benefits over and above understanding 
their environmental fate (Carson 2002; Krebs et al. 1999), stresses the need for information 
on the identity and toxicity of potential TPs resulting from natural and engineered degradation 
of pharmaceuticals. Thus, a detailed assessment of the fate of parent compounds in the 
environment will not be complete without holistic information on the formation of their TPs (Li 
et al., 2016). Such knowledge is especially relevant as transformation is often not 
detoxification and TPs may be persistent and/or biologically active and capable of eliciting a 
toxicological effect on non-target organisms (Li et al., 2016; Pico et al., 2015). An important 
consideration is that, TPs of some commonly used drugs (e.g. antibiotics, analgesics and 
steroids), have been reported to retain the structural backbone of the biologically active parent 
compounds and have exhibited equal or enhanced biological activity relative to the parent 
compound (Cwiertny et al., 2014; Diniz et al., 2015; Haddad & Kümmerer, 2014). 
Transformation of acyclovir, an antiviral drug produced two TPs that were reported to have 
adverse effects on Daphnia magna (reduction in reproduction levels) and inhibition of algae 
growth (Schlüter-Vorberg et al. 2015). Wang & Lin 2012 reported the increased potency that 
UV irradiation of surface water containing cephalosporin antibiotics had on algae. Back 
transformation of TPs to their corresponding parent molecules has been reported (Su et al. 
2016), a process that increases the exposure to parent pharmaceuticals downstream of point 
of initial transformation and/or the point of effluent discharge (Qu et al., 2013). The extent of 
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transformation can be high as shown in Huntscha et al. (2013) in a riverbank filtration study 
where atenolol was almost totally transformed to atenolol acid and further evidenced by 
studies on the attenuation of selected pharmaceuticals in the hyporheic zone of river beds (Li 
et al. 2015). Over 80% of acetaminophen was reported to be attenuated in the hyporheic zone 
of river beds (Li et al. 2016). In some case however, transformation may be partial to zero. For 
example, partial attenuation of tramadol and sulfamethoxazole (20%) in rivers was reported 
(Li et al., 2016). In the Li et al. (2016) study, carbamazepine was reported to be persistent 
(zero transformation), although its biotransformation to carbamazepine-10, 11-epoxide was 
reported by other workers (Li et al. 2014; Li et al. 2015) and detected in surface water 
(Huntscha et al. 2013; 2012; Langford & Thomas 2011). Carbamazepine was also reported to 
be recalcitrant to biodegradation and showed zero elimination during wastewater treatment 
with activated sludge (Kosjek et al. 2009). This shows the variability in the transformation 
potential of chemical compounds depending on structural complexity, especially as biological 
transformation reactions are reported to occur on locations in a compound’s structure with the 
most readily available electrons (Kosjek et al. 2009). 
 
1.2 Research Aim and Objectives 
This work aims to investigate removal and degradation of pharmaceuticals in natural (rivers) 
and artificial (constructed wetland) systems, with a focus on the identification and 
characterisation of transformation products. 
Objectives: 
i. Identify compound(s) to study depending on literature evidence on their amenability to 
biological degradation and degradation half-life. 
ii. Decide what systems (effluent receiving rivers or constructed wetland) to undertake 
transformation studies in, especially considering site accessibility. 
iii. Develop analytical methods for the detection of model compounds. 
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iv. Model pharmaceutical degradation pathways and evaluate possible transformation 
products from the literature.  
v. Undertake degradation studies and identify transformation products. 
vi. Assess biological activity of the transformation products. 


























It is well established that both aerobic and anaerobic processes in wastewater treatment result 
in breakdown of pharmaceutical compounds, the extent of which is compound specific (Wols 
et al. 2015; Gros et al. 2014; Salgado et al. 2013; Lee & von Gunten 2010; Khanal et al. 2006). 
These biodegradation processes are used either alone, or with increasing frequency, 
alongside advanced processes such as photolysis, adsorption and oxidative technologies in 
“advanced engineered treatment” which aims to achieve more effective removal of 
pharmaceutical residues (Chen et al. 2012; Wols et al. 2013). However, it is evident that 
residues are still discharged to receiving waters, and it is therefore desirable that 
concentrations of residues are further reduced, along with associated ecotoxicological risks, 
through natural attenuation to minimize treatment cost and reduce ecological exposure to 
potent compounds (Long et al. 2013; Cruz-Morató et al. 2013; Sándor et al. 2012; Fayad et 
al. 2013).  
The underlying assumption that drives risk-based approaches to environmental protection and 
many contaminant fate characterisation models, is that, analytical evidence of the removal of 
previously identified toxic parent compounds following treatment, translates to removal of its 
associated adverse biological effects. Thus, after treated effluents are analysed for targeted 
parent compounds (assuming such molecules degrade), and analytical results shows the 
none presence of such molecules, elimination of initially observed biological activity is most 
often inferred without further toxicological investigations. However, evidence emerging from 
research in the last decade suggests that there are occasions when degradation products 
formed following treatment may be of some concern (Cwiertny et al., 2014). For example, 
Diniz et al. (2015) reported that the photolytic degradation of diclofenac following UV irradiation 
resulted in products that were more toxic to zebrafish (Danio rerio) than the parent compound. 
Degradation products identified by Diniz et al. (2015) were previously reported by Salgado et 
al. (2013) to be present in drinking water and in treated effluent, thus, showing the potential 
ubiquity of such bioactive by-products in the water cycle. Similarly, sunlight irradiation of 
diclofenac contaminated water samples was reported to result in products that exhibited six-
14  
 
fold phytotoxicity on the unicellular chlorophyte, Scenedesmus vacuolatus after two days of 
direct sunlight exposure (Schmitt-Jansen et al. 2007). A solution resulting from photolytic 
degradation of 100 mg/L metronidazole was reported to have increased toxicity on Allium cepa 
relative to the parent compound (Dantas et al. 2010).  
Worldwide, many degradation products along with their parent compounds have been 
detected in WwTPs effluent (irrespective of the treatment methods) and in ground and surface 
waters (Fang et al. 2012; Fatta-Kassinos et al. 2011; Haddad et al. 2015; Heberer, 2002; 
Lopez et al., 2015; Moreno-González et al., 2014; Pereira et al., 2015; Schlüter-Vorberg et al., 
2015; Su et al., 2016). Adverse effects of degradation products on the biolouminscence of 
Vibrio fischeri was reported for the photocatalytic by-products of metoprolol degradation 
(Veloutsou et al. 2014).  Trovó et al. (2009) and Fatta-Kassinos, Vasquez, et al. (2011), 
reported the formation of 9 degradation products following solar irradiation of distilled water 
spiked with sulfamethoxazole. After 30 hours of irradiation, sulfamethoxazole was completely 
degraded. However, the system’s toxicity to Daphnia magna, measured by the mobility of the 
test organism, increased from initial 60% prior to irradiation to 100%, indicating that 
degradation products were more potent than the parent compound. DellaGreca et al., (2003) 
and Isidori et al. (2005) reported the formation of six (6) by-products following irradiation of 
water containing naproxen. Toxicity testing of the irradiated solution showed increased acute 
and chronic toxicity to Daphnia magna and Vibrio fischeri, relative to naproxen.  
Advanced oxidation treatment approaches have been applied in some parts of the world 
(industry scale) for the treatment of wastewater because of the process reputation for the 
transformation of a range of organic compounds including pharmaceuticals (Fayad et al. 2013; 
Wols et al. 2013; Chen et al. 2012; Fatta-Kassinos et al. 2011). For example, Lee & von 
Gunten (2010) reported the application of oxidation in the treatment of a range of 
pharmaceuticals including; atenolol, carbamazepine, EE2, ibuprofen and sulfamethoxazole in 
drinking and wastewater. Chen et al. (2012) reported the oxidative degradation of EE2 with 
hydrogen peroxide, with the formation of products that retained parent’s estrogenic potency. 
Furthermore, Fayad et al. (2013) reported the oxidative degradation of a range of 
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progestogens including progesterone spiked at a concentration range of 278-3,070 µg/L, in 
wastewater using potassium permanganate. Oxidative degradation of clofibric acid by 
ozonation was reported to result in the formation of seven (7) products (Rosal et al., 2009). 
Subsequent bioassay using Daphnia magna and Vibrio fischeri also showed enhanced toxicity 
of the products relative to the parent compound. Similarly, toxicity of aqueous solution from 
the  oxidative degradation of paracetamol by ozone and hydroxyl radicals on Vibrio fischeri 
was reported to increase, even though paracetamol concentration decreased (Hamdi  et al. 
2014). Hydroquinone and two other by-products were reported in that study. 
The above examples are of chemical pathways; however, there is also evidence that biological 
transformation can be important. For example, the conversion of the steroid estrone was 
reported to produce 17β-estradiol, a bioactive product much more potent than the parent 
compound (Khan et al. 2008; Khanal et al., 2006; Yang et al. 2011). Another example, is the 
use of activated sludge in the treatment of metoprolol, a β-blocker whose ecotoxicological 
effects on the rainbow trout Oncorhynchus mykiss has been reported (Huggett et al. 2002; 
Triebskorn et al. 2007; van den Brandhof & Montforts, 2010). Metroprolol was shown to form 
five (5) degradation products including O-desmethylmetoprolol which was reported to 
moderately inhibit the bioluminescence of the bacterium Vibrio fischeri. (Rubirola et al. 2014). 
In China, the degradation of progesterone by two freshwater algae, Scenedesmus obliquus 
and Chlorella pyrenoidosa, was reported to result in the formation of nine (9) products, four 
(4) of which (Testosterone, 5α-Dihydrotestosterone (5α-DHT), 4-Androstene-3,17-dione 
(AED) and 17β-Boldenone),  are known androgens regularly measured in rivers (Peng et al., 
2014; Thomas et al., 2002). Thus, a thorough assessment of the fate of parent 
pharmaceuticals in the environment will be incomplete without comprehensive information on 
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2.1 Transformation of Pharmaceuticals 
The biotic and abiotic treatment processes that parent pharmaceuticals undergo during 
engineered treatment and in the environment often do not drastically alter their structure, but 
transform them into compounds that bear structural resemblance to the parent molecule (Li et 
al., 2014; Llorca et al., 2015; Rubirola et al., 2014; Schlüter-Vorberg et al., 2015). For example, 
microbial transformation of clofibric acid in activated sludge produced 4-chlorophenol (Fig. 
2.1), a molecule that retained the core parent phenol ring (Kosjek et al. 2009). Wick et al. 
(2011) reported that TPs resulting from the biological degradation of the opium alkaloid, 
codeine only had slight molecular modification, such as double bond shift, introduction of 




Figure 2.1: Transformation of clofibric acid to 4-Chlorophenol. Product bear structural 
resemblance to the parent compound keeping the phenol ring structures as the parent (Da: 
Daltons). 
 
Thus, the term ‘transformation’ as would be used in this work refers to minor modification in 
the molecular structure of parent compounds involving the structural reorganisation of 
composite peripheral elements, functional groups and/or cleavage of side-chain or the 
substitution of a functional group and/or element with an external one. Pharmaceutical 
transformation as used in the present study would therefore convey the idea of substantial 
conservation of core parent structural backbone in products. 
Conservation of parent structure in TPs has been widely reported (Diniz et al. 2015; Kumar et 
al. 2015; Cwiertny et al. 2014; Kolodziej et al. 2013; Wang & Lin 2012; Wick et al. 2011). For 
example, photolytic degradation of diclofenac and atenolol was reported by Diniz et al. (2015) 
to result in the formation of five (5) TPs all of which retained the core structural backbone of 
their respective parent (Fig. 2.2A (diclofenac) and 2.2B (atenolol)). Similarly, algae 
biotransformation of progesterone resulted in the formation of nine (9) TPs including 3β-
Hydroxy-5α-pregnan-20-one and 3, 20-Allopregnanedione (Fig. 2.3A). Reported TPs all had 
the core parent tetracyclic backbone ring.  Furthermore, degradation of 17β-estradiol by 
activated sludge bacteria Nitrosomonas europaea and Nocardia sp. was reported to result in 
the formation of estra-1,3,5(10),16-tetraen-3-oll (Nakai et al., 2011) and estrone (Yu et al. 
2013; 2007). Both TPs retained the structural backbone of 17β-estradiol (Fig. 2.3B). 
Biotransformation of 17α-ethinyl estradiol by nitrifying bacteria was reported by Yi & Harper 
(2007) to result in the formation of 2-hyroxyl-17α-ethinyl estradiol (Fig. 2.3C). Similarly, 
biotransformation of 17α-ethinylestradiol by the sphingolipids producing environmental 
bacteria Sphingobacterium sp., was reported by Haiyan et al. (2007) to result in the formation 
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of estrone (Fig. 2.3C). Direct and indirect photo-transformation of three (3) β-lactam 
cephalosporin antibiotics, cephradin, cephalexin and cephapirin, resulted in twelve (12) by-
products, all of which bore striking structural resemblance to their respective parent molecules 
(Wang & Lin, 2012).  
  
Figure 2.2: Transformation products from photolytic degradation of diclofenac (A) and atenolol 
(B) showing significant conservation of parent structural backbone in products (Da: Daltons) 





Figure 2.3: Transformation products of progesterone (A), 17β-estradiol (B) and 17α-ethinyl 
estradiol. All TPs shown have structural resemblance to their respective parent compound. 
(M: molecular weight) (Peng et al. 2014; Nakai et al., 2011; Yu et al. 2013; 2007) 
 
Structural conservation in transformation products is ecotoxicologically important especially if 
a parent’s potency is structure dependent. The implication is that the given parent’s inherent 
biological acitivity(ies) can be conserved in TPs or new toxicity potency can be created across 
multiple biological end points (Cwiertny et al. 2014; Forsgren et al. 2014).  The latter point is 
especially relevant with TPs of steroidal hormones. Steroids can exhibit distinct biological 
activities though differing only by slight structural modification to their side chains.   
Progestogens, androgens, estrogens and glucocorticoids are examples of natural steroids 
secreted in the adrenal cortex, testis, ovary and the placenta of humans and animals.  Human 
excretion, animal waste disposal, surface run-off from livestock farms coupled with possibly 
high, though inadequate, removal in traditional WwTPs results in the regular discharge of 
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these micropollutants into surface waters (Johnson and Williams, 2004). All four steroid 
classes (progestogens, estrogens, androgens and glucocorticoids) making up this group of 
compounds have a common parent tetracyclic backbone. The target nuclear receptors that 
each steroid – progesterone (P4), estrogen, androgen or glucocorticoid - are designed to 
interact with, to elicit their intended biological activity, is achieved by slight alteration of their 
chemical structure (Fig. 2.4).  Thus, the slightest modification in the arrangements of the 
peripheral atoms and/or functional groups of these compounds due to environmental 
transformation can modify their pharmacophore, the electronic and spatial arrangement of a 
compound’s atoms, which determines its optimal binding with a target biological site to trigger 
or block biological signalling (Overington et al., 2006). Modification of the pharmacophore due 
to transformation could make resultant TPs bind to different ligands (nuclear receptors) and 
eliciting unintended biological responses (e.g. activation or deactivation of certain gene 
expression) (Cwiertny et al., 2014; Runnalls, et al., 2013; Jenkins, et al., 2004). 
To illustrate, structural modification to specific locations in P4, a C-21 progestational steroidal 
ketone and a progestogen secreted naturally by females, have been shown to not only modify 
its progestagenic activity, but resultant TPs may also demonstrate activity in other steroid 
pathways (e.g. androgenicity) (Besse & Garric 2008; 2009). Most transformation reported in 
the literature, occur in these positions. P4 differs from its androgenic counterpart testosterone, 
only by having a –COCH3 functional group at carbon 17 (C17). Thus, transformation involving 
cleavage of the –COCH3 and subsequent hydroxylation (-OH) at the C17, will yield 
testosterone, an androgen with differing biological activity relative to P4. Another example is 
the reported bacteria and algae transformation of P4 to known androgens (Carson et al. 2008; 
Jenkins et al., 2004; Peng et al., 2014). Two freshwater algae, Scenedesmus obliquus and 
Chlorella pyrenoidosa, were reported to form four (4) androgens including androsta-1,4-diene-
3,17-dione and 4-androstene-3,17-dione (Peng et al. 2014). 4-androstene-3,17-dione was 
formed by the cleavage of the –COCH3 side chain of P4 at C17. Subsequent dehydrogenation 
of 4-androstene-3,17-dione at C1 resulted in Androsta-1,4-diene-3,17-dione. Similar 
transformation and androgenic products (Fig. 2.7) had been previously reported by Carson et 
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al. (2008) and Jenkins et al. (2004) in a biotransformation reaction mediated by the bacterium 
Mycobacterium smegmatis. 
 
Figure 2.4: Chemical structures of representative members of different classes of steroidal 
hormones. All steroids shown have a common tetracyclic backbone and differ only by minor 





Figure 2.5: The significance of structural transformation on specific points (circled) in the P4 
structure and the effect on potency of the steroid. Most transformation reported in the 
literature, occur in these positions. Changes resulting from substitution or addition of a 
functional group can alter the affinity for receptors and consequently biological effects (Besse 
& Garric 2008; 2009) 
 
 
Figure 2.6: The significance of structural transformation on the potency of steroid. 
Transformation of P4 to testosterone formed by side chain transformation of the parent 







Figure 2.7: The significance of structural transformation on the potency of steroid. 
Transformation of P4 to 4-androstene-3,17-dione was formed by the cleavage of the –COCH3 
side chain of P4 at C17. Subsequent dehydrogenation of 4-androstene-3,17-dione at C1 
resulted in Androsta-1,4-diene-3,17-dione (Carson et al. 2008; Jenkins et al. 2004). 
 
Generally, transformation of organic contaminants is often equated with detoxification 
(Evgenidou et al. 2015; Pico et al. 2015; Cwiertny et al. 2014). Transformation is however, 
relevant environmentally if it results in products that are recalcitrant to further degradation or 
products that have similar or enhanced toxicity relative to their parents (Cwiertny et al. 2014; 
Evgenidou et al. 2015; Pico et al. 2015; Li et al. 2016). To illustrate the latter point, Boxall et 
al. (2004) showed that pesticide and biocide degradation produced TPs that were three times 
acutely toxic to daphnids, rainbow trout, earthworms and algae relative to their respective 
parent molecules. The activated sludge treatment of acyclovir was reported by Schlüter-
Vorberg et al. (2015)  to result in the formation of carboxy-acyclovir, which was further 
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transformed into N-(4-carbamoyl-2-imino-5-oxomidazolidin)formamido-n-methoxy-acid by 
ozonation. Both TPs have been detected in surface water, wastewater treatment influents and 
effluents and also in drinking water (Prasse et al. 2012; 2011; 2010). Using the Organisation 
for Economic Co-operation and Development (OECD) 211 guidelines Daphia magna 21 days 
reproduction test, Schlüter-Vorberg et al. showed that 102 mg/L concentration of carboxy-
acyclovir reduce reproduction levels of the test organism by 40%. The group also applied the 
OECD 201 72 hours algal growth inhibition test to the ozonation product and reported that it 
inhibited the growth of the green alga Raphidocelis subcapitata at a concentration of 14.1 
mg/L. Acridine and 4-chlorophenol (Fig. 2.1) were reported to be exhibit higher phyotoxicity 
on germinating seeds of Lycopersicon esculentum (tomato) and acute toxicity on the 
anthropod, Folsomia candida than their parent molecules (Chiron et al. 2006; Petrovic & 
Barceló 2007; Kosjek et al. 2009; Elghniji et al., 2012).The potency of transformation products 
can differ from that of their parents in the mechanism of their bioconcentration (toxicokinetics) 
and/or their mode of action (toxicodynamics) (Evgenidou et al. 2015). To illustrate this point, 
the biological activity of parent pharmaceuticals is generally a function of the interaction of a 
distinct part (moiety) of the compound with a target receptor in an organism (Boxall et al. 
2004). Such interactions are largely a function of the amount of the compounds active moiety 
reaching the target receptor which is dependent on the compounds octanol-water portioning 
coefficients or hydrophobicity (Hermens et al. 1984a; 1984b; Deneer et al. 1988; Könemann 
1981) and the degree of dissociation (pKa) (Boxall et al. 2004). Thus, a transformation 
products retaining parental active structural moiety and has a higher dissociation constant 
(less prone to dissociation) or is more hydrophobic (perhaps rare as metabolism often result 
in more hydrophilic compound) than the parent compound, would be more potent than its 
parent molecule. The latter point on hydrophobicity could be applied to prodrugs. Prodrugs 
are compounds administered pharmacologically inactive, and only become active following 
metabolism (Foe et al. 1998; Wilcox & Avery, 1973). Higher activity following metabolism 
would also been increased absorption into tissues, which means reasonable hydrophobicity. 
An example of a prodrug is beclomethasone dipropionate (BDP), a glucocorticoid steroid used 
mostly by inhalation for treatment of respiratory disorders e.g. asthma. The hydrolytic 
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breakdown of the compound’s ester side chain was reported to yield a much more potent 
monopropionate derivative, 17- beclomethasone monopropionate (BMP) (Foe et al., 1998).  If 
BDP was to be flushed down the drain and degraded in the environment by a metabolic 
pathway similar to that of human metabolism, the active molecule, BMP, will be produced and 
will show higher toxicity relative to BDP in a toxicity test. It is worth mentioning that rarely does 
transformation results in products with completely new structures (toxicophores) to their parent 
compounds and that shows higher potency using similar or dissimilar mode of action as their 
parent molecule (Evgenidou et al. 2015; Farré et al. 2008). 
Transformation products exist largely in mixture with their precursor parent compounds (Li et 
al. 2016; Evgenidou et al. 2015; López-Serna et al. 2012). For example, thirty (30) known TPs 
of pesticide origin were detected in mixture with their parent compounds in Swiss rivers 
(Moschet et al. 2014). There may have been many more unknowns present; that the target 
analytical procedure applied in that study for data acquisition will have missed.  
Microbial back-transformation of TPs to parent compounds have been reported in the 
environment (Qu et al., 2013; Su et al., 2016), a process that potentially increases 
environmental exposure to parent compounds downstream of effluent discharge points or 
point of initial transformation. For example, degradation of the antibiotic sulfamethoxazole 
resulted in transformation products that were reported to be back-transformed by sediment-
based bacteria to the parent compound (Su et al., 2016).  Similarly, Qu et al. (2013) reported 
the back-transformation of animal metabolites and TPs of the growth promoter trenbolone 
acetate at conditions representative of surface waters. Thus, pharmaceutical compounds just 
do not disappear following treatment or when discharged into the environment, but remain in 
the environment either as the original parent compounds (in the case of persistent 
compounds) or as TPs. 
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2.1.1 The Potency of Natural and Synthetic Steroids and the Effects of 
Structural Transformation 
Synthetic steroids are excellent examples of compounds where minor modifications to the 
structure of their endogenous analogue(s), a process explored for their synthesis, can result 
in cross-binding affinity to multiple receptors and triggering biological response(s) (cross-
reactivity) that are not immediately obvious from structural inspection (Kumar et al. 2015; 
Cwiertny et al. 2014; Liu et al. 2011). The relative effect of structural modification on the 
binding properties of synthetic steroids can be illustrated by the receptor binding affinity of 
synthetic derivatives of P4 and testosterone (progestins and androgens) relative to their 
respective natural molecules. Although designed to bind with either the progesterone or 
androgen receptor and mimic the action of their endogenous compounds, synthetic steroids 
have been reported to have varying binding affinities to other non-target receptors namely the 
androgen, estrogen, mineralocorticoid and glucocorticoid receptors (Africander et al. 2011; 
Kumar et al., 2015; Regine Sitruk-Ware, 2004; Zapater et al. 2013). For example, medroxyP4-
acetate is derived from P4 by modification to its side chain. Hydrogen attached to C17 was 
substituted with a –OCOCH3 functional group (Fig. 2.8A). This structural modification has been 
reported to result in medroxyP4-acetate possessing 36 and 42% enhanced binding affinity to 
the androgen and glucocorticoid receptors relative to P4 9 and 5% binding affinity to these 
receptors (Kumar et al. 2015; Sitruk-Ware 2004; 2008). MedroxyP4-acetate is reported to 
possess anti-estrogenic and gonadropic properties ( Kumar et al. 2015; Schindler et al. 2003) 
and have been demonstrated to suppress the immune system of stimulated juvenile carp 
(Cyprinus carpio L.) in a 96-hour test. Another example is the synthesis of normegestrol 
acetate from P4. Normegestrol acetate is synthesized following the same process applied in 
the synthesis of medroxyP4-acetate but with the substitution of hydrogen at C6 with a methyl 
group and subsequent dehydrogenation at C7 (Fig. 2.8A). This progestin is also reported bind 
to have enhance binding affinity for the androgen (42%) and glucocorticoid (6%) receptors 
(Kuhl, 2005) and possessing anti-estrogenic, androgenic and gonadropic properties (Kumar 
et al. 2015; Shields-Botella et al. 2003; Schindler et al. 2003). Similarly, levonorgestrel a mirror 
form of norgestrel is synthesized from testosterone by side chain modification involving 
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substitution of hydrogen at C17 with alkyne group (CCH) and the addition of a methyl group 
to C18 (Fig. 2.8B). Gestodene is another progestin derived from testosterone following the 
same synthetic process as levonorgestel but with the addition of dehydrogenation at C15 and 
C16 (Fig. 2.8B). Gestodene is reported to have enhanced binding affinity of 71, 38 and 202% 
to androgen, glucocorticoid and sex hormones binding globulins (present fish gills) 
(Fuhrmann, Slater, & Fritzemeier, 1995; Schindler et al., 2003). P4 binding affinity to these 
sex hormones binding globulins is less than 0.5% (Kumar et al. 2015; Kuhl 2005; 1996). 
Gestodene is reported to show anti-estrogenic, mineralcorticoid and gonadropic activities 
(Schindler 2014; Africander et al. 2011; Kuhl 2005; Krattenmacher 2000). Furthermore, 
cleavage of the ester side chain of trenbolone acetate produces trenbolone, the anabolic 
growth promoter known for its androgenic potency, and exhibiting not only higher (37%) 
binding affinity to the progesterone receptor than P4, but it also possess anti-glucocorticoids 
activity (Bauer, Daxenberger, Petri, Sauerwein, & Meyer, 2000). The effect of minor structural 
modification on higher potency of synthetic steroids can be further illustrated with the toxicity 
of ethinyl estradiol (EE2). EE2 differs from its natural analogue, 17β-estradiol (E2) by the 
annealing of an ethyne group to C17. Yet, EE2 is reported to be 27-fold greater estrogenic 




Figure 2.8: Structural modifications explored in the synthesis of progestins from endogenous 
progesterone and testosterone (Kumar et al. 2015) 
 
2.1.2 Role of TPs in Observed but Unexplained Biological Activity 
The general desire for ecological risk mitigation is that the reduction in concentration of a 
parent bioactive compound is followed by a corresponding reduction in previously observed 
biological activity. Sometimes, products of transformation are unknown, but when removal of 
parent compound is marked by significant reduction in system bioactivity, identification of such 
TPs is often not necessary (Cwiertny et al., 2014; Escher & Fenner, 2011). There are however 
many instances reported in the literature, where significant activities are detected in 
environmental systems with results of chemical analysis unable to link such observation to 
known specific causative chemicals (Cwiertny et al., 2014; Diniz et al., 2015; Evgenidou et al., 
2015; Stalter et al. 2010). For example, 27% glucocorticoid and 35% androgen receptor 
activities were reported by Stavreva et al. (2012) in surface water systems across the United 
States. However, results of chemical analysis were unable to link such observed potency to 
29  
 
known glucocorticoid and androgenic chemicals present in the samples collected. In another 
example, screening of 41 known glucocorticoid compounds could not account for the 
persistent and widespread glucocorticoid activity observed in WwTP effluents and 
wastewater-impacted rivers in Australia (Escher et al., 2014), even though the level of activity 
was higher than those observed for estrogen and androgen receptor activities. Still on 
glucocorticoid activities, Schriks et al. (2013) assessed the presence of glucocorticoids and 
the extent of their biological activities in Dutch surface waters that serve as sources of water 
treated for domestic use. Though the assay results of their study were positive for 
glucocorticoid activities in four out of the eight rivers investigated, the results of chemical 
analysis were unable to determine which specific glucocorticoid was responsible for the 
observed effect in the GR CALUX bioassay used. CALUX bioassays are 96-well plate 
androgen-and-estrogen-responsive bioassays developed by Sonneveld et al. (2005) through 
genetic engineering of the human U2-OS osteosarcoma cells. In the case of the GR CALUX 
assay, the human glucocorticoid receptor and the luciferase (bioluminescence) reports gene 
were transfected into the human osteosarcoma cells. Bioactivity is determined by measuring 
luciferase bioluminescence activity with a luminometer.  
Furthermore, Stalter et al. (2010), reported development retardation in rainbow trout 
(Oncorhynchus mykiss) after exposure to conventional WwTPs effluent, but were unable to 
attribute the observation to any known chemical agent. Stalter et al. (2010) assessed effluent 
toxicity using the fish early life stage toxicity test and the yolk-sac larvae test and reported 
significant reduction in the fish body weight, length and vitellogenin levels. Likewise, Bellet et 
al. (2012) investigated the agonist and antagonist activities of steroids in sewage influent from 
six WwTPs in France. Results of targeted chemical analysis showed that a number of 
androgens including testosterone, dihydrotestosterone and epiandrosterone were present in 
tested samples. However, a comparison of the strong androgenic response observed in that 
study with results of chemical analysis revealed that there may have been other unknown 
androgens present in samples as combined androgenic effects of measured androgens could 
only account for part of the observed androgenic response. Van Der Linden et al. (2008) 
working in The Netherlands, reported a similar finding to Bellet et al. (2012), from their 
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screening of industrial, hospital and municipal effluent for steroid receptors activity using 
human cell derived CALUX reporter gene bioassays mentioned earlier. Observed receptor 
activities were generally higher than could be explained with known specific chemicals. 
Observed glucocorticoid-like receptor activity in surface water was over 2,500 times higher 
than the conventional response of the natural glucocorticoid, cortisol (about 2900 ng cortisol 
equivalent/L). Observed receptors activities were generally higher in effluent samples. Van 
Der Linden et al. (2008) were unable to establish the identity of the compounds responsible 
for the reported biological activity. Reference to biological activity in WwTPs influent was made 
in this section because, poor removal during reatment would result in the dischare of potent 
steroids to receiving surface waters. 
 
2.1.3 Key Transformation Pathways in the Environment 
Microbial mediated degradation in the environment and during wastewater treatment is an 
important micropollutant breakdown process reported to produce TPs, some of which have 
similar or enhanced potency relative to their parent compounds. This section gives examples 
of some key biological pathways resulting in the formation of TPs. Discussed pathways have 
been reported to occur in both biotic and abiotic treatment systems (Li et al. 2014; Kolodziej 
et al. 2013; Wang & Lin 2012; Fatta-Kassinos, Vasquez, et al. 2011). Thus, reference is made 
to abiotic treatment processes to highlight similarities in degradation pathways.  
Generally, hydroxylation, oxygenation, hydrogenation, dehydrogenation and sidechain 
breakdown (Gros et al. 2014; Peng et al. 2014; Peart et al. 2011; Winkler et al. 2001) are the 
common biological transformation pathways reported in the literature which result in the 
formation of pharmaceutical TPs. Sometimes, individual pathways proceed solely to form 
products. But most often, several pathways act together to produce a given TP. Some 
products of biological degradation have been reported to be highly reactive, serving as 
precursors for a range of other biotic and abiotic transformation pathways (Wick et al. 2011; 
Kosjek et al. 2009). For example, activated sludge treatment of the opium alkaloid, codeine 
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was reported to result in the formation of unsaturated α, β-ketone codeinone, an intermediate 
product and precursor of a range of abiotic and biotic transformation processes resulting in 
the formation of nine TPs (Wick et al., 2011). 
2.1.3.1 Hydroxylation 
Hydroxylation is a dominant pathway in the transformation of pharmaceuticals. For example, 
the microbial mediated hydroxylation of the ketone group on carbon 14 of 14-
Hydroxycodeinone, a metabolite of codeine, to 14-hydroxycodeine was reported by Wick et 
al. (2011). The hydroxylation of diclofenac and ibuprofen in activated sludge studies was 
reported by Kosjek et al. (2007). Activated sludge treatment of ibuprofen was reported by 
Pérez & Barceló (2007) to occur by hydroxylation resulting in the formation of three hydroxyl 
isomers (1, 2 and 3 hydroxy-ibuprofens) of ibuprofen. Biodegradation of iopromide, the X-ray 
contrast agent and the antibiotic floroquinolone by the white rot fungus Trametes vesicolor, 
was reported by Gros et al. (2014) to yield hydroxyl transformation products. Hydroxylation is 
a key pathway in the degradation of steroid hormones. For example, degradation of 17β-
estradiol into 4-hydroxy-17β estradiol by the aerobic bacteria Sphingomonas sp. was reported 
Kurisu et al. (2010) to proceed by the hydroxylation of its C4. Similarly, hydroxylation of C2 in 
17α-ethinyl estradiol by nitrifying bacteria was reported to result in the formation of 2-hydroxy-
17α-ethinyl estradiol (Yi & Harper, 2007). Similarly, the hydroxylation of C6 of 17α-ethinyl 
estradiol by the microalgae Ankistrodesmus braunii is reported to yield 6-hydroxy-17α-ethinyl 
estradiol (Della Greca et al., 2008). Hydroxylation is one of the major pathways reported for 
the microbial degradation of progesterone (Table 2.1). Reference to progesterone stems from 
its usage patterns globally, regular measurement in the water environment due to its 
incomplete removal during wastewater treatment, direct human and animal excretion and 
sometimes direct discharge of untreated wastewater (Liu et al. 2012b) and its reported 
adverse effects on fish reproduction and chemoreception at environmentally relevant 
concentrations (Liang et al. 2015a, b; Murack et al. 2011; Havens et al. 2010; Kolodziej et al. 




Table 2.1: Pathways of steroids transformation and TPs reported potency 














ketone at C3; 




























Cleavage of –COCH3 
at C17; Oxygenation 








Cleavage of –COCH3 
at C17; Hydroxylation 
at C17; 
Dehydrogenation at 









Cleavage of –COCH3 
at C17; hydroxylation 








Cleavage of –COCH3 
at C17; Hydroxylation 
at C17; 
Hydrogenation at C4 
and C5 1,4 
Yes Algae 
transformation 
Nk – not known; M – molecular weight 
                                               
1 (Peng et al., 2014) 
2 (Thomas et al., 2002) 
3 (Cwiertny et al., 2014) 
4 (Parthasarathi et al. 2004) 
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Table 2.1: Pathways of steroids transformation and TPs reported potency (cont’d) 
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5 (Salgado et al., 2013) 
6 (Yang et al., 2011) 
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Table 2.1: Pathways of steroids transformation and TPs reported potency (cont’d) 
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7 (Chen et al., 2012) 
8 (Frontistis et al., 2012) 
9 (Barr et al. 2012) 
10 (Della Greca et al., 2008) 
11 (Forsgren et al. 2014) 
12 (Kolodziej et al., 2013) 
13 (Khan et al., 2008) 
14 (Whidbey et al., 2012) 
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The overall observation in Table 2.1 is that microbial breakdown of steroids does not 
necessarily involve the cleavage of the parental tetracyclic ring, but the transformation of 
peripheral elements by substitution and/or side chain breakdown. For example, hydroxylation 
of carbon 17 in P4 following cleavage of its side chain, was a contributory pathway in the 
formation of boldenone, testosterone and 5α-dihydrotestosterone, all of which are potent TPs 
(Peng et al., 2014). Biotransformation of a range of other steroids including progesterone and 
testosterone, was reported by Peart et al. (2011) to occur by hydroxylation of their respective 
carbon 7. Furthermore, a range of other microbial transformation by hydroxylation at different 
positions in the P4 structure were reported in the literature. Several species of fungi were 
noted to introduce a hydroxyl group at the 14α-position of the compound and were further 
transformed chemically to the 14β-hydroxy substituent (Bhatti and Khera, 2012; Manosroi et 
al. 2008). For example, P4 was transformed into 14α-hydroxyprogesterone and 9α-
hydroxyprogesterone by Thamnostylum piriforme (Manosroi et al. 2008).  Other reported 
microbial transformations of progesterone include; 14α-hydroxyprogesterone transformation 
into 6β, 14α-dihydroxyprogesterone and 7α, 14α-dihydroxyprogesterone (Mucor 
griseocyanus) (Hu et al. 1995), P4 into 11α-hydroxyprogesterone, 15β-hydroxyprogesterone, 
7β-hydroxyprogesterone, 7β–15β-dihydroxyprogesterone and 11α–15β-
dihydroxyprogesterone (Aspergillus fumigatous) (Smith et al. 1994). Bhatti and Khera, (2012) 
also noted the formation of 4-androstene-3, 17-dione (50), testosterone (2) and testololactone 
when progesterone was incubated with Saprolegnia hypogyna, 15α-hydroxyprogesterone and 
12β–15α-dihydroxyprogesterone with Fusarium culmorum culture. However, when P4 was 
incubated with thermophilic bacterium (Bacillus stearothermophilus), three monohydroxylated 
metabolites (20α-hydroxyprogesterone 6β-hydroxyprogesterone and 6α-
hydroxyprogesterone) and a new metabolite (9, 10-sco-4-pregnene-3, 9, 20-trione) were 
reported to be isolated and identified (Bhatti and Khera, 2012). 
Hydroxylation reactions are not limited to biological processes alone. Abiotic degradation 
procedures such as photolysis have been shown to produce hydroxyl TPs. For example, 
photolytic breakdown of diclofenac was reported to yield hydroxyl TPs (Petrovic & Barceló 
2007). Similarly, Salgado et al., (2013) and Diniz et al., (2015) both reported the hydroxylation 
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as a contributing pathway in the formation of 2-(8-hydroxy-3-oxo-3H-carbazol-1-yl)acetic acid, 
from the photolysis of diclofenac (Table 2.2). 
Table 2.2: Pathways of diclofenac transformation and TPs reported potency 


















































                                               
15 (Diniz et al., 2015) 
16 (Jelic et al., 2012) 
17 (Chiron, Minero, & Vione, 2006) 
18 (Tina Kosjek et al., 2009) 
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Nk – not known 
2.1.3.2 Ketone and Hydroxyl Function Groups Interconversions 
Interconversions of ketone and hydroxyl functional groups are reported in the literature. For 
example, androstenedione was formed by conversion of the hydroxyl group at C17 of 
testosterone to ketone and 17β-estradiol from estrone by the hydroxylation of the ketone group 
at C17 of parent estrone (Yang et al. 2011; Khanal et al., 2006; 2008). Conversly, 
backtransformation of 17β-estradiol to estrone by Sphingomonas sp. was reported by Kurisu 
et al. (2010) to occur by the conversion of the hydroxyl group at C17 to ketone, an oxidation 
pathway.  The unicellular algae Scenedesmus quadricauda was reported by Della Greca et 
al. (2008) and Yu et al. (2013) to transform 17α-ethinyl estradiol to 3-keto-17α-ethinyl estradiol  
by the oxidation of the hydroxyl group at C3 with a ketone group. Similarly, hydroxyl to ketone 
conversion at C17 of 17α-ethinyl estradiol by Sphingobacterium sp. was reported by Haiyan 
et al. (2007) as a contributory pathway in the formation of five TPs. Hydroxyl to ketone 
conversion at C3 and subsequent dehydrogenation at C1 and C2 can be observed in table 
2.1 to produce trendione from estrone. Biological conversion of hydroxyl groups to ketones is 
reported to yield tredione from 17β-trenbolone (Fig. 2.9) (Cwiertny et al. 2014; Forsgren et al. 
2014; Qu et al. 2013; Khan et al. 2008), thus showing that a given pathway can act with other 
pathways to produce the same TP from two different parent compounds. Another example of 
a ketone to hydroxyl interconversion is the contributory pathway in the formation of 3β-
Hydroxyl-5α-pregnan-20-one from P4. The hydroxylation of the ketone group in carbon 3 of 
P4 is followed by hydrogenation at C4 and C5 (Table 2.1). Hydroxylation of Ethinyl estradiol 
at C19 produced 17α-ethinyl-1-4-estradiene-10,17β-diol-3-one, a TP more estrogenic that the 




Figure 2.9: Interconversion of one metabolites of trenbolone acetate into the other by the 
oxidation of a hydroxyl group into a ketone and reduction of ketone to hydroxyl group, an 
oxidation/reduction pathway (Cwiertny et al. 2014; Forsgren et al. 2014) 
 
2.1.3.3 Hydrogenation 
Hydrogenation, the addition of hydrogen atom(s) to a compound is an important biological 
transformation pathway for pharmaceuticals. For example, Peng et al., (2014) reported algae 
mediated hydrogenation of carbon 4 and 5 of P4 and norgestrel to produce 3,20-
allopregnanedione and 4,5-dihydronorgestrel (Table 2.1). Hydrogenation of carbon 5 of P4 
was a contributing pathway in the formation of 3β-Hydroxyl-5α-pregnan-20-one. Similarly, 
hydrogenation of carbon 5 contributed to the formation of 5α-dihydrotestosterone from 
progesterone (Table 2.1). Hydrogenation like hydroxylation was reported to account for the 
formation of photolytic transformation products of diclofenac (Table 2.2), showing the 
versatility of the pathway to biotic and abiotic treatment processes. 
 
2.1.3.4 Dehydrogenation  
Dehydrogenation, the removal of hydrogen atom(s) from a compound, is another major 
pathway in the breakdown of pharmaceuticals. Boldenone (1-dehydrotestosterone) an 
anabolic agent exhibiting over 50% greater binding affinity to the androgen receptor relative 
to testosterone, is formed from a bacteria-mediated dehydrogenation reaction at carbon 1 of 
the parent molecule, at environmentally relevant conditions (Cwiertny et al., 2014; Yang et al., 
39  
 
2011). Boldenone thus has a double bond at C1 and C2 relative to testosterone (Fig. 2.10). 
This is a common transformation reaction occurring in natural and engineered systems. Table 
2.1 shows that an algal mediated dehydrogenation reaction has been reported to result in the 
formation of boldenone from both P4 and testosterone. In the formation of boldenone from P4, 
dehydrogenation was a contributory reaction pathway occurring before or after cleavage of -
COCH3 at C17 and its subsequent hydroxylation. Microbial (Nocardia sp.) mediated 
dehydrogenation of ring D of 17β-estradiol at C17 was a contributory pathway in the formation 
of estrone (Yu et al. 2013; 2007). 
 
 
Figure 2.10: Formation of boldenone from testosterone by dehydrogenation (cleavage of the 
hydrogen atoms) at carbons 1 and 2 (Cwiertny et al., 2014; Peng et al. 2014; Yang et al., 
2011). 
 
2.1.3.5 Side Chain Breakdown and other Pathways 
Side chain breakdown is one of the major contributing pathways in the formation of algae 
related TPs from P4 (Table 2.1). Dehydration, the loss of a water molecule is another 
biologically mediated pathway reported for the transformation of steroids. For example, 
dehydration of the D-ring in 17β-estradiol was reported by (Nakai et al., 2011) to result in the 
formation of estratetranol, a TP retaining parent compound’s estrogenicity. Nitrification, 
nitration, carboxylation and decarboxylation, dechlorination, deaklylation and lactam formation 
(Cwiertny et al., 2014; Kosjek et al. 2007; Kosjek et al., 2009; Qu et al., 2013) are examples 
of other biological mediated pathways not often reported in the literatures to account for 
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pharmaceutical transformation, perhaps because of their rare occurrence.  Nitrification and 
nitration (addition of a nitro group into an organic compound) are shown to produce two TPs 
(M324 and M340) from diclofenac in a membrane reactor treatment (Table 2.2).  
Other abiotic treatment processes are also known to produce potent TPs. For example, 
lumiesterone, a TP formed from epimerization reaction involving the photochemical inversion 
of the methyl group in C13 of estrone, is reported to be more photopersistent than estrone and 
retaining 40% estrogenicity of the parent compound (Trudeau et al., 2011; Whidbey et al., 
2012). Transformation by oxidative degradation is an important abiotic degredation process 
which may be chemically  or photolytically driven (Chen et al., 2012; Fayad et al., 2013; 
Frontistis et al., 2012; Lee & von Gunten, 2010; Wols et al., 2015, 2013). Common oxidants 
that have been used in the breakdown of pharmaceuticals include; chlorine, chlorine dioxide, 
ozone, hydroxyl radicals, ferrate (IV), potassium permanganate and hydrogen peroxide (Wols 
et al. 2015; Tisa et al. 2014; Fayad et al. 2013; Wols et al. 2013; Chen et al. 2012; Zhang & 
Geißen 2010; Lee & von Gunten 2010).  
 
2.2 Approaches to Studying Degradation and Identification of TPs 
Two major approaches (laboratory experiments and environmental screening) are generally 
followed in the study of pharmaceutical degradation and the subsequent identification of their 
TPs. For laboratory biodegradation experiments, samples can be provided directly from 
WwTPs or a pilot-scale WwTP or from natural waters (e.g. rivers) (Prasse et al. 2011; Helbling 
et al. 2010; Kern et al. 2009). The two identified approaches are not mutually exclusive but 
complimentary of each other. While laboratory studies offer the advantage of simulating 
degradation in controlled laboratory conditions with appropriate controls that can be compared 
to treatments, the results of such studies are most relevant if identified TPs are detected in 
environmental samples (Pico et al., 2015; Jelic et al. 2012; Trautwein and Kümmerer, 2012; 
Prasse et al. 2011). Bletsou et al. (2015) recommended that following preliminary laboratory 
studies (e.g. batch experiments), verification of results obtained should be carried out using 
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real environmental samples. Reason; the result of the latter, will demonstrate the relevance of 
the former and batch studies results can be reflected on in the design of environmental 
monitoring studies and in the development of risk mitigation strategies. However, as 
concentrations of TPs are usually lower in the environmental systems, coupled with the 
complexity of such samples, analytical methods must be adapted to obtain reliable results 
(see section 2.2.1 for further details). The advantage of transformation studies performed 
under well-controlled conditions compared to environmental screening is the relative ease of 
identification of unknown peaks (TPs). The number of chemically possible molecular formula 
and structures that could be assigned to an unknown detected peak, is limited to structures 
showing close relationship to the parent compound (Bletsou et al. 2015; Ruff et al. 2015; Hug 
et al. 2014; Krauss et al. 2010). Also, it is easy to eliminate non-relevant peaks from 
identification process, simply my comparison of the peaks detected in control sample with 
those found in test samples. Nature is known to synthesise a range of products due to its 
highly diverse microbial communities and the range of physical and chemical process 
occurring within it (Kind and Fiehn, 2006; 2010). Thus, attempts to identify unknown peaks in 
environmental samples with uncontrolled conditions is often very challenging involving several 
work intensive data collections and sophisticated processing steps often involving highly 
specialised instruments (Pico et al. 2015; Bletsou et al. 2015; Ruff et al. 2015; Hug et al. 2014; 
Lambropoulou and Nollet, 2014) which may be unavailable locally due to their high cost.   
The two identified approaches to studying pharmaceutical transformation, have been applied 
to studying a range of drugs. For example, Prasse et al. (2011), investigated the degradation 
of the antiviral drugs acyclovir and penicyclovir and their resultant TPs in a batch activated 
sludge experiment. Acyclovir was transformed into carboxyl-acyclovir by the oxidation of the 
hydroxyl group side chain in the compound into a carboxyl functional group. Carboxyl-acyclovir 
was reported to be detected in drinking water at a concentration of 40 ng/L (Prasse et al., 
2011). Penicyclovir was transformed into eight products by a number of pathways occurring 
alone or as contributory pathway(s). Reported pathways were; oxidation of hydroxyl and 
aldehyde groups, hydration and dehydration of hydroxyl groups, cleavage of a formaldehyde 
group and of an acetate group after β-oxidation. Another  example is the aerobic degradation 
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of the opium alkaloid, codeine, a process that yielded ten TPs that were subsequently detected 
in WwTPs effluents and surface water (Wick et al., 2011). Pathways reported to be responsible 
for the formation of codeine TPs were hydroxylation, oxidation into ketone, hydrogenation and 
dehydrogenation. Biotransformation of progesterone was reported to yield amongst others 
TPs testosterone and Boldenone (Peng et al., 2014), compounds that have been measured 
in surface waters (Ternes & Joss, 2006; Thomas et al., 2002). Reaction pathways reported by 
Peng et al. (2014) were side chain breakdown, hydroxylation, hydrogenation and 
dehydrogenation. These examples show the wider range of pathways which can create subtly 
different transformation products. Thus, understanding pathways could help more widely in 
understanding transformation. 
 
2.2.1 Analytical Procedure for the Detection and Identification of TPs 
Following degradation studies, a multistep workflow analytical approach is often applied to 
samples to detect and confirm the identity of TPs. Target analysis, suspect screening and non-
target screening are three main methods applied in the analysis of collected samples 
depending on the availability of reference standards for known TPs or prior knowledge of 
compounds suspected to be in samples (Fig. 2.11) (Zonja et al. 2014; Schymanski et al. 2014; 
Kind & Fiehn 2010; Kosjek et al. 2007). Achieving good results (peak detection, identification 
and confirmation) in the three analytical approaches mentioned above, could depend on the 
extraction procedures (sample extraction, enrichment/purification, chromatographic 
separation and ionisation) applied to cleaning-up samples and preconcentrating analytes prior 
to instrumental analysis (Ibáñez et al. 2012; del Mar Gómez-Ramos et al. 2011; Hernández et 
al. 2011).  These preceding analytical steps are significant in minimizing matrix (background) 
effects and its associated ion suppression especially in target analysis. For example, sample 
preparatory step was noted to be crucial in the target analysis of metabolites of the analgesic 
dipyrone in effluent samples and for the avoidance of assignment of erroneous identifications 
to detected TPs (Ibáñez et al. 2012).  A major drawback however in the application of sample 
extraction steps to degradation studies involving suspects and non-target screen, is the 
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potential loss of TPs due to breakthrough. These compounds are mostly unknown and 
therefore analytical standard are largely unavailable to understand their binding properties to 
sorbent materials, a factor critical to selecting solid-phase extraction (SPE) procedure and 
chromatographic column (Pico et al. 2015; Krauss et al. 2010; Kern et al. 2009). Thus, 
extraction procedures that have been applied by some researchers in transformation studies, 
are usually not sophisticated, but generic and robust since the physicochemical characteristics 
of the TPs are sometimes unknown (Pico et al. 2015).  Hydrophiliclipophilic balance reversed-
phase sorbents (e.g. Oasis HLB) are the most popular owing to their ability to retain several 
polar compounds. Oasis HLB sorbent is commonly used because of its hydrophilic–lipophilic 
balance, proven versatility and efficiency in the extraction of analytes of a wide range of 
polarities and acid/base characteristics at different pH values, including neutral pH (Bletsou et 
al. 2015; Jelic et al. 2012; Ibáñez et al. 2012; del Mar Gómez-Ramos et al. 2011; Genena et 
al. 2013; Pérez‐Parada et al. 2011; Hernández et al. 2011; Fatta-Kassinos et al. 2011; Kern 




Figure 2.11: Systematic Approaches to Studying Pharmaceutical Degradation and 
Comparison of Analytical Workflows for Target, Suspect and Non-Target Screening of 







2.2.1.1 Analytical Method Development and Validation 
Analytical approach to studying pharmaceutical compounds in water samples generally 
involve sample preparatory steps involving the extraction of a suitable volume of water for 
concentrating-up of desired analytes and the clean-up of matrix component to minimize matrix 
effect (interferences). This is followed by instrumental analysis for separation and 
quantification of analytes. The development of analytical methods for the analysis of 
pharmaceutical contaminants could be very challenging and time-consuming owing to the 
trace levels of these compounds in environmental samples. Furthermore, these 
micropollutants often occur as a complex mixture of a range of pollutants from different 
chemical classes with different chemical and physical properties (Al-Odaini et al. 2010). 
Extraction is usually performed by SPE utilizing different types of sorbent materials such as 
silica-based C18 and polymer sorbents (Togola and Budzinski, 2007; Gros et al. 2006). Oasis 
HLB and MCX are examples of polymer sorbents that have been widely applied in the 
extraction of pharmaceuticals from environmental samples (Al-Odaini et al. 2010; Kasprzyk-
Hordern et al. 2007; 2009a, b). Owing to its hydrophilic–lipophilic balance, Oasis HLB is a 
multipurpose and efficient sorbent for the extraction of pharmaceuticals with a wide range of 
polarities and pH values. The drawback however, with using multipurpose sorbents like the 
HLB is their less selectiveness which often can result either in lower SPE recovery or more 
likely, higher matrix effect in electrospray ionisation source (Al-Odaini et al. 2010; Kasprzyk-
Hordern et al. 2007; 2009a, b). 
Extraction recoveries are generally evaluated (validated) with field samples by comparing the 
concentration of an analyte found in a spiked sample matrix to its corresponding concentration 
in a reference sample of the same matrix (Pérez-Carrera et al. 2010; Al-Odaini et al. 2010). 
Replicates samples of a given matrix are spiked prior to extraction with a known volume of an 
analyte standard or standard mixtures of analytes. This is followed by the addition of an 
internal standard (I.S.) or a mixture of I.S. (determination of multiple analytes) to the spiked 
samples, also prior to extraction, to minimize matrix effect (Rodil et al. 2009; Jelic et al. 2009). 
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2.2.1.2 Target, Suspect and Non-Target Approaches to TPs Identification 
The invention of liquid chromatography tandem mass spectrometry technology (LC-MS), 
particularly the coupling of LC to high resolution mass spectrometers (LC-HRMS), has been 
very useful in the development of novel analytical methodologies for the detection and 
identification of TPs in mixture of polar micropollutants (known and unknown), present in very 
low concentration in complex environmental matrixes (Bletsou et al. 2015; Lambropoulou et 
al. 2014; Zonja et al. 2014; Schymanski et al. 2014; Krauss et al. 2010).  High resolution and 
accurate hybrid mass spectrometers have been applied in screening environmental samples 
via a range of analysis (target, suspect and non-target screening) and for the identification and 
structural elucidation of TPs. Examples of some commercially available mass spectrometers 
and their characteristic features in decreasing performance, are presented in Table 2.3 for 
ionic mass (m/z) range 300 - 400. 
Table 2.3 Commercially Available Mass Spectrometers and their Characteristic 









Fourier Transform Ion 
Cyclotron Resonance 
(FT-ICR) 
1,000,000 ≤1 104 Picogram (FS) 
Orbitrap 100,000 2 103 – 104 Femto – 
picogram (FS) 
Time-of-flight (ToF) 20,000 3 102 – 103 Picogram 
Quadrupole Ion Trap 
(QIT) 







50 104 Femto – 
picogram 
(SRM) 
 *FWHM: Peak Full Width at Half Maximum; FS: Full scan mode; SRM: Selected Reaction Monitoring 
 
Target analysis, the quickest and most reliable method of confirming the identity of TPs can 
be done with low (unit) resolution tandem mass spectrometers or in full-scan in high resolution 
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mass spectrometers, but is dependent on the availability of reference standard(s) (Evgenidou 
et al., 2015; Pérez & Barceló, 2007; Petrovic & Barceló, 2007; Pico et al., 2015). Target 
analysis, is based on the determination of already known TPs, and identification is carried out 
with standard solutions (Fig. 2.11). In this analytical approach, TPs can be concentrated by 
solid phase extraction due to the availability of reference standards. In target analysis, known 
TPs are included within a defined target list in an MS method and can be monitored in routine 
analysis. LC tandem triple quadrupole (LC-QqQ-MS/MS) is the most commonly used system 
in target analysis. The QqQ mass analyzer user-friendly interface allows application of MS/MS 
modes (e.g. selected reaction monitoring (SRM) of parent-precursor ion transitions). 
Monitoring in two transitions (MS/MS) instead of one is reputed for providing several 
advantages and interesting characteristics for target analysis, such as reduction in false 
positives, increased selectivity, reduced interferences and high sensitivity, which allows robust 
quantification (Bletsou et al. 2015; Ruff et al. 2015; Hug et al. 2015; Krauss et al. 2010). When 
high resolution mass spectrometer is used in target analysis, limitations of SRM analysis, 
which allows only the monitoring of selected TPs in target list, is eliminated and almost every 
compound present in a sample can be determined simultaneously with HRMS instruments 
operating in full-scan mode (Pico et al. 2015; Bletsou et al. 2015; Fenner et al. 2013; Krauss 
et al. 2010). This makes it unnecessary to pre-select compounds and associated SRM 
transitions. Using HRMS, target compounds included in a database are screened based on 
retention time, isotopic pattern, mass accuracy and MS/MS fragments (Agüera et al. 2013; 
Nurmi et al. 2012; Díaz et al. 2012). Furthermore, HRMS instruments higher resolution power 
make them capable of differentiating isobaric compounds with similar nominal mass but 
different molecular formula (Pico et al. 2015; Bletsou et al. 2015; Nurmi et al. 2012). When 
hybrid instruments are used, they offer the opportunity of data-dependent MS/MS acquisition, 
where MS transitions are triggered once a compound from a target-ion list is detected in the 
full scan (Bletsou et al. 2015; Krauss et al. 2010).  
Suspect screening as the name implies, involves screening samples for compounds 
suspected to be there based on prior knowledge of sample(s) origin and the probable sources 
of contamination of the sampled matrix. In suspect analysis, a list of possible degradation 
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product is put together from the literature or from prediction models (Prasse et al. 2011; 
Helbling et al. 2010). Suspect screening is the technique of choice, when the confirmation of 
TPs with no reference standard, but whose molecular formula and structure can be predicted 
(Fig 2.11). Examples of suspect TPs prediction models are EAWAG-BBD (recently replaced 
with enviPath in 2016) CATABOL, PathPred, Meteor (Wicker et al. 2016; Bletsou et al. 2015; 
Elis and Wackett, 2012). More details on these prediction tools are presented in section 2.3. 
The major drawback of this approach is its dependence on databases for information, that are 
usually very large, for the retention times, accurate mass spectra and isotopic patterns of 
suspected molecules and their fragments (Evgenidou et al., 2015). Following HRMS analysis, 
exact mass of each predicted TP is extracted from the chromatogram and compared with 
control samples. Unclear mass spectra are excluded by applying an intensity-threshold value 
that stretches mass spectra separating peaks of interest from background noise (Schymanski 
et al. 2014). Additionally, peaks of interest are further filtered by applying the most plausible 
retention time, isotopic pattern, ionization efficiency and fragmentation pattern using MS/MS 
or MSn (Li et al. 2014). Computer software such as MZmine (peak peaking) and enviMass 
(chromatograms processing) are used for data processing by noise removal and blank 
subtraction (Li et al. 2014). The level of confidence of suspect analysis method in the 
identification of TPs, is dependent on the extent to which the above-mentioned steps were 
followed. When all the above criteria are fulfilled, a probable structure is proposed based on a 
library-spectrum match or diagnostic evidence. If some steps are missed, unsure candidates 
or just clear molecular formulas will be the result of suspect screening (Schymanski et al. 
2014; Li et al. 2014). Some workers have applied the characteristic fragmentation pattern of 
TPs in their identification during suspect analysis. This approached is based on the underlined 
assumption that TPs bear structural resemblance to parent compounds and will therefore 
produce similar fragments ions (Bletsou et al. 2015; Kern et al. 2009). Accordingly, searching 
for specific fragment ions in MS/MS spectra throughout a chromatographic run and applying 
techniques such as mass-defect filtering run is reported to lead to new TPs (Ruff et al. 2015; 
Bletsou et al. 2015; Hug et al. 2014; Kern et al. 2009). 
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Non-target screening, unlike suspect screening involves screening for unknowns without any 
prior information on possible compounds (Fig. 2.11). Non-target screening and identification 
of unknown TPs is a challenging and time-consuming venture, but could be facilitated by the 
availability of information on the molecular formula, MS/MS spectrum, retention time and 
physicochemical data of potential parent compound (Evgenidou et al., 2015; Pico et al., 2015; 
Jeon et al. 2013). The confirmation of the identity of detected masses, assignation of molecular 
formula and reliable interpretation of the MS/MS spectra is highly dependent on instrument 
performance in producing high resolution, accurate mass and isotopic pattern data of detected 
TPs (Evgenidou et al., 2015). High resolution mass spectrometers e.g. triple quadrupole time-
of-flight mass spectrometers (QToF-MS), linear ion trap (QLIT) and more recently hybrid linear 
ion trap Orbitrap (LTQ-Orbitrap), a system that combines conventional ion trap system with 
an exact accurate mass analyser, are examples of high resolution MS instruments (Table 2.3). 
In the absence of an Orbitrap, QToFs are appraised for their suitability for identification of 
transformation products of organic compounds (Kosjek et al., 2007; Pérez & Barceló, 2007) 
due to their sensitivity in full scan mode, high mass resolution and the accuracy of mass data 
they generate. For example, Kosjek et al. (2009) used QToF to identify the TPs of diclofenac 
and clofibric acid following activated sludge treatment. ToF instruments measure the time it 
takes ions of different mass-to-charge ratios (m/z) to travel (accelerate) from the entrance of 
analyser where they are orthogonally fired in pulsated fashion to the detector. Upgraded 
versions of ToFs give fragmentation data to a precision in the low parts per million (ppm) range 
(<5ppm), data that are coupled with products ions accurate mass measurements for TPs 
identification and confirmation (Hug et al. 2014; Kind & Fiehn, 2010; Llorca et al., 2015).  
A major challenge however with the use of HRMS in non-target screen is the generation of 
huge amounts of data and their subsequent evaluation and results export (Llorca et al., 2015; 
Pico et al., 2015; Hug et al. 2014). Furthermore, their simultaneous operation in full scan and 
MS/MS modes produces a lot of data point in a single run. Post-acquisition data-processing 
tools such as XCMS, MetLin, MZmine, MassBank and enviMass are thus useful in providing 
rapid, accurate and efficient data mining (Bletsou et al. 2015; Evgenidou et al., 2015; Jeon et 
al. 2013). Mass Spectrometers vendors often provide associated data processing software, 
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such as MassHunter by Agilent Technologies, Metabolite Tools and Profile Analysis by Bruker, 
Applied Biosystems Data Explorer (MDS-Sciex Analyst QS), Waters MassLynx and 
MetaboLynx, Thermo Scientific Metworks and Sieve. The first and important step in the 
processing of non-target screen data, is peak picking, involving the comparison of peaks in 
the sample with control and the exclusion of irrelevant peaks (Bletsou et al. 2015; Krauss et 
al. 2010). This is followed by the elimination of noise peaks, mass recalibration and breakdown 
of isotopes and adducts into well-defined and easily identifiable units (Bletsou et al. 2015; Hug 
et al. 2014). Next, the Kind and Fiehn (2007) seven golden rules for heuristic (empirical) 
filtering of molecular formulas obtained by accurate mass spectrometry is applied for the 
assignment of molecular formula to the accurate mass of each peak (Bletsou et al. 2015; 
Krauss et al. 2010). Plausible structure for determined molecular formula is achieved via 
search of databases such as PubChem, NIST, ChemSpider and DAIOS database. The latter 
step often results in several hits which would therefore require ranking with obtained HRMS 
data (Krauss et al. 2010).  To facilitate the structural assignment process, parent compounds’ 
molecular formula and substructures information are useful in restricting the number of hits 
during databases search and possible structures are likely to be proposed for the unknown 
TP (Little et al. 2012; Müller et al. 2011; Krauss et al. 2010). It must be noted however that 
even after following strictly the above described steps in non-target screening, peaks 
corresponding to possible TPs can still be large, sometimes above a thousand. Thus, 
prioritisation of the most intense peak is generally recommended (Ruff et al. 2015; Bletsou et 
al. 2015; Hug et al. 2014; Schymanski et al. 2014). Like in suspect screening, the presence or 
absence of similar characteristic ions in parent and product fragmentation pattern, showing 
the stability or reactivity of certain parts of the molecule, often help to reduce the number of 
peaks (Agüera et al. 2013). Database generated structures are often ranked using a range of 
databases including MOLGEN-MS, MassFrontier, MetFrag, SIRIUS, MetFusion, ACD/MS 
Fragmenter including MassBank and MetLin (mentioned earlier) (Ruff et al. 2015; Bletsou et 
al. 2015; Hug et al. 2014; Schymanski et al. 2014). 
There are number of report in the literature on the successful application of the analytical 
approaches described above in the identification of photolytic and biotransformation products 
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of a range compounds including pharmaceutical. Hug et al. (2014) reported the application of 
suspect and non-target screening in the identification of a range of compounds including the 
herbicide clomazone and UV filter benzophenone-4, and benzothiazole in WwTPs effluent. 
Huntscha et al. (2014) successfully applied the above mentioned non-target workflow in the 
identification of biotransformation products of three benzotriazoles (1H-benzotriazole, 4-
methyl-1H-benzotriazole and 5-Methyl-1H-benzotriazole). Ruff et al. (2015) applied target 
screen in the measurement of a range of chemicals (artificial sweeteners, pharmaceuticals, 
pesticides) in surface water. The authors (Ruff et al. 2015) also applied non-target screen in 
the identification and confirmation of two substances (the relaxant tizanidine and the solvent 
1,3-Dimethyl-2-imidazolidinone) that had never been detected before in their studied river. 
Kosjek et al. (2007; 2009), reported the application of target and non-target screening in the 
identification of the biotransformation products of analgesics, antiepileptic and steroidal 
compounds. Evgenidou et al. (2015), Pérez & Barceló (2008; 2007) and Petrovic & Barceló 
(2007) all reported the application of the above analytical methods in the identification of TPs 
of drugs covering all therapeutic classes of pharmaceuticals. 
 
2.3 Biotransformation Prediction Tools 
Computer based predictive tools that help understand the fate and possible microbial 
mediated transformation of organic chemicals especially those of environmental concern, 
have been developed and applied as a high throughput and cost-effective approach to 
understanding environmental processes. Examples of such strategic predictive tool of the 
environmental fate of organic chemicals are; the EAWAG Biocatalysis/Biodegradation 
Database and Pathway Prediction System (http://eawag-bbd.ethz.ch), CATABOL 
(http://oasis-lmc.org/products/models/environmental-fate-and-ecotoxicity/catabol-301c.aspx), 
PathPred (http://www.genome.jp/tools/pathpred/) and very recently enviPath 
(https://envipath.org/). CATABOL and EAWAG-PPS predict microbial metabolic reactions 
based on biotransformation rules. The EAWAG BBD associated pathway prediction system’s 
free accessibility, clear assignation of biotransformation rule, relative ease of use and in 
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obtaining predicted TPs information (structure, molecular formula and mass number), makes 
it the most common tool used in suspect screening (Helbling et al. 2010; Kern et al. 2009, 
2010). PathPred performs a multi-step reaction prediction for the biodegradation pathways of 
xenobiotic compounds and biosynthesis pathways of secondary metabolites. PathPred is 
linked to the Kyoto Encyclopedia of Genes and Genomes (KEGG) metabolic pathway maps 
and thus, capable of linking predicted result to genomic information. Meteor 
(http://www.lhasalimited.org/products/meteor-nexus.htm), the Human Metabolome Database 
(HMDB) (http://www.hmdb.ca/) and KEGG (http://www.genome.jp/kegg/) are some examples 
of other predictive tools, but for the metabolic fate of organic compounds. For example, Meteor 
was built based on mammalian biotransformation reactions of common functional groups and 
allows for prediction of metabolic fate in mammals. The above mentioned predictive tools are 
used together with a range of other data processing software (MassHunter, MassBank, 
enviMass, MetLin, MZmine, MOLGEN-MS, MassFrontier, MetFrag, SIRIUS, MetFusion, 
ACD/MS Fragmenter) and molecular structure search databases (e.g. PubChem, NIST, 
ChemSpider and DAIOS) for the identification and confirmation of suspect and unknown TPs 
in HRMS (Evgenidou et al. 2015; Llorca et al., 2015; Pico et al., 2015; Bletsou et al. 2015; Hug 
et al. 2014). MassBank and MetLin are mass spectra library database that help rank candidate 
structures during suspect and non-target screening by comparing their mass spectra with 
pattern within database. MOLGEN-MS and MassFrontier helps with TPs identification by 
matching of a compounds fragmentation pattern with those in the database (Bletsou et al. 
2015). MetFusion combines fragmentation pattern and mass spectral search in structural 
elucidation of TPs. 
 
2.3.1 The EAWAG Biocatalysis/Biodegradation Database and Pathway 
Prediction System (EAWAG BBD/PPS) 
The EAWAG BBD/PPS, originally developed by the University of Minnesota and transferred 
to EAWAG, has been a unique prediction tool used since the past decade and half for the 
prediction of microbial transformation of xenobiotic compounds (Wicker et al. 2016; Ellis & 
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Wackett, 2012). The database was developed by compiling experimental results from 
published literature and from the Kyoto Encyclopaedia of Genes and Genomes (KEGG) of 
pathways of microbial (mostly bacterial) breakdown of chemicals of environmental relevance. 
Soil-based bacterial degradative metabolism dominates the information in the database, as 
bacteria represent a more diverse community, consisting of rugged strains, able to survive 
limited resource and constantly changing environmental conditions (Ellis & Wackett, 2012). 
The integrated Pathway Prediction System (PPS) predicts possible bacterial catabolic 
reactions using atom-to-atom mapping, substructure searching and, most especially, a 
biotransformation (bt) rule-based approach. Biotransformation rules which are updated 
periodically, are ranked “very likely”, “likely” and “unlikely” according to the likelihood of their 
occurrence during aerobic biodegradation. However, some anaerobes can tolerate oxygen to 
certain degree and thus survive in aerobic systems (Kato et al., 1997). A compound whose 
transformation pathway is to be predicted, is submitted to the pathway prediction system using 
its simplified molecular-input line-entry system (SMILES). For example, the SMILES for 
progesterone is 
CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C. 
Following the submission of a compound during each prediction cycle, the PPS examines and 
detects organic functional groups present in compound(s) submitted, and matches such 
functional groups to appropriate bt rules incorporated into the database from literature reports 
and/or from KEGG, and thus predicts possible degradation pathways based on built-in 
biotransformation rules. The prediction pathway terminates only when it reaches a compound 
listed as a termination compound by the PPS or when it reaches a compound that cannot be 
further degraded using existing bt rules. The EAWAG BBD/PPS prediction output for the 
pathway for progesterone transformation in the environment is illustrated in Fig 2.12 (only 
aerobically likely pathways) and Fig 2.13 (all available pathways). The aerobic likelihood of 
the formation of the predicted intermediate product was neutral indicating that there was a 
50% chance of its formation in aerobic and anaerobic systems. The implication is that, where 
the odds are against its formation in a given system (aerobic or anaerobic), subsequent TPs 
resulting from its breakdown, would not be produced. The same is true of the formation of 
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products 5 and 6. However, the aerobic likelihood of the formation of products 3 and 4 is ‘very 
likely’. The pathway of formation of product 3, a product that does not involve cleavage of the 
B ring (Fig 2.13) is aerobically unlikely thus showing it is a product from anaerobic degradation 
pathways. See Table 4.4 in the result section of this thesis for the name of products 2-6. 
 
Figure 2.12: Progesterone (1) microbial biotransformation pathway prediction results from 
EAWAG-PPS, http://umbbd.ethz.ch/predict/ (JobID 2017.04.08-04.48.16-24). Green arrows 
mean that associated product have a 100% likelihood of being formed in aerobic conditions. 
bt: biotransformation rules that resulting the formation of associated product(s). (bt0356: 
oxidation, aromatization and spontaneous ring cleavage; bt0036: aromatic Methyl to primary 




Figure 2.13: Progesterone (1) degradation pathway prediction results from EAWAG-PPS, 
http://umbbd.ethz.ch/predict/ (JobID 2017.04.12-12.26.26-50). Green arrows mean that 
associated product have a 100% likelihood of being formed in aerobic conditions. Yellow 
arrows indicate 50% likelihood of products formation under aerobic conditions. Red arrow 
indicates an anaerobic pathway. bt: biotransformation rules that resulting the formation of 
associated product(s). bt0291: Alkene to Alkane 
 
The EAWAG BBD/PPS thus provides useful information on genes, enzymes, and pathways 
involved in biological transformation of contaminants, enabling us to appreciate environmental 
transformation processes, identify potential TPs and predict chemical fate in the environment. 
In the environment, biodegradation reactions occur alongside a number of physical breakdown 
processes, such as photolysis and hydrolysis. These physical processes influence the extent 
to which transformation processes occur in the environment, and are also very relevant in 
understanding the fate of certain compounds, especially those originally designed to resist 
microbial degradation (Fatta-Kassinos et al., 2011). The bio-persistence of many organic 
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compounds, limits the extent of biological transformation processes in the environment. While 
biochemical reactions are governed by specific pathways and enzymes, non-biotic 
degradation processes are less guided. This is especially true if radicals are involved, resulting 
in many TPs due to the non-specificity of radicals mediated abiotic reactions (Fatta-Kassinos 
et al. 2011). Microbes in the environment are diverse and constantly evolving in response to 
the influx of new chemicals and changing environmental conditions. Thus, metabolic pathways 
built into prediction tools such as the BBD, based on available knowledge at the time of their 
design, may minimise or overstate the reactions that occur in the field. To illustrate, certain 
microbial genes that encode enzymes for metabolic breakdown of some compounds can 
evolve a range of new metabolic pathways, due to current environmental pressures, that have 
not been previously studied, but that allow for the metabolism of new chemicals or mixtures of 
chemicals (Ellis & Wackett, 2012; Copley, 2009; Seffernick & Wacket, 2001). 
Despite the aforementioned limitations, recent studies evaluating the performance of the 
EAWAG BBD in predicting real time metabolism of pharmaceuticals and other contaminants 
(including pesticides), have established its efficacy (Prasse et al. 2011; Helbling et al. 2010; 
Kern et al., 2009). For example, the EAWAG BBD was reported to have successfully predicted 
21 TPs out of the 26 TPs detected in a batch reactor experiment seeded with activated sludge 
(Helbling et al., 2010). Database predicted TPs which were the result of a two-step 
(intermediate and final products) aerobic prediction system were compared to non-target 
screening full scan mass spectrometry data. Batch reactors were individually spiked with six 
pharmaceuticals and six pesticides. 
 
2.3.2 The Environmental Contaminant Biotransformation Pathway 
(enviPath) 
The environmental contaminant biotransformation pathway (enviPath) is also a database and 
prediction system designed for the prediction of microbial biotransformation pathways of 
organic contaminants in the environment. enviPath, also a property of EAWAG, was 
developed as an improvement on the low selectivity of the existing EAWAG BBD/PPS 
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prediction pathways and a planned future replacement for the latter (Fenner et al. 2008; 
Wicker et al., 2016). Relative to its predecessor reported to predict a number of irrelevant 
transformation products that are unlikely to occur in the environment (Fenner et al., 2008), 
enviPath is believed to focus on key enzyme catalysed biotransformation reactions that 
organic contaminants undergo in the environment. enviPath uses the EAWAG BBD/PPS 
database of experimental results of organic chemical biodegradation as a basis, but improves 
on this by allowing individual users to populate the database with their own data so as to 
increase the versatility of its use. The goal is that enviPath would provide predictions that could 
inform bioremediation technologies and that can be applied in understanding the fate and risk 
of organic contaminants in the environment. The full detail of the design of enviPath is 
available in the supplementary information of Wicker et al. (2016). enviPath was not used in 
this work because it was launched at a late stage of the present study. However, it was used 
to model P4 degradation at a later stage in this work and associated results are presented and 
compared to those of the BBD in chapter five of the present work.  A review  of literature on 
evidence of enviPath application was not successful. Publications available either referred to 
the Eawag-Soil public database developed in enviPath, and containing all freely accessible 
regulatory data on pesticide degradation in laboratory soil simulation studies for pesticides 
registered in the EU (Latino et al. 2017), or applied EAWAG BBD and only passively 
mentioned enviPath as a new tool (Tratnyek et al. 2017; Çeçen, 2017; Letzel et al. 2016).  
 
2.4 Model Compounds 
2.4.1 Diclofenac 
Diclofenac (2-(2-(2,6-dichlorophenylamino)phenyl)acetic acid) (DCF) is a common over-the-
counter non-steroidal anti-inflammatory drug (NSAID) sold under various trade names such 
as Acoflam, Arthrex, Diclac, Dicloabac, and Voltarol (Vieno and Sillanpää, 2014). Diclofenac 
is used orally as tablets or applied topically as a gel. Table 2.4 presents some relevant 
physicochemical properties of the compound. Dissociation constant (pKa) and partitioning 
coefficients Kow (octanol-water coefficient) and Kd (solid-water distribution coefficient) of DCF 
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in different sludge types have been included in the table because they influence the 
compound’s removal during wastewater treatment, and in the environment. Bioconcentration 
factor (BCF, μg/g wet weight)/(μg/mL), a parameter that expresses a chemical’s concentration 
in an organism relative to its surrounding environment, has not been included in Table 1. This 
is because reported BCF for DCF vary depending on the test organism and the prevailing pH 
of the test medium. Bioconcentration factor is often used to represent regulatory classification 
of a compound’s potential for chronic toxic effects and/or biomagnification across a food chain 
especially in higher trophic levels (Gomez et al. 2010). This concept took on greater 
importance with the implementation of the European Union regulation on the Registration, 
Evaluation and Authorisation of Chemicals (REACH) and the Canadian assessment of 
chemicals on the Domestic Substances List (DSL) (Gomez et al. 2010). Bioconcentration 
factor is reported in varying units such as µg/mL, g/mL, g/L or kg/L (Ding et al. 2016; 2015; 
Brozinski et al. 2012; Kallio et al. 2010; Ericson et al. 2010). Some reports on diclofenac BCF 
are discussed in the fourth paragraph of this section of the thesis.  
Table 2.4: Physicochemical Properties of Diclofenac 
Parameter Value Reference 
Chemical formula C14H11Cl2NO2 Pubchem 
CAS number 15307-86-5 Vieno and Sillanpää, 2014 
Molecular weight 296.15 g/mol Pubchem 
Solubility in water 2.37 mg/L @ 250C DrugBank 
Dissociation constant (pKa) 4.15 DrugBank 
Octanol-water coefficient (Log Kow) 4.51 DrugBank 
Log Kd, primary sludge 2.7; 2.3 Ternes et al. 2004; Radjenovic 
et al. 2009 
Log Kd, secondary sludge 1.2; 2.1 Ternes et al. 2004; Radjenovic 
et al. 2009 
Log Kd, membrane bioreactor 2.3-2.5 Vieno and Silapanää, 2014; 
Radjenovic et al., 2009 
Log Kd, digested sludge 1.3-2.2 Vieno and Silapanää, 2014; 
Carballa et al. 2008 
  
Applying Rogers (1996) general rule of thumb in using KOW as an estimate of sorption (log KOW 
< 2.5: low sorption potential, 2.5 < log KOW < 4: medium sorption potential, and log KOW > 4: 
59  
 
high sorption potential), DCF will have a high potential for adsorption to the lipophilic cell 
membrane of microorganisms and to the organic fractions of sludge/sediment. However, the 
reported effects of environmental pH on pharmaceuticals physicochemical properties (e.g. log 
KOW, alteration in sorption behaviours) (Luo et al. 2014; Schäfer et al. 2011), could be applied 
to DCF. For example, a pH greater than the dissociation constant (pKa) of chemicals was 
reported to potentially alter their sorption behaviour (Luo et al. 2014; Schäfer et al. 2011). Luo 
et al. (2014) noted that a compound’s acidity (pH) (determined by its functional group) can 
modify its sorption or/and electrostatic interactions. Schäfer et al. (2011) indicated that at pH 
above the acid dissociation constant (pKa), pharmaceuticals and hormones hydroxyl 
functional group dissociates, making them negatively charged and facilitating charge repulsion 
with the negatively charged adsorbing surfaces. Thus, at pH > 4, charge repulsion can be 
expected to occur between DCF and the negatively charged membrane surfaces and limiting 
adsorption. Nevertheless, it is worth noting that adsorption of pharmaceuticals onto sludge 
can also be influenced by weak intermolecular forces such as Van der Waals forces (Hyland 
et al. 2012; Radjenović et al. 2009; Kulshrestha et al. 2004). For example, Kulshrestha et al. 
(2004) noted that oxytetracycline could sorb onto sludge even in the form of zwitterion (a 
neutral molecule with both positive and negative electrical charges), which implies that 
hydrophobic interactions with sludge matrix could occur despite the presence of ionic charges 
and/or low octanol–water partition coefficient (log KOW). Solid-water distribution coefficient (Kd) 
is another parameter used in the determination of pharmaceuticals partitioning between 
sludge and the water phase. For compounds with Kd values below 300 L/kg (log Kd < 2.48), 
their sorption onto sludge is considered insignificant while those with log Kd > 4 are considered 
to have high sorption potential (Luo et al. 2014; Tadkaew et al. 2011). Thus, the low log Kd for 
diclofenac indicates that it is not likely to adsorb to solids and be removed by primary treatment 
(sedimentation). 
Diclofenac is an environmentally relevant compound due to reports of its regular detection in 
the water environment and its adverse effects on aquatic species at environmentally relevant 
concentration ≤1.0 µg/L (Acuña et al. 2015; Diniz et al. 2015; Vieno and Silapanää, 2014). In 
the effluents of municipal wastewater treatment plants, DCF is among the most frequently 
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detected pharmaceuticals (Verlicchi et al., 2012). Verlicchi et al., 2012 reported a daily 
average mass load of 240 mg/L. Some reported lowest observed effect concentrations of 
diclofenac are presented in Table 2.5. During a review of the Water Framework Directive 
(200/60/EC), the European Commission panel included diclofenac and two estrogenic 
hormones in a watchlist of compounds that could be classified as hazardous environmental 
compounds, depending on results of a four-year EU-wide environmental risk monitoring 
campaign (EU, 2013). 
In addition to its toxic effects, DCF apparent high octanol-water partition coefficient (log KOW 
>4 (Table 2.4)) has raised concerns about its potential for bioconcentration in fish and the 
subsequent possibility for secondary poisoning within the aquatic food chain and arboreal food 
chain (through fish-eating birds) (Schwaiger et al. 2004). Generally, the BCFs of hydrophobic 
compounds are closely correlated with their octanol-water partition coefficient (log Kow) (Dai 
et al., 2013). Bioconcentration of DCF in some aquatic organisms including fish has been 
reported.  For example, a higher concentration of diclofenac relative to measured water 
concentration was reported in mussels (Ericson et al. 2010). At a water concentration of 1 
µg/L in an 8-day exposure study, the authors reported a bioconcentration factor of 175. 
Similarly, at a 1 µg/L aqueous DCF concentration in a 28 days exposure study, 
bioconcentration factors of 2732, 971, 763 and 69, were respectively reported for the liver, 
kidney, gills and muscle tissues of the rainbow trout (Brozinski et al. 2012; Kallio et al. 2010; 
Schwaiger et al. 2004). Following exposure to aqueous DCF concentration of 1.7 µg/L in a 10-
day exposure study, Kallio et al. (2010) reported bioconcentration factors in the bile of the 
rainbow trout in the range of 320–950. In another study however, the BCF of DCF in rainbow 
trout was reported to be below 10, and the authors noted that this represented no relevant 
bioconcentration in the trout (Memmert et al. 2013). The variation in reports on potential 
bioconcentration of DCF in fish tissues may be related to the effect of pH on DCF solubility 
and octanol-water distribution coefficient (the common method of BCF determination).  For 
example, Avdeef et al. (1998) reported a log KOW (octanol-water partition coefficient) of 4.51 
and 1.3 for nonionised DCF at pH 3 and 7 respectively. Scheytt, et al. (2005) reported a log 
KOW of 1.9 at pH 7.0. Thus, as suggested by Memmert et al. (2013,) a more objective estimate 
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of fish DCF bioconcentration by the octanol-water distribution coefficient, should consider 
environmentally relevant pH range of 6 to 9. 










28 days Changes in liver 
ultrastructures, liver 
glycogen 




96 hr Reduction of 
haemocyte (blood cell) 
viability; Oxidative stress 
with high lipid 
peroxidation* 
1 Acuña et al. 2015; 
Parolini et al. 2009; 












96 hr Changes in enzymatic 
activity 






96 hr Increases lipid 
peroxidation 






Reduction in lipid 
peroxidation 




48 hrs Increased mitochondria 
activity 
0.3 Acuña et al. 2015; 
Vieno and Silanpanää, 
2014; Feito et al. 2012 




8 days Adverse effects on byssus 
strength 
1 Ericson et al. 2010 
* Lipid peroxidation refers to the process in which free radicals "steal" electrons from the lipids in cell 




2.4.1.1 Environmental Occurrence of Diclofenac 
Measured concentrations of DCF in the water environment vary depending on the source and 
type of water environment; surface, groundwater or wastewater, with the highest recorded 
concentrations being in hospital and pharmaceutical manufacturers wastewater (Vieno and 
Silanpää, 2014; Sim et al. 2011; Zhang et al. 2008). Some reported concentrations of DFC in 
the water environmental are presented in Table 2.6. Generally, reported surface water 
concentrations are <0.1-0.5 µg/L (Hernando et al., 2006; Hilton and Thomas, 2003; Kim et al., 
2007; Lin et al., 2005; Rabiet et al., 2006; Vieno, 2007). However, there are cases were higher 
concentrations have been measured (Table 3). Groundwater concentrations are often below 
instrument detection limits, although there are also cases where high values have also been 
measure (Table 3) (Lin et al., 2005; Loos et al., 2010; López-Serna et al., 2013; Rabiet et al., 
2006). Comparing the measured environmental concentration of DCF (Table 2.6) and the 
reported low effect concentration (Table 2.5), it is apparent that concentrations often detected 
in surface and groundwater may represent a problem for aquatic biota, thus, lending support 
to the EU’s decision to include the compound in a watchlist of potentially hazardous chemicals. 
Table 2.6: Measured Environmental Concentrations of Diclofenac and its Metabolites 
Compound Type of water Source Conc. (µg/L) Reference 
DCF Wastewater Hospital 6.9 Sim et al., 2011 
DCF Wastewater Pharmaceutical 
manufacturers 
203.0 Sim et al. 2011 
DCF Wastewater Hospital/Municipal 0.2 Zorita et al., 2009 
5-OH-DCF Wastewater Municipal 3.7 Langford and Thomas, 
2011 
DCF Surface water Rivers 1.2 Ternes, 1998 
DCF Surface water  8.5 Scheurell et al., 2009 
3’-OH-DCF Surface water  0.3 Scheurell et al., 2009 
4’-OH-DCF Surface water  1.8 Scheurell et al., 2009 
DCF Groundwater  0.4 Lopez-Serna et al. 2013, 
Heberer, 2002 
4-OH-DCF Groundwater  0.2 Lopez-Serna et al. 2013 





2.4.1.2 Removal of Diclofenac During Biological Wastewater Treatment 
Diclofenac is a poorly biodegradable compound resulting in its low removal during biological 
treatment process (Vieno and Silanpaää, 2014; Lee et al. 2012). A pseudo-first order rate 
constant of 0.018d-1 (approximately a 40 days’ half-life) was reported for DCF under biotic 
conditions (Vieno and Silanpaää, 2014; Lee et al. 2012). A biological degradation constant of 
<0.1 L g–1ss d-1 has been generally assigned to DCF (Vieno and Silanpaää, 2014; Suárez et 
al. 2012; 2010; Zhang et al. 2008), indicating very slow to no biodegradation potential. The 
biodegradation constant (kbiol) is an estimate of a compound’s biodegradation potential 
considering a first order degradation reaction (Joss et al. 2006). This classification system 
which was first suggested by Joss et al. (2006), revised by Suárez et al. (2010) for measuring 
micropollutants biological degradation potential and applied to DCF, is presented below; 
kbiol <0.5 – hardly biodegradable 
0.5 < kbiol < 1 – moderately biodegradable 
1 < kbiol < 5 – highly biodegradable 
kbiol > 5 – very highly biodegradable 
Diclofenac biodegradation constants (kbiol value) for different treatment configurations are 
presented in Table 2.7. Where removal and length of study information are available for the 
treatment method reported, these have been included in the table. Examples of process 
configurations reported to influence DCF removal are; conventional activated sludge (CAS), 
biological nutrient removal (BNR), membrane bioreactor (MBR) and a moving bed biofilm 
reactor (MBBR) (Vieno and Silanpää, 2014). Operational and environmental conditions such 
as sludge retention time, hydraulic retention time, pH, temperature and presence or absence 
of oxygen, are other factors reported to influence DCF removal during biotic treatment (Vieno 
and Silanpää, 2014; Zhang et al. 2008). Generally, kbiol for DCF in different treatment systems 
(including anoxic conditions) is <0.5 indicating poor removal via biodegradation. However, 
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nitrifying conditions were reported by Suarez et al. (2010), to account for moderate 
biodegradation of DCF, perhaps by co-metabolism by ammonium monooxygenase enzyme. 
Nevertheless, kbiol value of 1.2 l g−1 SS d−1 was reported for DCF under aerobic nitrifying 
conditions, thus, suggesting a moderate to high biodegradation potential (Vieno and Silanpää, 
2014). Similarly, Tran et al. (2009) noted that DCF was moderately biodegradable when 
enriched nitrifying activated sludge was used (kbiol of 0.31–0.52 l g−1SS d−1). These reports 
highlight that biological elimination of DCF can be improved depending on the treatment 
process configuration and operational conditions. Extended sludge retention time (SRT), 
which facilitates the build-up of the slowly growing nitrifying bacteria population (reputed for 
removal of a range of micropollutants) will be an important operational factor in the biological 
elimination of DCF during wastewater treatment.    
Diclofenac however, has been shown to rapidly phototransform in environmental waters, 
although with concerns over the increased toxicity of its phototransformation products relative 
to the parent compound (Avetta et al. 2016; Dinz et al. 2015; Salado et al., 2013: Svanfelt, 
2013; Zhang et al. 2008). For example, Zhang et al. (2008) reported the rapid 
photodegradation of DCF, with a half-life of 1 hour when an aqueous solution was exposed to 
sunlight. Incubation of lake water, spiked with DCF, showed no degradation in the dark, but 
rapidly phototransformed (half-life: 1 hr) when exposed to sunlight (Buser et al. 1998). 
Table 2.7: DCF Biodegradation Constant and Removal in Different System 
Configuration 
Treatment System kbiol Study Length  % Removal  References 
CAS <0.1 > 28 days 1 - 4 Vieno and Silapanää, 2014 
MBR <0.1 - - Zhang et al. 2008 
Anoxic+Aerobic <0.1 - - Joss et al. 2006 
Anoxic 0.4 - - Suarez et al. 2012 
Nitrifying conditions 1.2 - - Suarez et al. 2010 
Nitrification culture 0.31-
0.52 
- - Tran et al. 2009 
Aerobic <0.1 55 hours 1-4 Vieno and Silapanää, 2014 




2.4.1.3 Human Metabolism and Metabolites of Diclofenac 
Globally, the annual consumption of diclofenac varies from country to country, and from 
individual to individual (Zhang et al., 2008). For clarity and where data are available, the World 
Health Organization (WHO) statistically standardized measure of drug consumption, defined 
daily dose, has been used in this work. The WHO defined daily dose for diclofenac is 100 mg 
(Vieno and Silanpää, 2014). Oral and dermal (topical) administration are the two forms of use 
of DCF with oral application being the dominant mode of use. Topically applied diclofenac gel 
is absorbed up to 6-7% by the skin and the remainder is washed off during bathing or adheres 
to clothing and is subsequently washed off during laundry (Davies and Anderson, 1997). 
Dermal use is reported to limit the bioavailability of the compound by 50% by by-passing 
metabolism in the liver (Zhang et al., 2008) and could therefore result in the greatest amount 
of parent DCF discharged into rivers (Heberer and Feldmann, 2005). Orally administered DCF 
is almost completely metabolised, with a reported half-life of 2 hours (Wishart et al., 2006), 
with <1% excreted as unmetabolized DCF (Vieno and Silanpää, 2014). Due to Phase I hepatic 
reaction (oxidation, reduction and hydrolytic cleavage) and Phase II metabolism involving 
glucuronic acid and taurine, metabolites, glucuronide and sulfate conjugates are formed 
(Davies and Anderson, 1997). About 11% of the daily administered DCF is eliminated from 
the body as conjugates and the remaining 88% as metabolites (Stierlin and Faigle, 1979). 
Generally, there is an increasing number of -OH groups (representing increased polarity and 
facilitating quick elimination from the body), but no apparent ring cleavage. Between 65-70% 
of DCF is excreted in urine and 20-30% in faeces as a mixture of parent DCF, conjugates and 
mostly metabolites. The metabolic pathway of diclofenac in the human body and resultant 




Figure 2.14: Metabolic pathway and metabolites/conjugates of diclofenac (Adapted from 
Davies and Anderson, 1997; Blum et al. 1996; Fiagle et al. 1988; Sterlin and Faigle, 1979; 
Steirlin et al. 1979) 
 
2.4.2 Propranolol 
Propranolol (hydrochloride, 1-(isopropylamino)-3-(1-napthyloxy)-2-propanol hydrochloride), is 
a beta-blocker and one of the cardiovascular pharmaceuticals used to regulate blood flow 
through arteries and veins in the heart (Dantas et al., 2010). It is widely used for the treatment 
of tremors, angina (chest pain), hypertension (high blood pressure), heart rhythm disorders, 
and other heart or circulatory conditions (Uwai et al. 2005). It is also used to treat or prevent 
heart attack, and to reduce the severity and frequency of migraine headaches (Dantas et al., 
2010; Uwai et al. 2005). The physicochemical properties of propranolol are presented in Table 
2.8. Environmental fate parameters (Log KOW and Log Kd) have been included. 
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Bioconcentration factor (BCF) discussed in the work, is not shown in the table for similar 
reason presented for diclofenac. 
Table 2.8: Physicochemical Properties of Propranolol 
Parameter Value Reference 
Chemical formula C16H21NO2 Pubchem 
CAS number 525-66-6 Lin et al., 2010 
Molecular weight 259.35 g/mol Pubchem 
Solubility in water 61.7 mg/L @ 250C DrugBank 
Dissociation constant (pKa) 9.42; 9.14 DrugBank; Balon et al. 1999 
Octanol-water coefficient (Log 
KOW) 
2.60-3.48 ChemSpider 
Log Kd, primary sludge 641 ± 478 L/kg Radjenović et al. 2009 
Log Kd, secondary sludge 320 ± 58 L/kg Maurer et al. 2007; Lin et al. 
2010; Alder et al. 2010 
 
Going by the earlier mentioned classification of chemical sorption potential based on the 
octanol-water coefficient (Rogers, 1996), the Log KOW of 2.60–3.48, indicates a medium 
potential for bioconcentration in aquatic biota and a moderate potential for sorption into sludge. 
Furthermore, the compound’s high log Kd values (>300 L/kg) indicates that sorption to sludge 
is an important removal mechanism during wastewater treatment. Due to ionization of the 
PRPL amino group, the compound will have positive charges when the pH of the solution it is 
found is below its pKa and then carries negative charge as the solution’s pH rises above its 
pKa (Deng et al. 2011; Hansen et al. 2006). Maurer et al. (2007) noted that PRPL is a weak 
base that becomes protonated and positively charged at environmental pH values of around 
7. 
Sorption of propranolol onto solids was reported to be influenced by pH and ionic strength. 
For example, the sorption capacity of PRPL onto acid-activated attapulgite clay was reported 
to be higher than the natural attapulgite (Deng et al. 2011). The authors attributed their 
observation to the non-electrostatic surface complexation, electrostatic interactions and cation 
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exchange properties of the acid-activated attapulgite. Attapulgite natural sorbent (crystalline 
hydrated magnesium silicate with a fibrous morphology) is reported to be a low-cost and 
environmentally more relevant sorbent relative to activated carbon (Wang et al. 2011; Liu et 
al. 2011). Significant removal (83%) of PRPL concentration by sorption into sediment was 
reported following a 14-day study with a half-life of 2.2 days (Lin et al. 2010).  Similarly, 
sorption potential was reported for low- and high-organic-content soils as well as in 
acclimatized and non-acclimatized activated sludge (Drillia et al. 2005; Daniel et al. 2005). 
These reports suggest that sorption will be an Important dominant removal mechanism for 
PRPL during wastewater treatment.  
Following a 24-hour Daphnia exposure study at aqueous PRPL concentration of 5 µg/L, a 
bioconcentration factor of 83 kg/L was reported (Ding et al. 2016). The importance for 
accounting for pH influences when assessing the bioaccumulation and ecological risks of 
PRPL, being an ionizable organic compound, was also highlighted in the Ding et al. 2016 
study. Propranolol BCF was reported by the authors to increase in Daphnia with increasing 
pH levels, ranging from 7 to 9. The authors also noted the influence of PRPL hydrophobicity 
(log Kow 3.48) on its bioconcentration potential. At a nominal PRPL concentration of 1 µg/L, 
Ericson et al. (2010) reported a BCF of 160 in the Baltic Sea blue mussels, Mytilus edulis 
trossulus following an 8 days exposure study. Following a 21 days exposure study, Giltrow et 
al. (2009) reported an increased plasma concentrations (340 µg/L) of PRPL in male fathead 
minnows exposed to nominal PRPL concentrations of 100 µg/L. At an aqueous PRPL 
concentration of 10 μg/L, a BCF of 103.4 was reported for algae following a 48-hour exposure 
study (Ding et al. 2015). 
Propranolol (PRPL) is relevant environmentally because it is regularly detected in the water 
environment, especially in wastewater (Godoy et al. 2015; Gros et al. 2010; Alder et al. 2010; 
Robert and Thomas, 2006; Thomas and Hilton, 2004) and reported to have toxic effects on 
aquatic organisms (Ribeiro et al. 2014; Huggett et al., 2002; Ferrari et al., 2004; Escher et al. 
2005; 2006). The reported daily loading rate of PRPL in WwTPs effluent was 0.39 ± 0.07 L d-
1 g-1 (Alder et al. 2010; Maurer et al. 2007). Alder et al. (2010) reported that PRPL was detected 
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in 40 German rivers studied, at median and maximum concentration of 0.012 µg/L and 0.59 
µg/L respectively. Similarly, Thomas and Hilton, (2004) reported a widespread detection of 
PRPL in UK rivers being present in approximately 90% of the rivers sampled (n=45) at a 
median concentration of 0.029 µg/L. Following a 3-year monitoring study, Gros et al. (2010) 
reported a 100 and 79% detection rate for PRPL in effluent and river waters respectively. In 
terms of ecotoxicological effects, Escher et al. (2005; 2006) demonstrated that PRPL inhibited 
the photosynthetic efficiency of the green algae Desmodesmus subspicatus at 
environmentally relevant concentrations. Ribeiro et al. (2014) reported the death of Zebra fish 
embryos and a decrease in sea urchin larva exposed to 125 µg/L of propranolol. Huggett et 
al. (2002) reported a decrease in the reproduction of Hyalella azteca (amphipod crustacean) 
at a PRPL concentration of 100 µg/L.  A 4-week propranolol exposure study, at concentrations 
as low as 0.5 μg/L, resulted in a decrease in the total number of eggs produced by Medaka, 
Japanese rice fish (Oryzias latipes) and the number of viable eggs that were hatched (Huggett 
et al. 2002). Table 2.9 presents a summary of the reported lowest observed effect 














Table 2.9: Lowest Observed Effect Concentration of Propranolol in Environmental 
Species 
Species Exposure time Endpoint Conc. 
(µg/L) 
Reference 
Daphnia magna 9 days Reduced growth 440 Dzialowski et al. 
2006 
Daphnia magna 9 days Reduced 
reproduction 
110 Dzialowski et al. 
2006 
Daphnia magna 9 days Changes in heart 
rate 




10 days Changes in 
feeding rate 
147 Solé et al. 2010 
Adult Mytilus 
galloprovincialis 




11 Solé et al. 2010 
Daphnia magna 21 days Increased 
reproduction 
50 Stanley et al. 
2006 
Pimephales promelas 48 hrs Decreased growth 1210 Stanley et al. 
2006 
Hyalella azteca 48 hrs Decreased 
reproduction 
100 Huggets et al., 
2002 
Ceriodaphnia dubia 48 hrs Decreased 
reproduction 
250 Huggets et al., 
2002 
Medaka (Oryzias latipes) 4 weeks Decreased 
reproduction 
0.5 Huggets et al., 
2002 
 
2.4.2.1 Environmental Occurrence of Propranolol 
Like most pharmaceutical compounds, measured concentrations of PRPL vary depending on 
water type with the highest concentrations being in wastewater influent and effluents. Some 
measured concentrations of PRPL in the environment are presented in Table 2.10. 
Concentrations in drinking water were generally below instrument detection limits and 
environmental concentrations of its metabolites are scarce in the literature. Overall, measured 
environmental concentrations of PRPL are below the reported LOEC values. However, 
constant input of the compound with effluent into the environment and PRPL potential for 
bioconcentration and subsequent bioaccumulation makes it a chemical of concern. 
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Table 2.10: Measured Environmental Concentrations of Propranolol 
Type of water Source Concentration (µg/L) Reference 
Effluent Municipal 0.3 Ternes, 1998 
Surface water WwTPs effluent 0.6 Ternes, 1998 
Effluent Municipal 0.3 Ashton et al., 2004 
Surface water WwTPs effluent 0.2 Ashton et al. 2004 
Effluent WwTPs effluent 0.4 Roberts and Thomas, 
2006 
Surface water WwTPs effleunt 0.1 Roberts and Thomas, 
2006 
Effluent Municipal 0.2 Fono and Sedlak, 
2005 
Surface water  <0.1 Fono and Sedlak, 
2005 
Effluent Municipal 0.2 Morasch et al. 2010 
Drinking water  <0.01 Morasch et al, 2010 
 
2.4.2.2 Removal of Propranolol During Biological Wastewater Treatment 
Poor biodegradability and incomplete removal during wastewater treatment is an important 
pathway of propranolol contamination of surface water (Godoy et al. 2015; Maurer et al. 2007; 
Bendz et al., 2005). For example, a Swedish report noted poor removal (32%) of PRPL 
following activated sludge treatment (Bendz et al., 2005). Gros et al. (2010) reported 0-20% 
removal for PRPL in various activated sludge treatment plants operated at hydraulic retention 
times ranging from 6-33 hrs. However, Radjenović et al. (2009) reported a 60% (conventional 
activated sludge) and 66-78% (membrane bioreactors) removal rate for propranolol, perhaps 
due to sorption into sludge and not microbial degradation. The authors however noted that 
operation of one of their membrane bioreactors at prolonged sludge retention time, was 
unfavourable for the elimination of PRPL. Kasprzyk-Hordern et al. (2009) reported a 35% 
removal rate for PRPL following activated sludge treatment. Furthermore, PRPL is reported to 
exhibit a high degree of persistence in surface waters (Maszkowska et al. 2014; Bendz et al., 
2005), a factor that may contribute to its frequent detection in surface waters. Maszkowska et 
al. (2014) reported that the half-live of propranolol in surface water at 25 °C could be >1 year 
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and that in addition to the compound’s high hydrolytic stability, relatively limited immobilization 
in natural soils and/or sediments may cause PRPL to accumulate in the aquatic environment. 
 
2.4.2.3 Human Metabolism and Metabolites of Propranolol 
In Europe, the use of beta-blockers varies across member states, with the UK reported to have 
the highest consumption rate (approx. 3.2 g cap−1 a−1) in 2001 (Alder et al., 2010). In 2004, 
Robinson et al. (2007) reported an estimated UK use of PRPL as 10,000 kg-1a-1. The WHO 
defined daily dose for propranolol is 160 mg (WHOCC, 2016). Propranolol is administered 
orally or intravenously. Following use, PRPL is completely absorbed and extensively 
metabolised with a half-life of approximately 4 hours, with only 1–4% excreted unchanged with 
faeces (Alder et al. 2010). Because of Phase I and II metabolisms in the liver, the remainder 
of the administered dose is extensively metabolized and metabolites including conjugates are 
excreted via urine (Masubuchi et al. 1994; Walle et al., 1985). Walle et al. (1985) noted that 
the primary metabolic pathways and their relative contributions were; glucuronidation (17%), 
side-chain oxidation (41%) and ring oxidation (42%).  Some reported metabolites of 
propranolol are; propranolol-glucoronide; 4-hydroxy-, 5-hydroxy-, 7-hydroxy-, N-
desisopropylpropranolol, propranolol glycol and naphthoxylactic acid (Figure 2.15) (Celiz et 




Figure 2.15: The metabolic pathways for propranolol reported in human, showing 
glucuronidation (1); side-chain oxidation (2); ring oxidation (3) and N-desisopropylation (4) 
(Celiz et al. 2009; Masubuchi et al. 1994; Walle et al., 1985; Paterson et al.1970) 
 
2.4.3 Fluoxetine 
Fluoxetine ((±)-N-methyl-3-phenyl-3-[(α,α,α-trifluoro-p-tolyl)oxy]propylamine) (FLX) is a 
prescription only antidepressant sold popularly as Prozac, and a member of the selective 
serotonin reuptake inhibitor (SSRI) drugs class (Hazelton et al. 2014; Morando et al. 2009). 
Fluoxetine is administered orally for the treatment of major depression along with panic, 
bulimia nervosa, obsessive–compulsive behaviours and premenstrual dysphoric disorders 
(Hazelton et al. 2014; Morando et al. 2009). Fluoxetine acts by strongly and selectively 
inhibiting a transporter enzyme for serotonin reuptake at the presynaptic membrane, causing 
an increase in serotonin (5-hydroxytryptamine) concentrations at postsynaptic receptor sites 
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(Vaswani et al. 2003; Wong et al. 1995). It is mainly metabolized by the cytochrome P450 
enzyme system in the liver to yield several metabolites including norfluoxetine (Preskorn et al. 
1997; DeVane, 1999; Benfield et al. 1986). Norfluoxetine (N-FLX) is a pharmacologically 
active metabolite known to inhibit serotonin uptake (Lister et al. 2009; Fong et al. 2008) and 
which compared to the parent compound, has a longer elimination half-life in both rats (7-15 
days) and humans (1-3 days) (Kwon and Armbrust, 2006; Brooks et al. 2003). The 
physicochemical properties of FLX are presented in Table 2.11. Relevant treatment and 
environmental fate parameters such as Log KOW, Log KOC and Log Kd have been included. 
Table 2.11: Physicochemical Properties of Fluoxetine 
Parameter Value Reference 
Chemical formula C17H18F3NO Pubchem 
CAS number 54910-89-3 IPCS INCHEM 
Molecular weight 309.33 g/mol Pubchem 
Solubility in water 50 mg/mL at 25 °C DrugBank 
Dissociation constant (pKa) 10.06 ± 0.10 Brooks et al. 2003 
Octanol-water coefficient (Log KOW) 4 - 4.35 Radjenović et al. 2009; 
Brooks et al. 2003 
Octanol-carbon coefficient (Log KOC) 3 – 4.50 Hyland et al. 2012; Brooks et 
al. 2003 
Sediment-water coefficient (Kd) 368 L/Kg Bringolf et al. 2010 
 
Fluoxetine is environmentally relevant because research has shown that the compound is 
regularly detected in the water environment (Fernández et al. 2010; Neuwoehner et al. 2009; 
Radjenović et al. 2009; Kim et al. 2007). For example, Radjenović et al (2009) reported that 
on an average, 13 g/day of FLX is discharge with effluent into surface waters.   Fluoxetine is 
reported to be relatively stable to hydrolysis, photolysis, and microbial degradation during 
engineered treatment and in the environment (Radjenović et al. 2009; Redshaw et al. 2008; 
Kwon and Armbrust, 2006). The compounds relatively high Log KOW, KOC and Kd indicates that 
adsorption to sludge and sediment will be an important removal mechanism during wastewater 
treatment and from surface waters.  Radjenović et al. (2009) and Redshaw et al. (2008) 
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independently reported that FLX partitioned extensively to sediment. Kwon and Armbrust, 
(2006) reported higher concentrations of FLX in sediment relative to the aqueous 
concentration, indicating persistence and potential for bioaccumulation across the aquatic 
food chain (through benthos feeders). Fluoxetine was detected in sediment at 968-fold higher 
concentrations relative to aqueous levels (Furlong et al. 2004). Following their 44-days 
laboratory based FLX fate and exposure study, Sánchez-Argüello et al. (2009) reported a 10-
fold higher concentration of FLX in sediment relative to overlaying water concentration. The 
authors noted that at a water concentration of 125 µg/L, approximately 900 µg/kg of FLX was 
measured in sediment. Partitioning of FLX is potentially dependent on the content of organic 
material in water and sediment. The presence of suspended organic matter (OM) enhances 
removal via adsorption, but on the other hand, high OM content in sediment can increase 
adsorption to sediment through covalently bound residues (Kwon and Armbrust, 2006) and 
results in persistence. Sorption of FLX to aerobic granular sludge was observed by Moreira et 
al. (2015) in a sequential batch reactor study. Like diclofenac and propranolol, pH was 
reported to alter the sorption properties of FLX. For example, Brooks et al. (2003a, b) predicted 
FLX log KOW at pH 2.0 and 11.0 to be 1.25 and 4.30 respectively. Also, at pH 7.0, log KOW for 
FLX have been variously reported as 1.57 (Brooks et al. 2003a), 1.8 (Huggett et al. 2004), 
4.05 (Christensen et al. 2007), and 4.51 (Lienert et al. 2007).  
Fluoxetine has been reported to potentially accumulate in organisms (Bringolf et al. 2010; 
Schultz et al. 2010; Chu and Metcalfe, 2007; Brooks et al. 2005; Furlong et al. 2004). For 
example, BCF values of 74 and 80 were measured for FLX and N-FLX after a 5-day exposure 
of the Japanese Medaka to FLX concentration of 0.64 μg/L (Paterson and Metcalfe, 2008). 
Meredith-Williams et al. (2012) reported a BCF of 185,900 for the freshwater shrimp 
(Gammarus pulex) at aqueous FLX concentration of 100 μg/L. Bringolf et al. (2010) and 
Schultz et al. (2010) independently reported the accumulation of FLX and N-FLX in freshwater 
fishes. Like diclofenac and propranolol, reported BCF values for FLX vary with pH. For 
example, Nakamura et al. (2008) reported BCF values of 330, 580 and 310 μg/L at pH 7.0, 
8.0 and 9.0 respectively for the Japanese Medaka exposed to 15 μg/L FLX concentration. 
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Brooks et al. (2003a, b) predicted BCF values for Medaka at pH 2.0, 7.0 and 11.0 following a 
four-week FLX exposure at 1 μg/L were 1, 2 and 1071.5. 
Fluoxetine and Norfluoxetine have been demonstrated to be toxic to aquatic biota (Hazelton 
et al. 2014; Mennigen et al. 2010; Fong et al. 2008; Brooks et al. 2003). For example, FLX 
was reported to induce disruption in movement and burrowing of freshwater mussels at 
concentrations of 2.5 and 23.3 μg/L (Hazelton et al. 2014). Some reported LOEC for FLX and 
N-FLX and their corresponding biological endpoints are presented in Table 2.12. 
Table 2.12: Lowest Observed Effect Concentration of Fluoxetine in Environmental 
Species 





FLX Embryos without shell 0.81 Santos et al. 2010 
Chironomus 
riparius 
FLX Reduced emergence 1120 Nentwig, 2007 
Danio rerio FLX Reduced egg production 
and decreased 17β-
estradiol levels 
0.32 Lister et al. 2009 
Ceriodaphnia 
dubia 
FLX Increased fecundity 56 Santos et al. 2010 
Daphnia mana FLX Increased fecundity 36 Flaherty and 
Dodson 2010 
Daphnia magna FLX Deformity and Mortality 36 Flaherty and 
Dodson 2010 
Oryzias latipes FLX Increased 17β-estradiol 
levels 
0.1 Foran et al. 2010 
Raphidocelis 
subcapitata 
FLX Growth inhibition 13.6 Santos et al. 2010 
Dreissena 
polymorpha 













2.4.3.1 Environmental Concentrations of Fluoxetine 
Measured environmental concentrations of FLX and its active metabolite N-FLX are mostly in 
the low nanogram per litre levels. Thus, concentrations of these compounds are presented in 
Table 2.13 in nanogram per litre (ng/L) concentrations compared to the units used for 
diclofenac and propranolol (µg/L). Measured concentrations in water are in the region of 50% 
of cases where effects have been observed. However, with the reported partitioning and 
persistence of FLX in sediment, targeted risk assessment of fluoxetine must consider water 
and sediment exposures for epibenthic and benthic (sediment dwelling organisms). 
Table 2.13: Measured Environmental concentrations of Fluoxetine and Norfluoxetine 
Compound Type of water Conc. (ng/L) Reference 
FLX Effluent 0.6-8.4 Vasskog et al. 2006 
FLX Surface water 1.7 Santos et al. 2010 
FLX Effluent 12 Fent et al. 2006 
FLX Surface water 0.42-1.3 Santos et al. 2006 
FLX Surface water 21.4 Bedner and MacCrehan, 2006 
FLX Surface water 12 Santos et al. 2010 
FLX Ground water 56 Fent et al. 2006 
FLX Drinking water 0.64 Santos et al. 2010 
N-FLX Effluent <0.54-2.4 Vasskog et al. 2008 
N-FLX Effluent 1.7-1.8 Santos et al. 2010 
N-FLX Surface water 1.2-1.3 Santos et al. 2010 
N-FLX Drinking water 0.77 Santos et al. 2010 
 
2.4.3.2 Removal of Fluoxetine During Biological Wastewater Treatment 
Kwon and Armbrust, (2006) reported that FLX was recalcitrant to microbial degradation. In a 
28-day biodegradation study, seeded with varied microbial concentrations, the fluoxetine 
concentration remained constant, and no metabolites were observed (Kwon and Armbrust, 
2006). Borges et al. (2009) reported a zero biotransformation of FLX by endophytic fungi. 
Similarly, Redshaw et al. (2008) reported that FLX and NFLX were not degraded in sewage 
sludge-amended soils or in liquid cultures supplied with sewage sludge-amended soils as 
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inoculum. Moreira et al. 2014 reported a biodegradation half-life of 18 days and a complete 
removal of FLX in 30 days when the compound was degraded with Labrys portucalensis F11, 
a microbial strain with the capacity to degrade a range of fluorinated aromatic compounds. 
There are, however, reports were modification of operation procedures and/or the use of 
supplement or consortia of microbes, has resulted in significant (>50%) and up to 100% 
biodegradation of FLX (Rodarte-Morales et al. 2011; Suarez et al. 2010; Vasskog et al. 2009). 
 
2.4.3.3 Human Metabolism of Fluoxetine 
Following oral administration, fluoxetine is almost completely absorbed into blood through the 
gut. Due to hepatic metabolism, the concentration of FLX is significantly reduced before it 
reaches the systemic circulation. (Hiemke and Härtter, 2000; Catterson and Preskorn, 1996). 
After consumption, FLX undergoes extensive metabolic conversion, leading to the active 
metabolite norfluoxetine, which can act as an SSRI with similar potency to that of fluoxetine, 
and the formation of multiple other metabolites (Fuller et al. 1992; Hiemke and Härtter, 2000). 
Fluoxetine and norfluoxetine are then excreted from the human body primarily through urine, 
with up to 11% of the administered fluoxetine dose being excreted as the unchanged parent 
compound, 7% as norfluoxetine (N-FLX) and 73% as a combination of other metabolites and 
conjugates (Zhou et al. 2009; Hiemke and Härtter, 2000; Preskorn, 1997; Altamura et al., 




Figure 2.16: Fluoxetine metabolic pathway showing N-demethylation (1); glucuronidation (2); 
O-dealkylation (3); Oxidative deamination (4) and oxidation (5). FLX and N-FLX are believed 
to undergo O-dealkylation to form para-trifluoromethylphenol, which is then subsequently 
metabolized to hippuric acid (Zhou et al. 2009; Hiemke and Härtter, 2000; Preskorn, 1997; 
Altamura et al., 1994; Wong et al. 1974) 
 
2.4.4 Progesterone 
Progesterone (P4), a C-21 progestational steroidal ketone (aka Pregn-4-en-3,20-dione), is 
secreted naturally by females (Besse and Garric, 2009). The production rate and blood plasma 
levels are highest in females of reproductive age and during pregnancy (Quinkler et al. 2002). 
The production rate varies from 92 to 563 mg/day and blood plasma levels during pregnancy 
vary from 21 to 200 ng/mL in humans and 7 to 25 ng/mL in animals (EMEA, 2004). During a 
woman's monthly menstrual cycle, an egg matures and is released from the ovaries 
(ovulation). The ovary then produces P4 that prevent further release of eggs and prepare the 
lining of the womb for a possible conception (Schumacher et al. 2004). If pregnancy occurs, 
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natural P4 levels remain high in the body, maintaining the womb lining. If pregnancy does not 
occur, progesterone levels in the body fall, resulting in a menstrual period. Progesterone is 
rapidly conjugated and excreted by the body (Besse and Garric, 2009). Since natural P4 is 
inactivated very rapidly in the body, several synthetic forms of P4 known collectively as 
progestins have been developed and are now widely produced and regularly used in oral 
contraceptive formulations and as part of hormone replacement therapy (Fayad et al., 2013). 
Worldwide, progestins are probably the most widely used of all steroids (Zhang et al., 2014; 
Dinger et al. 2007), as contraception methods that use them have been reported to be the 
most desired by patients (Fayad et al., 2013). Reported yearly use of P4 in France (2004) and 
Switzerland (2010) were 9864.25 and 495 kg respectively (Fent, 2015; Besse and Garric, 
2009). The increased use of synthetic progesterone (progestins) may partly be due to their 
superior effectiveness in the inhibition of pituitary gonadotropins relative to the natural P4 
compound (Dukes, 2003; Sitruk-Ware and Nath, 2010; Liu et al. 2011). Furthermore, their 
combination with certain estrogens in oral contraception formulations means consumers can 
have an all-in-one combination therapy. Literature available physicochemical properties of P4 
are presented in Table 2.14. 
Table 2.14: Physicochemical Properties of Progesterone 
Parameter Value Reference 
Chemical formula C21H30O2  Pubchem 
CAS number 57-83-0 Pubchem 
Molecular weight 314.46 g/mol Pubchem 
Solubility in water 8.81 mg/L at 25 °C DrugBank 
Octanol-water coefficient (Log KOW) 3.87 HSDB; Lui et 
al. 2009 
* HSDB – Hazardous Substances Database  
Progesterone is relevant environmentally because it has been measured in the water 
environment due to its incomplete removal during wastewater treatment, direct human and 
animal excretion and sometimes direct discharge of untreated wastewater (Liu et al. 2012b). 
Surface water runoff of farms with concentrated animal feeding operations was reported to 
result in P4 concentrations as high as 375 ng/L in receiving surface waters (Havens et al. 
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2010). Furthermore, P4 has been reported to have adverse effects on fish reproduction and 
chemoreception at environmentally relevant concentrations (Liang et al. 2015a, b; Murack et 
al. 2011; Havens et al. 2010; Kolodziej et al. 2003; Kobayashi et al. 2002). For example, long-
term exposure to environmentally relevant concentration (63 ng/L) of progesterone was 
reported by Liang et al. (2015) to affect sex differentiation (higher female population relative 
to male) in zebrafish (Danio rerio). A reduction in sperm motility was reported following a one-
week exposure of the male fathead minnows to a P4 nominal concentration of 300 ng/L 
(Murack et al. 2011). Furthermore, P4 was reported to cause substantial decrease in 
fertilization of the male fat head minnows following a 21 days exposure at concentration of 
1,000 ng/L (Havens et al. 2010). Following a 21-day exposure study, DeQuattro et al. (2012) 
reported a P4 dose-dependent (10, 100, and1,000 ng/L) decrease in fecundity and fertility in 
fathead minnow and significant reduction in gonadosomatic index and vitellogenin gene 
expression in females. Table 2.15 presents reported LOEC of P4. Surface water 
concentrations are around the LOEC values. Table 2.16 presents some measured 
concentrations of P4 in different water systems with the highest concentrations being in 




Table 2.15: Lowest Observed Effect Concentration of Progesterone in Aquatic Species 





Fecundity, reproduction 100 21 days Fent, 2015; 
DeQuattro et al. 
(2012) 
 Vitellogenin mRNA 
decrease 




500 4 hours Garcia-Reyero et al. 
(2013) 
 Reduced sperm motility 300 7 days Murack et al. (2011) 
Danio rerio Transcripts activity 2 48 -144 hours Zucchi et al. 2012 
 Sex ratio and transcript 
activity 
63 40 days Liang et al. 2015 
 Transcripts, gonado-
somatic index 
25 21 days Blüthgen et al. 2013 
 Transcripts activity 254 120 hours Blüthgen et al. 2013 
 Transcripts activity 3.5 14 days Zucchi et al. 2013 
 Vitellogenin protein 304 14 days Zucchi et al. 2013 
Gambusia 
affinis 
Transcripts activity 1000 8 days Huang et al. 2013 
Table 2.16: Measured Environmental concentrations of Progesterone 
Type of water Conc. (ng/L) Reference 
Surface water 5 - 199 Koplin et al. 2002 
Surface water 30.5 Fent, 2015; Liu et al. 2012a 
Surface water 1.7 - 3.5 Vulliet et al. 2008 
Surface water 5 - 27 Kolodziej and Sedlak, 2007 
River & Drinking water <0.24 –1.39 Kuster et al. 2008 
Sediment 6.82 López de Alda et al. 2002 
Snowmelt runoff 375 DeQuattro et al 2012 
Groundwater 2.1 – 4.8 Vulliet et al. 2008; Besse and Garric, 2009 
Effluent 1 Liu et al. 2012b 
Wastewater (farm) 3470 - 11900 Liu et al. 2012a 
Effluent 33 Pauwels et al. 2008 
Effluent 3.2 Pauwels et al. 2008 
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2.2.4.1 Removal of Progesterone During Biological Wastewater Treatment 
Progesterone is reported to be rapidly biodegradable in surface water and as having a high 
removal rate during engineered treatment (Peng et al. 2014; Liu et al. 2013; Chang et al. 2008; 
Esperanza et al. 2007; Labadie and Budzinski, 2005; Jenkins et al. 2004). More than 95% of 
progesterone was reported to be transformed by the two freshwater microalgae 
(Scenedesmus obliquus and Chlorella pyrenoidosa) following a 5 days study (half-life: 16 and 
39 hours respectively; rate constants: 0.044 and 0.018) (Peng et al. 2014). The authors noted 
rapid transformation of progesterone within the first 48 h, followed by a slow transformation. 
Progesterone was reported to be completely biodegraded in an aerobic system seeded with 
activated sludge (half-life: 4.3 hours) (Liu et al. 2013). Chang et al. (2008) reported a 90 – 96% 
removal of P4 following aerobic biological treatment. Similarly, Carson et al. (2008) and 
Jenkins et al. (2004) observed a complete microbial breakdown of P4 resulting in the formation 
of androgens that may retain biological activity. 
2.4.4.2 Human Metabolism of Progesterone 
Progesterone is metabolized extensively in the liver mainly by reduction and hydroxylation 
(Stanczyk, 2003; Grady et al. 1952). Metabolism by oxidation of the P4 side chain has been 
reported (Grady et al. 1952). Reduction occurs primarily on a double-bond of ring A and then 
on the ketone function of carbon 3 (Besse and Garric, 2009; Wasser et al. 1994). Natural or 
oral or intravenously administered progesterone (P4) (Kuhl, 2005) is transformed into a range 
of metabolites, excreted mainly free (rather than conjugated), with the conjugated metabolite, 
pregnanediol-glucuronide, reported in some studies (Stanczyk, 2003; Wasser et al. 1994; 
1996; Adlercreutz and Martin, 1980). Progesterone is reported to be transformed to two 
isomers of dihydroprogesterone, four pregnanolone isomers, and eight isomers of 
pregnanediol (Stanczyk, 2003). Stanczyk, 2003 further noted that about 35 identified and 
theoretical unconjugated metabolites of P4 that may be found in blood, urine, and/or faeces. 
Figure 2.17 present some examples of these metabolites including the reported conjugate.  
Progesterone metabolites are excreted mainly through faeces followed by urine. (Stanczyk, 
2003; Wasser et al. 1994; 1996; Adlercreutz and Martin, 1980).  Pregnanediol is the main 
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metabolite of P4 (Besse and Garric, 2009; Stanczyk, 1996) with a daily excretion rates ranging 
from 1 mg for men to 70 mg for pregnant women (Hardman et al.,1996). Pregnanediol is not 
reported to be pharmacologically active. However, some metabolites such as 17-
hydroxyprogesterone and 20α-dihydroprogesterone are noted to still display parental 
progestagenic activity (Besse and Garric, 2009).  
 
Figure 2.17: Progesterone metabolic pathway (Besse and Garric, 2009; Stanczyk, 2003; 
Wasser et al., 1994; 1996; Adlercreutz and Martin, 1980) 
 
2.5 Selection of a Model compound for Degradation Studies – 
Progesterone 
Progesterone was selected based on its rapid biodegradability relative to the other model 
compounds (compare sections 2.4.1.2, 2.4.2.2, 2.4.3.2 and 2.4.4.1) and its usage patterns 
globally. In the United Kingdom, it is used as part of, hormone replacement therapy (Lobo, 
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1992; Rosano et al., 2001), preventive measure of endometrial cancer (Gambrell et al. 1983), 
as palliative appetite stimulant for cancer patients (Kornek  et al., 1996) and for the treatment 
of dysfunctional uterine bleeding (Kumar et al., 2015; Wilkinson & Kadir, 2010). Furthermore, 
progesterone has been measured in wastewater/surface waters and reported to have effects 
on aquatic organisms (see Table 2.15). Previous studies at Brunel by Janna (2011) had 
identified that P4 degrades to below detectable concentrations over 72 hours, a timescale that 
allows for laboratory scale microcosm studies. The review of literature highlighted some likely 
transformation products of P4, but no studies were identified where progesterone degradation 
studies had been undertaken in environmentally relevant samples, such as surface waters. 
2.6 Techniques for Screening for Biological Activity 
The assays used in the present study for screening for progestogenic and androgenic activity 
were based on well characterised methods using genetically modified yeast (Saccharomyces 
cerevisiae). These assays have been used to evaluate the activities of steroids and surfactants 
in environmental samples (Gaido et al., 1997; Lorenzen et al., 2004; Purvis et al., 1991; 
Routledge & Sumpter, 1996; Runnalls, Beresford, Losty, Scott, & Sumpter, 2013; Sohoni & 
Sumpter, 1998).  
2.6.1 Recombinant Yeast Development 
Two genetically modified strains of the yeast Saccharomyces cerevisiae are generally used 
for screening for progestogenic and androgenic activities. These recombinant yeast strains 
are engineered respectively by integrating the DNA sequence of the human progesterone 
receptor (hPR) (Gaido et al., 1997) and human androgen receptor (hAR) (Routledge & 
Sumpter, 1996) into the yeast genome. This genetic engineering process is necessary as 
yeast cells do not inherently have hPR and hAR, genetic receptors that provide binding sites 
for the compounds of interest and thus help identify biologically active compounds. The 
suitability of Saccharomyces cerevisiae stems from its possession of certain expression 
plasmids that carry progesterone or androgen-responsive sequences. These responsive 
sequences control the expression of the reporter gene lac-Z, a gene responsible for producing 
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the enzyme β-galactosidase, used for measuring the activities of hPR and hAR. Upon binding 
the test compound otherwise referred to as ‘active ligand’, the progesterone receptor or 
androgen receptor interacts with transcriptional factors in the cell resulting in the expression 
of lac-Z and the subsequent secretion of β-galactosidase into the test medium. 
Testing for progestogenic or androgenic activities is usually performed by incubating the hPR 
and hAR cells in a test medium containing the test compound. Incubation is performed so that 
on interaction of the test chemical with the relevant receptors, β-galactosidase is synthesized 
and secreted into the medium, where it breaks down the chromogenic substrate in such 
medium.  Breakdown of the chromogenic substrate cause a measurable colour change from 
yellow to red. In the progesterone screen, the yellow colour comes from the production of 
orthonitrophenol, a yellow product resulting from the cleavage of 2-Nitrophenyl β-D-
galactopyranoside (ONPG) by β-galactosidase enzyme. The chromogenic material in the 
androgen screen is Chlorophenol red-β-D-galactopyranoside (CRPG).  The intensity of the 
colour change, is measured at absorbance of 420nm (P4) and 540nm (androgens) using 
Molecular Devices plate reader (kinetic microtiter plate reader). Progesterone or 
dihydrotestosterone is appropriately used as positive controls in each screen. The assays 
have been reported to show no activity at P4 concentrations below 10-8 M, approximately 3.15 
µg/L (Gaido et al. 1997; Sohoni & Sumpter, 1998) and androgen concentrations below 10-10 
M (Runnalls et al. 2013; Sohoni & Sumpter 1998). 
2.6.2 Standard Procedure for Assay Reagents Preparation 
2.6.2.1 Progesterone Screen (Lorenzen et al. 2004; Gaido et al. 1997) 
Selection Medium: 6.7 g of yeast nitrogen base with ammonium sulphate, 0.15 g of adenine, 
0.15 g of lysine, 0.08 g of tryptophan is dissolved in 900 ml double distilled water (ddH2O) and 
stirred. 45 ml of the medium is dispensed in solvent (ethanol) rinsed 100 mL bottle and 
autoclaved at 1210C for 15 minutes. 
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20% D-(+)-Glucose: 20 g of glucose is weighed and a final volume of 100 mL is made by 
adding ddH2O. The content is stirred well and autoclaved 1210C for 15 minutes. 
20mM Copper (II) Sulphate: 0.1596 g of CuSO4 is weighed and a final volume of 50 mL is 
made by adding ddH2O. The solution is then sterilised by filtering 5 mL aliquots into sterile 
glass bottles through a 0.2 µm pore size disposable syringe filter. Sterilisation is done inside 
a laminar air flow cabinet. 
10% SDS (Soduim dodecyl Sulphate): 10 g of lauryl sulphate is weighed and made up to 
100 mL final volume by the addition of ddH2O. The mixture is stirred and transferred into a 
100 mL sterile bottle. 
 Z-Buffer: 8.05 g Na2HPO4.7H2O, 2.75 g Na2HPO4.7H2O, 0.375 g KCl and 0.123 g 
Mg2SO4.7H2O are added to 400 mL ddH2O and stirred. The pH of the solution is adjusted to 
7.0. The volume is subsequently adjusted to 500 mL and autoclaved at 1210C for 15 minutes. 
Assay Buffer: Depending on the number of plates to be screened a given volume of 2 mg/mL 
2-Nitrophenyl β-D-galactopyranoside (ONPG, 98% purity) into a given volume of z-buffer. To 
illustrate, assume two plates are being screened, 48 mg of ONPG is added to 23.8 mL z-
buffer. In a similar vein, if a plate is being screened, 24 mg ONPG is added to 11.9 mL z-
buffer. To dissolve the ONPG, the mixture is vortexed and put in 280C shaking incubator for 
approximately 30 minutes. It is important to ensure that the ONPG is in solution before adding 
any other components. To complete the preparation of the assay buffer, 65 µL (2 plates 
screening) of 50mM 2-ME (2-Mercaptoethanol) and 240 µL 10% SDS are added and inverted 
to mix. The assay buffer is prepared just before use as it is stable only for an hour.  
Preparation and Storage of 10X concentrated yeast stocks 
Day 1: Growth medium is prepared by the addition of 5 mL glucose solution to 45 mL selection 
medium (SM) in a sterile conical flask (final volume was approximately 50 mL). 125 µL of 10X 
concentrated yeast stock from a cryogenic vial stored at -200C is added to the growth medium. 
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The medium is incubated at 280C for approximately 24 hours on an orbital shaker until it is 
turbid.  
Day 2: Freshly prepared growth media are added 50 mL each to two conical flasks. 1 mL of 
yeast from the 24 hours culture is added to each flask. These new cultures are incubated at 
280C for approximately 24 hours on an orbital shaker until culture is turbid. 
Day 3: The culture from the previous day is transferred to a sterile 50 mL centrifuge tube and 
centrifuged at 40C for 10 minutes at 2,000 g. The supernatant is decanted, and the culture 
resuspended in 5 mL selection medium with 15% glycerol (8 mL sterile glycerol/45 mL SM). 
0.5 mL aliquots of the 10X concentrated stock solution is then transferred to 1.2 mL sterile 
cryovials and stored at -200C. Short term storage should be at -700C/-800C for a shelf-life of 
3-4 months. 
2.6.2.2 Androgen Screen (Beresford et al. 2000; Sohoni and Sumpter et al. 1998) 
Selection Medium (pH 7.1): To 1 L of ddH2O, 13.61 kg KH2PO4, 1.98 g (NH4)2SO4, 4.2 g 
KOH pellets, 0.2 g MgSO4, 1 mL Fe2(SO4)3 solution (40 mg/50 mL H2O), 50 mg L-leucine, 50 
mg L-histidine, 50 mg adenine, 20 mg L-arginine-HCl, 20 mg L-methionine, 30 mg L-tyrosine, 
30 mg L-isoleucine, 30 mg L-lysine-HCl, 25 mg L-phenylalanine, 100 mg L-glutamic acid, 150 
mg L-valine and 375 mg L-serine, are added and place on heated stirrer to dissolve. 45 mL 
aliquots are dispensed into glass bottles and sterilised at 1210C for 15 minutes, and store at 
room temperature. 
D-(+)-Glucose: 20 g of glucose is weighed and a final volume of 100 mL is made by adding 
ddH2O (20% w/v). The solution is sterilised in 20 mL aliquots at 1210C for 10 minutes and 
stored at room temperature. 
L-Aspartic Acid: A stock solution of 4 mg/mL is made and sterilised in 20 mL aliquots at 
1210C for 10 minutes and stored thereafter in room temperature. 
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Vitamin Solution: To 180 mL ddH2O, 8 mg thiamine, 8 mg pyridoxine, 8 mg pantothenic acid, 
40 mg inositol and 20 mL biotin solution (2 mg/100 mL H2O). Solution is sterilised by filtering 
through a 0.2 µm pore size disposable syringe filter in a laminar air flow cabinet. 10 mL aliquots 
of the solution were filtered into sterile glass bottles and stored at 40C. 
L-Threonine: A stock solution of 24 mg/mL is prepared. The solution is sterilised in 10 mL 
aliquots and stored at 40C. 
Copper (II) Sulphate: A 20mM solution is prepared and sterilised by filtering through a 0.2 
µm pore size disposable filter in a laminar air flow cabinet. 5 mL of the solution is filtered into 
sterile glass bottles and stored at room temperature. 
Chlorophenol red-β-D-galactopyranoside (CPRG): A stock solution of 10 mg/mL is made 
and sterilised by filtering through a 0.2 µm pore size disposable syringe filter into sterile glass 
bottles, in a laminar air flow cabinet and stored at 40C. 
Preparation and Storage of 10X concentrated yeast stocks 
Day 1: Growth medium is prepared by the addition of 5 mL glucose solution, 1.25 mL L-
aspartic acid solution, 0.5 mL vitamin solution, 0.4 mL L-threonine solution and 125 µL copper 
(II) sulphate to 45 mL minimal medium in a sterile conical flask (final volume is approximately 
50 mL). 125 µL of 10X concentrated yeast stock from cryogenic vial stored at -200C is added 
to growth medium. The medium is incubated at 280C for approximately 24 hours on an orbital 
shaker until it is turbid.  
Day 2: Freshly prepared growth media are added 50 mL each to two conical flasks. 1 mL of 
yeast from the 24 hours culture is added to each flask. These new cultures are incubated at 
280C for approximately 24 hours on an orbital shaker until culture is turbid. 
Day 3: The culture from the previous day is transferred to a sterile 50 mL centrifuge tube and 
centrifuged at 40C for 10 minutes at 2,000 g. The supernatant is decanted, and the culture 
resuspended in 5 mL minimal medium (MM) with 15% glycerol (8 mL sterile glycerol/45 mL 
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MM). 0.5 mL aliquots of the 10X concentrated stock solution is transferred to 1.2 mL sterile 


























Analytical method development is a critical component in analytical chemistry. The 
effectiveness of the process determines the reliability of data generated from the final 
analytical procedure and the quality of conclusions reached based on such data. This chapter 
presents the detailed analytical methods/procedures that were developed and applied for data 
acquisition in this research. Some of the methods described in this chapter have been 
published (see appendix). The standards and reagents used and their purity are presented. 
Sample preparation procedures and analytical instrumental methods used are also described. 
Field work and details of laboratory degradation study performed are presented. 
 
3.1 Reagents  
All analytical standards including deuterated internal standards used were greater than 98% 
in purity. Progesterone (P4) was purchased from QMx, (Essex, UK). Diclofenac sodium salt, 
Fluoxetine hydrochloride and Propranolol hydrochloride were purchased from Sigma Aldrich 
(Gillingham, UK). Table 3.1 provides summary information on the standards used. Isotopically 
labelled progesterone (P4d9) was used during the analytical method development stage of this 
study as the sole internal standard (IS) for the quantification of all compounds of interest. P4d9 
was purchased from Sigma Aldrich (Gillingham, UK). Summarised information on P4d9 is also 
presented in table 3.1. All reagents (Methanol and Acetonitrile) used were HPLC grade. 
Reference standards were made in methanol purchased from Rathburn Chemicals 
(Walkerburn, UK). Reagent grade MilliQ water (18.2MΩ) (Millipore, Watford, UK) was spiked, 
used as blank and for the preparation of standards. Ammonium hydroxide (NH4OH) and formic 
acid used for aqueous phase preparation were also purchased from Sigma Aldrich 
(Gillingham, UK). The ammonium hydroxide and formic acid used were TraceSELECT ultra 
and reagent grades respectively. Acetonitrile (Rathburn Chemicals (Walkerburn, UK)) and 
methanol were used for elution of target analytes during solid phase extraction. 
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Individually, standard stock solutions of model compounds and the isotopically labelled 
internal standard (P4d9) were prepared on weight/volume (w/v) basis in methanol. A 1000 mg/L 
individual stock of each compound was prepared by dissolving 10 mg of the standard in 10 
mL methanol respectively. A 10 µg/mL (10,000 ng/mL) sub-standard of each compound was 
prepared by 1-100 dilutions. Four sub-standards namely; 1000 ng/mL; 100 ng/mL; 10 ng/mL 
and 1 ng/mL were respectively prepared starting with the 10 mg/L sub-standard for each 
compound through serial dilution (precisely 1-10 dilutions with each new standard serving as 
the stock for the next). Similarly, an 800 ng/mL (0.8 µg/L) sub-standard of P4d9 was prepared 
by appropriate dilution (10 µL in 12.5 mL) of stock solution in methanol. Prepared standards 
were stored at -200C for preservation. Prepared standards were used within two weeks and 
new ones prepared following every field work and laboratory degradation study. 
For the analysis of field samples, a series of five-point working (calibration) standards ranging 
from 1 - 100 ng/mL and containing all four analytes and 200 ng/mL (0.2 µg/L) IS respectively 
were prepared in chromatographic vials by appropriate dilution of sub-standards with 
methanol/water (50/50, v/v). For the analysis of samples from laboratory based degradation 
study, another five-point calibration standard ranging from 0.25-2500 ng/mL, each containing 
200 ng/mL of the IS was also prepared. Working standards were freshly prepared for each 




Table 3.1: Summarized information of Analytical Standards 
Compound Abbr. CAS a,d Mol. Wt.  
a,b,d 
Formulaa,d pKaa,c,e IUPAC Name a,d Structure a,d 
Progesterone P4 57-83-
0 
314.46 C21H30O2 - Pregn-4-ene-3,20-
dione 
 
Progesterone d9 P4d9 15775-
74-3 






















a: DrugBank; b: Chemspider; c: TOXNET; d: Sigma-Aldrich MSDS; e: Brooks et al. 2003 
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Table 3.1: Summarized information of Analytical Standards (continued) 
Compound Abbr. CAS a,d Mol. Wt.  
a,b,d 
Formula a,d pKaa,c IUPAC Name a,d Structure a,d 
Diclofenac 
Sodium Salt 





a: DrugBank; b: Chemspider; c: TOXNET; d: Sigma-Aldrich MSDS
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3.2 Method Development 
3.2.1 Solid Phase Extraction (SPE) 
Solid phase extraction (SPE) was performed using Oasis HLB (500mg, 6cm3) cartridges 
purchased from Waters Ltd. (Watford, UK). In this work, only Oasis HLB cartridges were used 
for extraction of target analytes although a common procedure is to examine different 
cartridges for best recoveries. Oasis HLB was the sorbent selected because of its hydrophilic–
lipophilic balance, proved versatility and efficiency in the extraction of analytes of a wide range 
of polarities and acid/base character at different pH values, including neutral pH (see section 
2.2.1) The SPE protocol was optimized through several preliminary experiments involving the 
following; 
 Eluting with different types of solvents (Methanol and Acetonitrile) to determine which 
gave better recovery. Methanol and Acetonitrile are the most widely reported solvents 
for the elution of model compounds.  
 Eluting with a different volume (4 mL and 8 mL (2 x 4mL)) of selected eluent to 
determine which volume gave better recovery. The two solvent volumes used are 
those commonly reported in the literature. 
 Spiking different volumes (0.5 and 1 Litres) of MilliQ water respectively with 0.1mL of 
10 µg/mL mixture of all four pharmaceuticals. This was performed to determine if 
loading a high volume of sample into Oasis HLB resulted in loss of any of the analytes 
of interest due to breakthrough. This is with a view to determining what volume of field 
sample to extract assuming that distribution of a given analyte in a sample, may not 
be even. 
 Sample loading rate was adjusted manually (timed) to have a fast (5 mL/min) and slow 
flow (2 mL/min) rates to determine which gave a better recovery. 
 The comparable effects of drying samples down and re-concentration with a given 
volume of solvent sample vis-à-vis samples used wet (not dried down), on the 
percentage of any given analyte recovered following extraction was tested. Sample 
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drying is a recommended step for concentrating up analytes for target analysis but 
uncertain for suspect and non-target screening. 
The investigation of the first four SPE condition above, worked with high concentrations of 
each compound (100 µL of 10 mg/L standard mixture of all model compounds in 500 mL milliQ 
water), such that sample drying and concentrating up was not necessary. Spiking with high 
concentration of analytes was performed to determine if locally available mass spectrometer 
(unit resolution) was sensitivity enough to detect and quantify analytes of interest when sample 
extraction step is not done prior to instrumental analysis. This investigation was important as 
the plan was not to extract degradation samples prior to instrumental analysis for suspect and 
non-target TPs based on the drawback highlighted in section 2.2.1, the potential loss of TPs 
due to breakthrough as the binding properties of these TPs to sorbent materials are largely 
unknown, a factor critical to selecting solid-phase extraction (SPE) procedure. Furthermore, 
there will be uncertainty in results obtained for presence or absence of TPs when SPE is 
applied. If not detected, it would be thought that they were present but lost during extraction 
process. Prior to sample loading, each cartridge was conditioned with 5 mL of MilliQ water 
and the respective eluent to be used. This was done to activate by protonation the strong 
cation-exchange sulfonic acid groups in each sorbent surface. 
For the investigation of the best type of eluent to use, 4 mL of methanol and acetonitrile were 
used respectively for elution of cartridges. Thus, the representative concentration of individual 
compounds in the 4 mL extract (eluate) was 0.25 µg/mL. Concentration of analytes in 
chromatographic vial was 0.125 µg/mL, as this represented a 50:50 dilution of the eluate 
sample with double deionised water. Following the determination of what eluent (methanol) to 
use, the best volume of MeOH to use for elution was investigated by eluting cartridges with 4 
mL and 8 mL (i.e. 2 x 4 mL) of methanol respectively. Subsequently, different volumes (0.5 
and 1 L) of MilliQ were respectively spiked with 100 μL of the analytes mixture to investigate 
the relative effects that loading varying volumes of a sample will have on analytes recovery. 
Following this, loading rates were adjusted for the optimal sample volume determined to see 
what effects this will have on recovery.  
98  
 
For the investigation of the last SPE condition, 0.5 L of MilliQ water was spiked with 10 µL of 
the standard mixture of all model compounds, a much lower concentration relative to the initial 
studies, since model compounds are often present at very low concentrations in the 
environment and sample extraction was to be performed. This last SPE optimization protocol 
was performed because of the planned measurement of model parent pharmaceuticals in reed 
beds. Accordingly, 0.5 L of MilliQ water was spiked with 10 µL of the 10 mg/L standard mixture 
of all model compounds. Cartridges were eluted with 8 mL (2 x 4mL) of MeOH, such that 
concentration of analytes in eluent was 0.125 µg/mL. Extracts were then dried under a gentle 
stream of nitrogen gas and reconstituted to 1.2 mL with a mixture of methanol and water (50/50 
v/v). A representative concentration of 0.08 µg/mL was thus expected for individual analytes 
in the chromatographic vial. Analytical results for concentrated samples were compared to the 
non-concentrated samples where 0.5 L of MilliQ water was spiked with 100 µL of 10 mg/L 
standard mixture of all model compounds. 
 
3.2.2 SPE Method Validation 
The SPE conditions developed were validated using wastewater influent and effluent sampled 
from pilot scale reed beds at a sewage treatment works (see section 3.2.2.1 for description of 
sample pilot reed bed). An additional aim of this validation exercise, was to determine the 
number of TPs that will be detected in samples, seeing that SPE extraction step is applied to 
samples processing and considering that the concentrations and degradability of some of the 
model compounds. Seeing that P4 degrades rapidly relative to the other model compounds 
(see section 2.4), attention was focussed on the number of detected P4 suspected TPs in the 
reed beds’ samples. Wastewater samples were collected in amber coloured bottles pre-rinsed 
with MilliQ water and immediately transported to the laboratory for analysis. Samples were 
manually extracted using vacuum manifold and with Oasis HLB cartridges (500 mg/6cm3) after 
the addition of the internal standard. Pilot scale reed beds sampling was undertaken on 30th 
March 2015 at Severn Trent sewage treatment works (STW) located in Barston. The primary 
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aim of this sampling session was the validation of the developed SPE method, establishing 
the concentrations of target parent compounds in influent and final effluent of reed beds. The 
secondary aim was to determine reed bed performance in removing model compounds. 
However, because spot samples (zero hydraulic retention time) were taken at the in/out of 
reed beds and further access to site was not possible, the results presented for performance 
of reed beds will require further study to verify their reliability. Two litres (2L) samples were 
respectively taken in triplicate. Samples were divided into two groups. One group was spiked 
with a 100 µL of a 10 µg/L concentration of the target pharmaceutical mix and the other group 
were not. Before field samples were extracted, they were respectively spiked with 0.1 mL of 
0.8 µg/L of the IS (P4d9) as the quantitation method used in this study was based on internal 
standard calibration. Addition of the IS was done to correct for any losses in extraction and 
matrix effects that could result in suppression or enhancement of ion signal (Note: SPE 
method development was done with distilled water and no IS was used). Initial work in reed 
beds used P4d9 as a sole IS, with the intention that further work will use compound specific 
IS, which were not available at the time the first sampling was carried out. The sole use of one 
IS was thought to lead to some bias, in that we were correcting for recovery using a compound 
with different characteristics, which may respond differently in different matrices. Extracts were 
dried under a nitrogen stream and reconstituted to 1.2 mL with a mixture of methanol and 
water. Percentage recovery and reed bed performance for removal of target compounds were 
calculated using the mathematical relations below; 
 
Equation 1: Analyte Recovery (%) 
 
Equation 2: Model Compounds Removal Efficiency (%) 
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3.2.2.1 General Process Description of the Barston STW 
The STW used biological trickling filter technology for the treatment of sewage. The operating 
procedure involved continuous spraying (trickling) of post primary sedimentation sewage from 
a settlement tank through the surface of a fixed filter bed filled with gravel to which 
approximately 0.1 - 0.2 mm thick biofilm layer had grown over time. With the help of the good 
oxygenation provided by the rotating sprinkler, favourable aerobic conditions were created in 
the filter, which allows the aerobes in the thin layer of biofilm to oxidize organic compounds 
present in sprinkled wastewater to water and carbon dioxide, raw materials that support further 
photoautotrophic production of new biomass. 
Pilot scale vertical subsurface flow reed beds used as a tertiary treatment step for polishing 
effluents prior to discharge were sampled. They were 2.5 m x 2.5 m x 1m high (area: 6.25 m2) 
in size. The reed bed composition from bottom up were; drainage, 0.15 m of large gravel 
(diameter: 16 to 32 mm), transition, 0.10 m of pea gravel (diameter 4 to 8 mm), main layer, 
0.5 m of concrete sand (<4 mm) and the remaining 0.25 m was freeboard. Influent loading 
rate was 0.4 m3/m2/day. 
 
3.2.3 Chromatography and Mass Spectrometry Analysis 
Samples were analysed using high performance liquid chromatography (HPLC) coupled to a 
triple quadrupole mass spectrometer using an electrospray ionisation source. A high-
resolution Agilent 6540 accurate-mass quadrupole time-of-flight mass spectrometer was used 
for accurate mass analysis. The two mass spectrometers used are described in detail in 
sections 3.2.3.2 and 3.2.3.3. Agilent MassHunter software and Analyst software 1.4.2 (Applied 
Biosystems, Warrington, UK) were used for data acquisition and evaluation as well as 
instrument control. HPLC analysis was performed using an ACE C18 (10 cm x 2.1 mm) 3 μm 
particle size column (Hichrom, UK) and protected by a C18 guard column. 
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3.2.3.1 High Performance Liquid Chromatography Method 
Column separation was realised by pumping two eluents (Mobile phase A and B) at a flow 
rate of 210 µL/min. Mobile phase A (aqueous phase) varied depending on whether analyte of 
interest was positively (P4, FLX and PRPL) or negatively (DCF) ionised. Variation in pH of the 
aqueous phase was observed to cause significant changes in ion selectivity, peak shape and 
retention time. Peak shape and retention time was observed to improve at low aqueous phase 
pH (lower than pKa of the positively ionized analytes) and at higher pH (higher than pKa for 
DFC). This because when acidic analytes (positively ionized analytes) are present in acidic 
solution (at pH at least two 2 units below their pKa), there is an abundance of protons (H+) in 
such a solution that these analytes (acidic) retain their protons and thus become ion-
suppressed, a condition that improves their retention on HPLC column.  On the other hand, 
when basic analytes (negatively ionized analytes) are present in a basic solution (at a pH at 
least two units above their pKa), there are too few protons (H+) in solution for the basic analyte 
to become protonated, and so they remain in their ion-suppressed, neutral form, improving 
their retention on HPLC column. See section 2.4 on the effect of pKa on the sorption properties 
of model compounds. 
Thus, in this work, the final method aqueous phase was MilliQ water (+ formic acid (999:1 v/v)) 
(pH: 2.6) for the positively ionised analytes and MilliQ water (+ ammonium formate (97:3 v/v) 
(pH; 8.2) for negatively ionised analytes. Mobile phase B was acetonitrile. Total run time was 
43 minutes (Fig. 3.1) with data acquisition over gradient program of;  
1. 5% acetonitrile for 11 minutes (Isocratic period to allow separation. Methods with 
gradient starting earlier were tried but did not allow for separation, and gave broader 
peaks),  
2. linear gradient to 75% acetonitrile over 19 minutes and  
3. held at 75% for 1 minute. Column wash (short column wash, no evidence of peaks in 
blanks) followed for 1 minute and thereafter  




Figure 3.1: Acetonitrile (Eluent B) gradient profile for model compounds HPLC analysis 
showing retention times. Aqueous phase was MilliQ water (+ formic acid (999:1 v/v)). (P4: 
Progesterone; FLX: Fluoxetine; DCF: Diclofenac; PRPL: propranolol) 
 
3.2.3.2 Unit Resolution LC-MS/MS  
The unit resolution analytical system consisted of a Perkin Elmer Series 200 pump equipped 
with autosampler and mobile phase mixer connected in series to a PE SCIEX API365 triple 
quadrupole mass spectrometer with turbo ion spray source in positive and negative ionisation 
modes (LC/ESI+/MS/MS). System parameters (e.g. Declustering, Focusing and Entrance 
Potentials (Fig. 3.2)) were optimized by varying values for each parameter to obtain higher 
signal strength (sensitivity). Instrument calibration for model compounds (P4, FLX, PRPL and 
DCF) masses and the optimization of source-dependent parameters was achieved by manual 
tuning. Prior to sample analysis and as part of method development, the mass spectrometer 
was manually tuned to determine the best possible ion source of two available ion sources 
(electrospray ionisation (ESI+) and atmospheric pressure chemical ionisation (APCI+)). 
Optimization of source parameters also involved the determination of the best mode (+) or (−) 
suitable for each analyte. Using positive and negative modes respectively, the instrument was 
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manually tuned to determine which source gave the best ionisation judged by signal to 
background noise (sensitivity), signal strength (intensity) and nature of peak produced. Using 
a 250 μl syringe installed on syringe pump, each analyte standard (standard diluted (50:50) 
with corresponding aqueous mobile phase), was infused at a rate of 50 μl/min. For the acidic 
analytes, the positive mode on the ESI produced more parent ions relative to the negative 
mode on either ion sources. Running on the negative mode, was good for DCF.  
Consequently, other system parameters were optimized to get higher signal strength. Choice 
of a unique product ion that can be monitored and quantified for each compound was also 
determined by manual tuning using the parent to product ion transition scan mode. The most 
intense product ion was then selected for multiple reaction monitoring mode (MRM) analysis. 
Parent and product ions monitored are presented in Table 3.2. Other instrument parameters 
were optimized as presented in Table 3.3 below to get better signal strength.  
 
Figure 3.2: Screenshot of system parameters optimization output for propranolol 
104  
 





  Parent (M1) Product (M2) 
P4 25.50 315.3 97.1 
P4d9 25.30 324.3 100.2 
PRPL 15.19 260.0 116.2 
FLX 20.07 310.0 44.0 
DCF 15.16 294.0 250.0 
 
Table 3.3: Optimized Instrument Parameters for Enhanced Signal Strength 
 Mass Spec Parameter Compound 
  P4 PRPL FLX DCF 
 Nebulizer Gas (NEB) 9 9 9 8 
 Curtain Gas (CE)  8 8 8 8 
 IonSpray Voltage (IV) 4500 4500 4500 -4300 
 Collision Gas (CAD) 10 2 2 11 
 Temperature (TEM)(0C) 350 350 350 350 
 Declustering Potential (DP) (V) 35 3.1 11 -55 
 Focusing Potential (FP) (V) 92 61 69 -55 
 Entrance Potential (EP) (V) 4.5 10 2.5 -2.5 
 Collision Energy (CE) (eV) 36 25 30 -20 





3.2.3.3 Accurate Mass Measurements and Collision Induced 
Dissociation 
Separation was conducted on a 1290 Series LC from Agilent (Stockport, UK) equipped with 
the same ACE column. The injection volume was 20 L. The mobile phase consisted of water 
(A) and acetonitrile (B), with both eluents containing 0.1% formic acid. An elution gradient (0.3 
mL/min) was applied with the initial concentration (5% B) held for 1 min, after which it was 
linearly increased to 75% B for 9 min and then held for 5 min. A 3-min post run was required 
after analysis. The LC was connected to an Agilent 6540 accurate-mass quadrupole time-of-
flight mass spectrometer. Sample ionization was achieved with jet stream electrospray 
operated in positive ion mode under the following conditions: sheath gas temperature 250 C; 
nebulizer 45 psi, gas flow 8 L/min; gas temperature 250 C; skimmer 65 V, fragmentor 175 V, 
nozzle 0 V; octopole RF 750 V; and capillary 3500 V. Accurate mass spectra were acquired 
in scan mode (50 - 1200 m/z). Reference masses were 121.0509 and 922.0098 m/z with a 
resolution of 19,546 at 922.0106 m/z. Data were acquired with Agilent MassHunter software. 
Considering P4 as the parent compound, a mass defect filter (0.2246  0.05 Da) was applied 
to identify TPs. 
Ion fragmentation was performed by collision-induced dissociation (CID) mass spectrometry 
in the Agilent 6540 time-of-flight instrument equipped with the column used previously. 
Collision-induced dissociation and source-induced dissociation (SID) are two common 
methods applied in mass spectrometry for ion fragmentation. CID was used in this work 
because of its reputation for being a simpler analytical method and for producing effectively 
controlled fragmentation data that are reproducible and easy to interpret. Acquisition 
parameters remained the same, with fragmentation carried out at collision energy of 15 V. Ion 





3.3 Progesterone Degradation Study 
3.3.1 River Water Sampling 
A total of three river sampling campaign on 7th December 2014; 5th November 2015 and 23rd 
November 2016, were carried out for this study. Sampling events were carried out around the 
same season (winter) for easy comparison of results. River water (20 litres) for the first two 
degradation studies were collected from the Grand Union Canal in Maple Cross, Hertfordshire 
(Figure 3.3) at approximately 1 km downstream of the effluent discharge point of the Maple 
Lodge Sewage Treatment Works (National Grid Reference (NGR): (TQ0406491270). 
Sampling was carried out at 1 km downstream and from sewage works effluent discharge 
points, to allow for mixing the of effluent (and associated microbial community) with the river, 
to be as representative as possible of the microbial community downstream of sewage works. 
River waters for the last degradation study were collected from approximately the same 
distance downstream of the effluent discharge point of selected STW. Sample locations 
according to their related STW were; Blackbirds ((NGR): TL1371001060), Chesham (NGR: 
SU9810099601) and High Wycombe ((NGR): SU8825092210) (Figure 3.3). Water samples 
were collected with the aid of a sampling bucket (1 L) with an attached adjustable 2-3 metres 
handle. Prior to sample collection, sampling bucket and sample container where rinsed twice 
with river water. Afterward, sampling bucket handle was adjusted such that a representative 
sample was picked from a point 2 metres from the bank of the canal. Samples were taken 2 
metres from the river bank to get close to mid-stream flow. Sample was immediately 




Figure 3.3: Sampling Locations and their corresponding National Grid Reference (NGR) 
 
3.3.2 Laboratory Progesterone Degradation Study 
Three degradation studies using river water from four different locations, were conducted. The 
first set-up on 7th December 2014 used river water from the Grand Union Canal. This initial 
study was designed to test the overarching hypothesis that P4 would degrade in rivers. The 
second study set up on the 5th of November 2015 and used sample from the same location as 
the first study, was aimed at confirming the first study results with the addition of biological 
assays to test for progestogenic and androgenic activities. The third study set up on the 23rd 
of November 2016 was designed to test the hypothesis in three other locations since the first 
two studies were based on samples collected from the same location. 
The initial study used 9 L degradation tanks. However, the subsequent unavailability of the 
tanks used in the first study led to the use of 4 L tanks for subsequent degradation studies 
(Figure 3.4). Tanks were grouped into two categories; Spiked and Control Tanks. Prior to the 
start of study, the tanks were respectively rinsed twice with the river water sample after which 
4 litres of associated river water was measured into each tank. Aerators with fitted air stone 
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endings and connected to air pumps, along with agitators (magnetic stirrers) were installed in 
each tank to ensure even aeration and good mixing of tank content. The tanks containing river 
water were left to stabilise (equilibrate) and assume stable laboratory conditions for 24 hours 
to get dissolved oxygen (DO) and temperature stable. Prior to the installation of air pumps and 
stirrer, the initial DO levels, pH and temperature of samples was measured. These parameters 
were regularly measured in each sampling regime for the spiked and control tanks. Following 
the 24hour equilibration period, the ‘Spiked’ tanks were spiked with 4 mL of 1,000 mg/L P4 
stock solution and the ‘control’ tanks were not. Sampling regimes in hours were 0 (20 minutes 
following spiking), 4, 8, 12, 24, 48 and 72. For each sampling period, 0.6 mL of water was 
sampled respectively for the spiked and control set-up into a chromatographic vial followed by 
the addition of 0.3 mL each of methanol and the IS (P4d9). Samples were taken in triplicate 
for each sampling time. Overall, three batch of samples were taken altogether and analysed. 
Tanks were spiked at 1,000 mg/L so that any major degradation products were expected to 
be detected without pre-concentration using SPE. This was also appropriate as recovery by 
SPE could not be tested for unknown compounds (see section 2.2.1). 
Progesterone degradation kinetic rate constant was calculated using the first-order reaction 
kinetic model (equation 3). Degradation half-life was calculated using the relationship shown 
in equation 4. 
Equation 3: Kinetic rate constant (h) 
 
Equation 4: Degradation half-life (h) 
 
*where Ct: concentration at a given time; C0: starting concentration; k: kinetic rate constant; 




Figure 3.4: Laboratory Degradation study. Tinfoil was used to minimise evaporation and to 
allow air flow. 
 
3.4 Selection of Suspect TPs to be monitored 
The choice of target progesterone TPs to be monitored under low resolution was guided by 
the outputs from the EAWAG BBD predictions alongside literature reports of products resulting 
from the biodegradation of P4 (Peng et al. 2014; Ellis & Wackett, 2012). Progesterone was 
submitted to the EAWAG BBD associated pathway prediction system (PPS) using its 




Later, in the present study, the improved version of the EAWAG BBD (enviPath), was used to 
model P4 degradation and results were compared. Putative products detected under low 
resolution and those confirmed by high resolution mass spectrometry (HMRS) are presented 
in the Results section. Comparison of P4 predicted TPs and associated pathways by the two 
databases is presented in the discussion chapter (Chapter 5) of this thesis. 
 
3.5 Methodology for Screening for Biological Activity 
3.5.1 Progesterone Screen Procedure: 
Planning was important and timings critical to get the assays to work. Progesterone screen 
procedure was based on the protocol described by Gaido et al., 1997 and modified for use 
with 96-well assay plates by Lorenzen et al., 2004 (see section 2.6.2.1). 
Day 0: The inner chamber of a type II laminar flow cabinet where yeast work was to be 
performed was wiped with 70% ethanol. Thereafter, 5 mL of 20% glucose was added to 45 
mL selection medium. At 10am, a yeast culture was started by adding 125 µL human 
progesterone (hPR) yeast from cryovial stored at -200C into the 50 mL growth medium. The 
yeast culture was placed on a PSU-10i orbital shaker set at 200 rpm and incubated at 280C 
for 24 hours.  
Day 1:  At 10am, the incubated yeast culture from day 0 was diluted 50% by the addition of 
25 mL of the culture to 25 mL minimal growth medium in a fresh flask. The old culture was 
disposed of for autoclaving and the new one shaken at 280C and incubated for 4 hours. At 1 
pm, 3 hours following incubation of the new yeast culture, two 96-well assay plates were 
respectively designated as ‘dilution plate’ and ‘progesterone screen plate’.  100 µL ethanol 
was pipetted respectively into wells A2 - A12. 100 µL P4 stock (5 x 10-6M) (positive control) 
was pipetted into well A1 and also well A2. The content of well A2 was mixed by simultaneous 
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pipetting and expelling for 5 times. Thereafter, by serial dilution, 100 µL of the diluted content 
in one well was used to dilute the well after it. 
Using an automated 120 µL 12 point multichannel pipette, 10 µL dilutions of progesterone in 
ethanol, were transferred to designated wells in the ‘progesterone screen plate’ in duplicate 
and allowed to evaporate to dryness for approximately 30 minutes. Similarly, 10 µL ethanol 
was also transferred to control wells in ‘progesterone screen plate’ and left to dry. At 2pm, 4 
hours after incubation, the turbidity of the new yeast culture was checked using a SpectraMax 
340pc Molecular Devices plate reader to ascertain if the turbidity was within the acceptable 
range of 1-2 x 107 cells/mL. The absorbance for the device was set at 600 nm for a 100 µL 
culture volume. If the culture turbidity was high, it was diluted appropriately to the acceptable 
range. Thereafter, 250 µL (50mL culture; 500 µL/100 mL) 20mM CuSO4 and 200 µL aliquots 
were transferred to the 96-well assay plate. Plate was sealed and then shaken for 2 minutes 
after which it was incubated at 320C for 19–20 hours.  
Day 2: At 10am, yeast cells in previous day incubated plate were resuspended by shaking for 
5 minutes. The cells were pipetted to mix further. Thereafter, 50 µL of the suspension was 
transferred to corresponding wells of a new 96-well plate to which 50 µL minimal medium had 
been previously added. The new assay plate was shaken for 2 minutes and read at 600nm to 
determine where cell lysis had occurred. 
Thereafter, cells were lysed by freeze thawing in 3 cycles of 4 mins on dry ice, followed by 4 
minutes at 420C. Assay plate was thereafter shaken for 5 mins. Using a reverse pipetting 
method, 100 µL of assay buffer was added to all wells in the multiwall plate.  The assay plate 
was shaken for 2 minutes at a low speed of 2 m/s to minimize foaming of the SDS and then 
incubated at 370C. Plate was read every 30 minutes of incubation at 420 nm and 600 nm until 
colour development stopped. To correct for turbidity, the following equation was applied; 





3.5.2 Androgen Screen Procedure 
Like the progestogenic screen, planning and timing were critical to get the assays to work. 
The androgenic screen procedure was based on the protocol described by Sohoni & Sumpter, 
1998 (see section 2.6.2.2).  
Day 0: Growth medium was prepared by the addition of 5 mL glucose solution, 1.25 mL L-
aspartic acid solution, 0.5 mL vitamin solution, 0.4 mL L-threonine solution and 125 µL copper 
(II) sulphate to 45 mL minimal medium in a sterile conical flask (final volume was 
approximately 50 mL). 125 µL of 10X concentrated yeast stock from cryogenic vial stored at -
200C (see day 3 of ‘preparation and storage of 10X yeast stock’ above) was added to growth 
medium. The medium was incubated at 280C for approximately 24 hours on an orbital shaker 
until it was turbid. 
Day 1: Similar to the progesterone screen, test chemical 10-6 M (290.4 µg/L ethanol) of 
dihydrotestosterone (DHT) (positive control) was serially diluted and  10 µL aliquots were 
transferred to 96-well optically flat bottom assay plate and left to evaporate to dryness. 10 µL 
absolute ethanol was also transferred to blank wells. Thereafter, assay medium was prepared 
by the addition of 0.5 ml CPRG to 50 mL fresh growth medium. The assay medium was seeded 
with 4x107 yeast cells from the previous day (24 hours) culture (about 0.5 mL to 2 mL, 
determined after absorbance readings). 50 mL assay medium was prepared (enough for 2.5 
plates). 200 µL of the seeded assay medium was pipetted with a multichannel pipette into 
wells in assay plate. This gave a 1/20 dilution in each well (10 µL/200 µL). Plates were sealed 
with autoclave tape and shaken vigorously for 2 minutes on a titre plate shaker. Thereafter, 
assay pales were incubated at 320C in a naturally ventilated heating cabinet.  
Day 2: Assay plates were again shaken vigorously for 2 minutes to mix and disperse the 
growing cells. Plates were returned to 320c incubator after shaking. 
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Day 3: After 3 days of incubation, assay plates were again shaken for 2 minutes and left for 
an hour to allow yeast cells to settle. Plates were read with plate reader at 540 nm (optimum 
absorbance for CPRG) and 620 nm (for turbidity). To correct for turbidity, the following 
equation was used; 
Corrected value = chem. abs. (540 nm) – [chem. abs. (620 nm) –blank abs. (620 nm)] 
 
3.5.3 Calculation of Assay Results 
The absorbance readings for the individual wells in assay plate were plotted against the log of 
the molar concentration of the test compound in the corresponding wells. The position of the 
activity curve produced for the test compound relative to that of the positive control is used to 
determine and measure the presence and extent of biological activity. The activity expressed 



















4.1 Analytical Methods Development and Validation 
4.1.1 Method Development 
The first step in the development of analytical method for the present study was the 
optimization of system parameters in the locally available PE SCIEX API365 triple quadrupole 
mass spectrometer (MS) to obtain higher signal strength (sensitivity). The data for MS 
parameters optimization had been presented in section 3.2.3.2 of this thesis, but repeated 
here for easy reference. Using the electrospray source and in the manual tuning mode, 
parameters were optimized in the positive mode for positively ionised analytes and in the 
negative mode for the negatively ionised analytes. The choice of product ion to monitor for 
each compound was also determined by manual tuning using the parent to product ion 
transition scan mode. Previously reported most intense product ion selected for multiple 
reaction monitoring mode (MRM) analysis and final values of other optimized instrument 
parameters are also presented in Table 4.1 and 4.2. An example of the most intense product 
ion peak selected for MRM is illustrated in Fig 4.1 for propranolol. Following set up of 
parameters for the electrospray source and mass spectrometry, chromatographic separation 
was then developed. 
 





  Parent (M1) Product (M2) 
P4 25.50 315.3 97.1 
P4d9 25.30 324.3 100.2 
PRPL 15.19 260.0 116.2 
FLX 20.07 310.0 44.0 




Table 4.2: Final Optimized Values of MS Parameters for Higher Sensitivity 
 Mass Spec Parameter Compound 
  P4 PRPL FLX DCF 
 Nebulizer Gas (NEB) 9 9 9 8 
 Curtain Gas (CE)  8 8 8 8 
 IonSpray Voltage (IS) 4500 4500 4500 -4300 
 Collision Gas (CAD) 10 2 2 11 
 Temperature (TEM)(0C) 350 350 350 350 
 Declustering Potential (DP) (V) 35 3.1 11 -55 
 Focusing Potential (FP) (V) 92 61 69 -55 
 Entrance Potential (EP) (V) 4.5 10 2.5 -2.5 
 Collision Energy (CE) 36 25 30 -20 
 Collision Cell Exit Potential (CXP) 8 4.5 3.3 -15 
 
 
Figure 4.1: Selected PRPL product ion for MRM obtained from parent to product ion transition 
scan mode. Peak116.2 was more intense relative to other product ion peaks and was therefore 
selected for MRM. 
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4.1.1.1 Liquid Chromatography 
For the development of chromatographic methods, a series of five-point working (calibration) 
standards ranging from 1 - 100 ng/mL prepared in chromatographic vials by appropriate 
dilution of sub-standards with methanol/water (50/50, v/v) were used. Analytical standards 
contained all four analytes and 200 ng/mL of the internal standard (P4d9) respectively. 
Calibration curves for the four model compounds and their corresponding correlation 
coefficient are presented in Figures 4.2 – 4.5. Three of the target compounds, P4, FLX, and 
PRPL separated well producing distinct peaks with good resolution, peak shapes and 
response. Diclofenac also produced a distinct peak. However, the instrument sensitivity was 
lower in the negative mode. The total ion chromatograms of the target compounds for a 100 
ng/mL standard are presented in Figures 4.6 and 4.7. The intensity of DCF peak (3x103 cps) 
was low relative to propranolol response (7x104 cps), which was the lowest response of the 
positively ionised analytes. 
 
Figure 4.2: Calibration curve for diclofenac (standard concentration: 1 – 100 ng/mL 
(R2=0.99)) 
Jas_Barston_30_03_15_Pharms_Negative.rdb (Diclofenac): "Linear" Regression ("No" weighting): y = 0.00106 x + -9.62e-005 (r = 0.9996)
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Figure 4.3: Calibration curve for fluoxetine (standard concentration: 1–100 ng/mL (R2=0.99)) 
 
Figure 4.4: Calibration curve for propranolol (standards concentration: 1–100 ng/mL 
(R2=0.99)) 
Jas_Barston_Pharm_Positive_30_03_15.rdb (Fluoxetine): "Linear Through Zero" Regression ("No" weighting): y = 0.0282 x (r = 0.9983)
5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100





































Jas_Barston_Pharm_Positive_30_03_15.rdb (Propranolol): "Linear Through Zero" Regression ("No" weighting): y = 0.00906 x (r = 0.9994)
5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100






































Figure 4.5: Calibration curve for progesterone (standard concentration: 1–100 ng/mL 
(R2=0.99)) 
 
Figure 4.6: Total ion chromatogram of the positively ionised target compounds in a 100 ng/mL 
standard. Propranolol response of 7x104 was the least of the positively ionised analytes. 
Progesterone (P4) peak and that of the IS (P4d9) are combined as shown in the figure. 
 
Jas_Barston_Pharm_Positive_30_03_15.rdb (Progesterone): "Linear Through Zero" Regression ("No" weighting): y = 0.00768 x (r = 0.9994)
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Figure 4.7: Total ion chromatogram for diclofenac for 100 ng/mL standard. Period 1 was in 
the negative ionisation mode Period 2 in the positive mode. 
 
4.1.1.2 Recoveries from SPE 
This section of the present work presents result of experiments on SPE protocol optimization. 
Some brief of the methods described in chapter 3 are mentioned here to provide context for 
the results presented. Initial studies focussed on the relative effect that the following 
parameters, type of elution solvent, volume of elution solvent used for cartridge washing, 
volume of sample loaded on the cartridges and the rate of loading would have on analyte 
recovery. These studies worked with high concentrations of each compound (100 µL of 10 
mg/L standard mixture of all model compounds in 500 mL milliQ water), such that sample 
drying and concentrating up was not necessary. For the investigation of the best type of elution 
solvent to use, 4 mL of methanol and acetonitrile were used respectively for elution of 
cartridges. Thus, the expected concentration of individual compounds in the eluent was 0.25 
µg/mL. Eluent sample for instrumental analysis were diluted 50:50 with MilliQ water, making 
the concentration of analytes in chromatographic vial for LC-MS/MS analysis to be 0.125 
µg/mL.  The result demonstrated that methanol was a better elution solvent for the recovery 
of model compounds relative to acetonitrile (Fig. 4.8A). Overall, recovery for all compounds 
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was above 80% when cartridges were eluted with methanol, whereas with acetonitrile they 
were below 50%.  
Following the determination of what elution solvent (methanol) to use, the best volume of 
methanol to use for elution was investigated by eluting cartridges with 4 mL and 8 mL (2 x 4 
mL) of methanol respectively. The recovery obtained for all four model compounds were 20% 
higher when cartridges were washed with 2 x 4 mL (8 mL) of methanol relative to washing 
with 4 mL methanol (Fig. 4.8B). The higher recovery observed when eluting with increased 
volume of methanol, is probably because, eluting with a second 4 mL solvent volume helped 
free-up any residue of target analytes still bonded to the cartridge adsorbent material after the 
initial wash with 4 mL MeOH. Irrespective of the volume of elution solvent used, P4 had 20% 
more recovery when compared to the other compounds. 
 
 
Figure 4.8: Relative effects of type of elution solvent (A) and volume used (B) in washing 
cartridges on model compounds recovery (Error bars = SD; n=3; Flow rate: 2 mL/min) 
 
Additionally, different volumes (0.5 and 1 L) of MilliQ water were respectively spiked with 100 
µL of 10 mg/L mixture of all five pharmaceuticals. This was done to determine if loading a 
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higher volume of water resulted in loss of analytes due to breakthrough. The extraction of 0.5 
L of MilliQ water spiked with mixture of model compounds in this study, produced a recovery 
that was 50% higher relative to extracting a 1 L (Fig. 4.9A), the common approach reported in 
literature. The results thus, showed that extracting a lower volume of samples would generally 
result in improved recovery of compounds of interest. An advantage of extracting lower sample 
volume, is high throughput, and results obtained can be used to estimate analytes 
concentration in higher sample volume. The lower recovery observed when 1 L of water was 
extracted may be due to breakthrough of previously bonded compounds to cartridge adsorbent 
material. Furthermore, 0.5 L of water was loaded at different rates corresponding to fast (5 
mL/min) and slow flow (2 mL/min) to determine which loading rate gave better recovery. The 
two loading rates were randomly chosen as variable loading rates (1–20 mL/min) are reported 
in the literature for both manual and automated SPE operations. Furthermore, there was also 
the desire for a quicker procedure, hence the 5 mL/min flow (loading) rate was tested against 
the 2 mL/min used in the optimization of the previous SPE conditions. Overall, analyte 
recovery was 20% better when cartridges were loaded at a slow rate of 2 mL/min relative to 
loading at a higher rate of 5 mL/min (Fig. 4.9B).  
 
 
Figure 4.9: Relative effects of extracting varying volume of samples (A: 4 mL volume used; 




Next, the relative effect of drying SPE extracts down relative to when they were not, on target 
compounds recovery was investigated, especially since model compounds are often present 
at very low concentrations in the environment. Thus, 0.5 L of MilliQ water was spiked with 10 
µL of the 10 mg/L standard mixture of all model compounds, a much lower volume of 
pharmaceuticals standard mixture relative to the initial studies (100 µl of 10 mg/L). Cartridges 
were eluted with 2 x 4 mL of methanol, such that concentration of analytes in extracts not dried 
down (referred to as ‘non-concentrated’ in Fig 4.10) was 0.0125 µg/mL, a lower concentration 
compared to the initial study of 0.125 µg/mL. Extracts for samples designated for drying 
(‘concentrated’ in Fig 4.10), were then dried under a nitrogen stream and reconstituted to 1.2 
mL with a mixture of methanol and water (50/50 v/v). Dried extracts were reconstituted to 1.2 
mL to have enough sample volume for multiple instrumental run. A representative 
concentration of 0.08 µg/mL was thus expected for individual analytes in the chromatographic 
vial. Analytical results for concentrated samples were compared to the non-concentrated 
samples. The study result demonstrated that samples that were concentrated up, had better 
recovery for target analytes relative to the non-concentrated samples (Fig 4.10). Overall, 
locally available unit resolution mass spectrometer could hardly detect and quantify the low 




Figure 4.10: Effect of sample dry down on recovery of target compounds (Error Bars = SD; 
n=3). Concentrated: extracts dried down and reconstituted; Not Concentrated: extracts not 
dried down. 
 
4.1.1.2.1 Validation of SPE Method 
The SPE method developed was validated using wastewater influent and effluent sampled 
from pilot scale reed beds at a Severn Trent Water STW located in Barston. Two litres (2L) 
spot samples (HRT <1 min) were respectively taken in triplicate. In the laboratory, samples 
were subsequently then divided into two groups of 0.5 L each. One group was spiked with a 
100 µL of a 10 mg/L concentration of the target pharmaceutical mix and the isotopically 
labelled P4d9 and the other group was used as a control. The internal standard was added 
prior to sample extraction, to minimize matrix effect. However, as noted in section 3.2.2, Initial 
work in reed beds used P4d9 as a sole IS, the use of P4d9 as a sole IS in the initial study with 
the reed beds, was thought to lead to some bias, in that we were correcting for recovery using 
a compound with different characteristics, which may respond differently in different matrices. 
Overall, the optimized SPE protocol was adequate for recovery of all model compounds. 
Recovery was however higher in influent samples when compared to effluent. Also, the 























standard deviation (%RSD aka Coefficient of Variation (CV)) (Fig. 4.11). Variation in influent 
data can be attributed to the more complex nature and possibly presence of more interference 
in these samples relative to the effluent.  The latter point must have also accounted for the 
enhanced recovery recorded for the influent samples (slower flow rate through cartridge and 
therefore higher contact time with cartridge sorbent material). Interferences in these samples 
may have slowed down the rate of flow of target analytes through cartridge adsorbent 
materials allowing for higher contact time, which makes for increased bonding. DCF recovery 
was relatively high when compared to other target compounds in both influent and effluent 
samples. DCF recovery was >50% in influent relative to other compounds and about 80% in 
effluent. Perhaps, the use of P4d9 as a sole IS in this study, coupled with the switching of 
ionisation modes from negative for DCF in period 1 to positive for the IS in period 2 (Fig. 4.7) 
may have resulted in false positives. See Figure 4.2 for the DCF calibration curve showing 
that standards selected for quantitation covered a broad range of concentration points, like 
the other model compounds. Recovery data were used to correct for concentration of model 
compounds in reed beds (Table 4.1). However, because of the uncertainty in recovery of 
model compounds, spot sampling (zero hydraulic retention time) of the in/out of reed beds and 
lack of further access to site, the results presented for performance of reed beds will require 




Figure 4.11: Model compounds recovery in influent and effluent of pilot reed beds (Error Bars 
= %RSD; n=3) 
 
4.2 Application of Analytical Methods in the Measurement of 
Target Compounds in Reed Beds 
4.2.1 Concentration and Removal of Target Analytes in Reed Beds 
A further aim to the sampling of reed beds was to establish the concentrations of target 
compounds in influent and final effluent. Percentage recovery values were used to correct for 
analytes recovery in influent and effluent. Target compounds were present in both influent and 
effluent of reed beds (Table 4.3 and Fig. 4.12). Similar to data for SPE validation, influent data 
were more varied relative to the effluent. Progesterone concentration in the samples was the 
lowest of all four compounds. Influent B data point for P4 appears to be an outlier. A review of 
the raw datasets reveals this was not a typo. Data reported for diclofenac in Table 4.3 are 


























Also, reed bed performance in removing model compounds was investigated by comparing 
target compounds concentration in influent with their corresponding concentrations in effluent 
following influent polishing by the reed bed. Generally, all analytes were removed to varying 
degrees by the reed beds. Removal of target compounds was generally above 65% for all 
model compounds except DCF (Fig 4.13). As noted in section 4.1.1.2.1, further work will be 
needed to validate reed bed performance results. 
Table 4.3: Concentration of target compounds in reed beds (±SD) 
  Concentration (ng/L) 
Sample Name P4 FLX PRPL DCF 
Influent A 11.0 106 372 605.0 
Influent B 6.9 67.1 250 271.7 
Influent C 8.0 89.9 382 577.0 
Mean 6.6 ± 5.1 87.7 ± 19.6 335 ± 73.7 484.6 ± 184.9 
Effluent A 1.3 2.5 113 112.6 
Effluent B 1.3 5.3 101 150.9 
Effluent C 1.0 2.7 122 132.4 
Mean 1.2 ± 0.2 3.5 ±1.6 112 ± 10.5 132.0 ± 19.2 




Figure 4.12: Occurrence of target compounds in influent and effluent of pilot reed beds (Error 
Bars – SD). Influent data were more varied when compared with effluent (P4=Progesterone; 
FLX=Fluoxetine; PRPL=Propranolol; DCF=Diclofenac) 
 
  
Figure 4.13: Performance of reed beds in the removal of target compounds. Removal was 













































4.3 Progesterone Degradation Study 
4.3.1 Target Transformation Products Monitored 
A summary of target TPs predicted by the EAWAG BBD is shown in Fig. 4.14 and compounds 
selected from the literature and that were produced through algal degradation of P4 are shown 
in Fig. 4.15. Some of the information provided in this section had been mentioned in chapter 
2, but repeated here to put the results context. The details of compounds monitored in the 
suspect analysis is summarised in Table 4.4. Progesterone details are also included in this 
table for easy reference, especially when comparing the properties of individual TP with the 
parent molecule. Table 4.4 also details the chromatographic retention times (RT) of the target 
compounds and their relative retention times (R/RT) to that of the P4d9 internal standard.  
The biodegradation database predicted products (TP-BBD) resulting from the cleavage of the 
‘B’ ring in the P4 C21 pregnane skeletal backbone (Fig. 4.14).  The aerobic likelihood of the 
formation of the predicted intermediate product (TP-BBD-1) was neutral indicating that there 
was a 50% chance of its formation in aerobic and anaerobic systems. The implication is that, 
where the odds are against its formation in a given system (aerobic or anaerobic), subsequent 
TPs (TP-BBD 2-5) resulting from its breakdown, would not be produced.  
Literature search, however, identified algal products (TP-ALG) (Fig. 4.15) that do not show 
ring cleavage, but the hydroxylation, oxidation, hydrogenation, dehydrogenation and 
breakdown of attached side chain. Thus, the biodegradation database predicted ‘B’ ring 
cleavage may be related more to anaerobic degradation pathways. Anaerobic transformation 
pathways are relevant as they are probably the dominant reaction pathways in the breakdown 
of pharmaceuticals in sewers and in many conventional treatment processes such as primary 




Figure 4.14: The EAWAG BBD prediction for the environmental transformation of P4. The 







Figure 4.15: The predicted transformation products from the literature. Peng et al. 2014 
identified these products from their algal studies (TP-ALG). There are two possible compounds 








Table 4.4: Characteristics of the BBD and algal metabolites monitored using unit 
resolution mass spectrometer in this study 
Name Abbr. Mol. Wt. 
(Da) 










































TP-BBD-5 344.5  345.3   
1,4-Pregnadiene-3,20-
dione 















TP-ALG-4 286.5 846-48-0 287.3 18.5 
(0.1) 
0.73 




4.3.2 Progesterone Degradation in Reed Beds 
Initial work on identifying putative degradation products in the reed bed samples was done 
using the unit resolution mass spectrometer at Brunel. Unit resolution mass spectrometry was 
performed using the selected ion recording mode that targeted the unit masses of suspect 
transformation products identified in Table 4.2. Presence of a suspected TP in samples was 
determined by extracting chromatogram for that product in sample and overlaying it with 
corresponding extracted chromatogram in the control (blank: double deionised water). All 
peaks found in samples that were also present in the control, were excluded. Response had 
to occur only in the spiked sample for peaks to be considered as possible degradation 
products.  
In the reed bed study, none of the algae products were detected. It was the expectation that 
algal products will be present in at least the influent samples. The thick biofilm layer in the 
trickling filters applied for treatment of post primary sedimentation sewage at Barston, 
consisted of green algal layer. However, the m/z 329.3 corresponding to one of the predicted 
bacterial product, TP-BBD-1, was found (Fig. 4.16). This mass was consistently detected in 
all replicate samples. The height of the peak in effluent samples was smaller relative to the 
corresponding height in influent samples, indicating the possible removal of this product by 
the reed beds.  The peak to the right of the one marked ‘TP-BBD-1’ in Figure 4.16 was 
excluded from consideration because, a similar peak was found in the blank. The detection of 
TP-BBD-1 and absence of the algal products was thought to be that bacterial mediated 
degradation process was the dominant metabolic process occurring in the reed beds. The 
non-detection of the algal-based products could also be because of their low concentration 
and/or perhaps reed beds conditions were not suitable for their formation. The application of 
the concentration step (SPE) to TPs whose sorption properties are unknown, may have added 
some uncertainty, as if the products were present, but not retained by cartridges, resulting in 
a false negative outcome. Generally, the work on the reed beds indicated that unit resolution 
work would not be enough to confirm the presence of target transformation products as 





Figure 4.16: Overlaid extracted chromatograms of product TP-BBD-1 in influent (A) and 
effluent (B) of reed beds and associated mass spectra (C). Red (Blank: MilliQ water). Peak to 




4.3.3 Monitoring the Degradation of Progesterone in Laboratory 
Conditions 
Following on from the assessment of samples from the reed beds, where perhaps low 
concentration was thought to lead to uncertainty in determining the presence or absence of 
degradation products, it was decided that a laboratory based degradation study in which river 
water was spiked with progesterone be undertaken (refer to section 3.3 for details of sampling 
and laboratory degradation set-up). In addition, these studies would be supported with the use 
of high resolution data from a time-of-flight instrument at Cranfield University. 
Conditions within the spiked and control tanks were relatively stable for the entire study period. 
Of the parameters measured, Dissolved oxygen (DO) was stable at 8.1 to 8.9 mg/L, pH started 
at 8.7 in each tank, and decreased to 8.2 in the spiked and 8.5 in the control. Decrease in pH 
possibly due to metabolic activity in the closed degradation system. Temperature in both tanks 
ranged from 20 to 22°C (Table 4.5). There were no significant differences (p > 0.05) between 
all these parameters in the spiked and control tanks. 
Table 4.5: Physical-chemical conditions in degradation tank 









pH Temp. (0C) 
A 8.61 8.72 20.9 8.61 8.72 20.9 
0hr 8.60 8.58 20.7 8.69 8.57 19.8 
4hrs 8.59 8.56 20.8 8.75 8.51 19.8 
8hrs 8.53 8.55 21.3 8.79 8.50 20.0 
12hrs 8.63 8.58 20.9 8.80 8.67 19.8 
24hrs 8.46 8.46 20.9 8.89 8.48 19.7 
48hrs 8.09 8.24 22.0 8.61 8.54 20.8 
72hrs 8.01 8.22 22.3 8.57 8.48 21.1 




Overall, the outcome of the degradation study was that progesterone degraded rapidly from 
an initial 1,000 µg/L concentration (Fig. 4.17), with the concentration falling to <1.05 µg/L 
(method limit of quantification (LOQ)) after 72 h. This highlighted that it was a useful compound 
to study due to the time period for the reduction of concentration and likely formation of 
degradation products. Unit resolution results showed the formation of six putative 
transformation products of the nine target products monitored, as indicated by the relative 
retention times provided in Table 4.4. 
 
Figure 4.17: Progesterone concentrations with time (Instrument LOD 0.35 µg/L). There was 
a decrease in P4 concentration (1000 µg/L) with increasing incubation time, with concentration 
falling to <1.05 µg/L (methods LOQ) by 72 hours (n=3 (three batch of samples). 
 
Unit Resolution Detection of Putative Transformation Products 
Under unit resolution monitoring, a number of masses corresponding to suspected TPs were 
detected as the progesterone concentration declined. TPs were observed as peaks in 
chromatograms. A typical outcome of this work is shown in Fig 4.18, where a m/z 287.3 



























the two peaks observed were compared to those found in the control tank (blank). The blank 
also had a response at RT 12.56 minutes, so the peak at that time point was dismissed as 
being linked to spiking with P4. The response at RT 18.46 minutes was recorded as no similar 
response was seen in the blank. In all instances where m/z responses linked to possible TPs 
were identified, target ions eluted before the parent (Table 4.2). In reversed-phase 
chromatography this is indicative of increasing polarity, which is reflected in the structures 
shown in Figs. 4.14 and 4.15. 
 
 
Figure 4.18: Overlaid chromatograms (top) and mass spectra (bottom) showing the formation 
of TP-ALG-4 by side chain breakdown (-2C and -4H) of the parent progesterone molecule. 
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The algal metabolic reactions were the dominant pathways observed in the degradation tanks, 
with fewer occurrences of the bacterial degradation products predicted by the BBD. In order 
to have a picture of the formation of these TPs with time, their corresponding peak areas were 
plotted against time (Fig. 4.19).  All suspected TPs except TP-ALG-1 were formed four hours 
into the degradation study and degraded after 8 hours. TP-ALG-4 degraded after 12 hours. 
However, the formation of TP-ALG-1 peaked at 4 hours and build up to a maximum level in 
48 hours and then also rapidly degraded in 72 hours. Of the potential products predicted by 
the biodegradation database, only TP-BBD-1, predicted as a first level product of progesterone 
degradation, was detected in the study. The m/z associated with this TP was detected only in 
the 4 h spiked sample (Fig. 4.14). The products predicted by the BBD have all undergone ring 
cleavage, and TP-BBD-1 eluted earlier than other TPs observed, with a R/RT of 0.58 (Table 
4.4). Using the peak area approach, the associated pathways responsible for the formation of 
TPs is presented in Figure 4.20. 
 




























Figure 4.20: Reaction pathways that yielded the transformation products identified in this 
study. Based on peak area, dehydrogenation was the dominant pathway 
 
High Resolution Detection of Putative Transformation Products 
An Agilent Technologies ToF mass spectrometer associated data processing software, 
MassHunter, was used for processing of data acquired during HRMS run. Steps taking for 
data processing involved peak picking, involving the comparison of peaks in the sample with 
control and the exclusion of irrelevant peaks. This was followed by the elimination of noise 
peaks, mass recalibration and breakdown of isotopes and adducts into well-defined and easily 
identifiable units. Characteristic fragmentation pattern of TPs relative to P4, was used in the 
identification of TPs. Fragmentation pattern technique involved searching for specific fragment 
ions in MS/MS spectra throughout the chromatographic run and applying mass-defect filtering. 
See section 2.2.1.2 for the reputation and reliability of the process followed. Note: The range 
of other software comparison steps mentioned in section 2.2.1.2 were not followed in this 


























Following unit resolution analysis, high resolution time-of-flight results confirmed the presence 
of two of the products detected in unit resolution with their chemical formulae and accurate 
masses determined to four decimal places (Table 4.6). A third product seen under unit 
resolution was also detected in HRMS (TP-ALG-2; mass: 316.2402), however, this was with 
a lower degree of confidence, and lacked a molecular formula, as the intensity was very low. 
Detected TPs were seen in the 4, 24 and 48 hours samples. High resolution MS work could 
not be done for the reed bed study because, further access to site was not possible and 
previous samples collected were too old (over a year) at the time access to HRMS analysis 
was possible at Cranfield University. 
By applying a mass defect filter (0.2246  0.05 Da) in the identification of TPs in HRMS, two 
features were found at m/z 313.2170 (TP-ALG-1) and m/z 287.1997 (TP-ALG-4). The former 
corresponded to a mass of 312.2097 (-2.48 ppm error), a double bond equivalent of 8 and 
proposed molecular formula C21H28O2. The latter resulted in a mass of 287.1997 (0.28 ppm 
error), double bond equivalent of 7 with C19H26O2 being its molecular formula (see Table 4.6). 
Collision induced dissociation (CID) fragmentation of the aforementioned features showed 
similar fragment ions at m/z 121.0648 and 121.0643 respectively (Table 4.7 and Fig. 4.21). 
Fragmentation of both TP-ALG-1 and TP-ALG-4 was believed to have occurred in the A-ring, 
most probably due to protonation of the ketone group attached to C3. Subsequent relocation 
of the positive charge either on carbon 1 or 5 due to resonance resulted in the dissociation of 
the bond between C9 and C10. CID experiments for m/z 287.1997 helped to identify this feature 
as boldenone since its two main product ions m/z 121.0643 and 135.1161 (Fig. 4.21) have 
been previously reported elsewhere. Thus, the identity of TP-ALG-4 as confirmed by high 
resolution mass spectrometry was boldenone and not androstene previously proposed in Fig 
4.15. 
The greater number of transformation products detected in unit resolution was probably a 
result of operating the triple quadrupole in selected ion monitoring mode, increasing sensitivity 
for the specific ions. The high-resolution work was undertaken in non-scanning mode that only 
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target specific ions for the collision induced fragmentation. However, other, instrument specific 
factors, such as the ionisation source, may also play a role in determining sensitivity. 
 










TP-ALG-1 312.2089 312.2097 313.2170 C21H28O2 90.42 8 -2.48 
TP-ALG-4 286.1932 286.1932 287.1997 C19H26O2 99.8 7 0.28 
* m/z: mass-to-charge ratio; MFG: molecular formula generator; DBE: double bond 
equivalents 
 
Table 4.7: Fragmentation pattern of the putative transformation products 
Precursor Ion Base Peak 






TP-ALG-1 313.2173 C21 H28 O2 121.0648 C8 H9 O 192.1514 C13 H20 O 









4.3.4 Second Progesterone Degradation Study 
Following the initial degradation study, a second study was performed using a water sample 
collected from the same location as the first study, one kilometre downstream of the effluent 
discharge point of the Maple Cross STW, and at the same time of the year. The second study 
was aimed at determining the reproducibility of progesterone degradation and undertaking 
yeast based biological assays to determine if resultant TPs were biologically active and to 
establish the nature (progestogenic or androgenic) of their activity. Similar to the first study, 
conditions within the spiked and control tanks in the second study were relatively stable for 
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the entire study period. DO was stable at 8.1 to 8.2 mg/L in both tanks for up to 12 h and then 
dropped to 7.0 to 7.7 mg/L in the spiked tanks. Of the other parameters, pH started at 8.4 in 
each tank and dropped to 8.0 in the spiked tanks. Temperature in both tanks ranged from 23 
to 240C (Table 4.8). There were no significant differences (p > 0.05) between all these 
parameters in the spike and control tanks. 
 
Table 4.8: Physical-chemical conditions in degradation tank in second study 











A 8.11 8.38 24.0 8.07 8.42 23.9 
0hr 8.16 8.38 23.4 8.14 8.39 23.3 
4hrs 8.11 8.36 23.9 8.09 8.38 23.8 
8hrs 8.13 8.37 24.0 8.12 8.40 24.0 
12hrs 8.11 8.39 24.3 8.12 8.43 24.2 
24hrs 7.51 8.23 24.6 8.10 8.44 24.3 
48hrs 7.21 8.04 24.3 8.19 8.40 24.1 
72hrs 7.35 7.99 24.0 8.22 8.41 24.0 
*A: conditions in degradation tanks prior to spiking 
 
The sensitivity of the analytical method (LOD) was determined at each run by calculating the 
signal-to-noise-ratio of the progesterone peak recorded in the lowest calibration standard. In 
the present study, the instrument recorded a distinct peak for progesterone in the 0.25 ng/mL 
standard compared to 1 ng/mL which was the lowest standard in which a peak was recorded 
in the first study. The overall outcome of the study was that P4 again degraded rapidly from 
an initial 1,000 µg/L concentration (Fig. 4.22), with the concentration falling to <0.81 µg/L 
(method LOQ) after 48 h.  Comparing only the total time it took for spiked progesterone 
concentration to be completely degraded in both studies, it would appear P4 degraded faster 
in the second study relative to the first as nominal concentration fell to <0.81 µg/L just after 48 





Figure 4.22: Comparison of the rate of degradation for P4. Similar to the first study, P4 
concentration decreased with increasing incubation time, with concentration falling below 0.81 
µg/L (method LOQ) by 48 hours (Instrument LOD (0.27 ng/ml). Total degradation time was 24 
hrs quicker in the second study 
 
Low Resolution Detection of Putative Transformation Products 
Similar to the first study results, a number of suspected masses corresponding to TPs were 
detected under both low-resolution monitoring, as the P4 concentration declined. Prior to the 
second study mass spectrometry suspect screening, a further review of literature (Peng et al. 
2014; Carson et al. 2008; Jenkins et al. 2004) had identified three additional transformation 
products (testosterone, 5α-dihydroxytestosterone and epi-androsterone) resulting from 
progesterone degradation, compounds which are also known to exhibit androgenic effects. 
The molecular weights of 5α-dihydroxytestosterone and epi-androsterone were the same (290 
Da).  Thus, the list of suspect masses monitored in unit resolution was updated in the second 
study by the addition of two more masses (289.5 (TP-ALG-5) and 290.5 (TP-ALG-6)) (Table 
4.9). Eight putative TPs of the eleven target products monitored in unit resolution were 
detected, some just 20 minutes after spiking. Peaks corresponding to TP-ALG-5 and TP-ALG-






























Table 4.9: Additional masses monitored under unit resolution 
Name Abbr. Mol. 
Wt. 
CAS m/z RT* 
(%RSD) 
R/RT* 












Figure 4.23: Overlaid chromatograms (top) and mass spectra (bottom) showing the formation 
of TP-ALG-5 formed by a side chain breakdown (-2C and -4H) of the parent progesterone 
molecule. TP-ALG-5 appeared 4hrs after spiking. Peak height progressively increased in size 





Figure 4.24: Overlaid chromatogram and mass spectra for the two peaks corresponding to 
TP-ALG-6. Mass for the peak at 15.80 seconds shows it is most likely m/z 329.3 (TP-BBD-1) 
as it recorded the highest response relative to m/z 291.3. Conversely, the peak at 18.39 
seconds is most probable peak for TP-ALG-6 (m/z 291.3 had the highest response. 
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High Resolution Detection of Putative Transformation Products 
High resolution mass spectrometry confirmed the presence of four of the products detected in 
unit resolution. These products were seen only in the 24 h samples, indicating that they 
degraded afterwards. Two of the products, TP-ALG-1 and TP-ALG-4 were present in the initial 
degradation study. However, two new products (TP-ALG-2 and TP-ALG-5) not found in the 
first study were confirmed to be present in the second study.  The chemical formulae of these 
new products and their accurate mass determined to four decimal places are presented in 
Table 4.10. CID fragmentation of these new products was attempted, but concentrations were 
too low to work with. 











TP-ALG-2 316.2387 316.2402 317.2466 C21H32O2 75.7 -4.61 
TP-ALG-5 288.2088 288.2089 289.2160 C19H28O2 97.9 0.28 
 
4.3.4.1 Linking the Degradation of Progesterone to Biological Activity 
It was deemed important to assess not only chemical degradation, but also evaluate any 
possible biological activity associated with degradation products. This was particularly 
important as putative products such as testosterone, may exhibit activity and cause effects in 
the environment. Sampling for ecotoxicological work was done by measuring 5 mL of sample 
from the spiked and non-spiked tanks followed by the addition of 5 mL of ethanol, representing 
a 50:50 dilution. Volume of sample taken was such that there was enough sample stored at -
800C for multiple confirmatory yeast screen. Sample dilution with ethanol was done following 








4.3.4.1.1 Progesterone Screen 
For the yeast screen, all calculations are done relative to a standard curve (P4 curve in Figure 
4.19 (now Figure 4.25)). The P4 concentration used for the screen ranged from <0.1 to 78 
µg/L. Concentration of P4 in test tanks at different sampling times relative to P4 equivalent 
concentrations are shown in Figure 4.25. The analysis of samples using the yeast screen 
supported chemical analysis results. The P4 concentration decreased with increasing 
degradation time. Figure 4.25 shows a decrease in spiked P4 potency with time. No activity 
was recorded in the control tanks. No progestogenic activity was noticed in spiked tanks after 
24 h of incubation. After 24 h there was a reduction in progestogenic activity compared with 
P4 standard curve (no dose response was seen in the other times (curves flatten out). This is 
most probably because residual P4 concentrations if any in samples beyond 24 h were not 
high enough to elicit a dose-response curve and/or that degradation products formed did not 
retain the parent compound’s biological activity. Chemical analysis results indicated that 
residual P4 concentrations in spiked tanks were <0.81 µg/L at 48 h, lower than the minimum 
concentration (3.15 µg/L LOD and literature reported P4 concentration below which no activity 
is seen. See section 2.6.1)) needed to activate the progesterone receptor in the assay. 
Absorbance correction is a standard literature supported protocol performed to eliminate 




Figure 4.25: Yeast assay for P4 receptor activity. Potency of spiked P4 decreased with time 
until the 24 h, after which concentrations were too low to elicit a dose-response curve. (DT: 
Degradation Tank; CT: Control Tank) 
 
4.3.4.1.2 Androgen Screen 
The androgen screen response curve for the positive control dihydrotestosterone (DHT) 
relative to other degradation time points is shown in Figure 4.26. Absorbance was plotted 
against the equivalent concentration of DHT in assay wells to give an indication of the relative 
concentration of androgenic TPs. Androgenic response for the positive control was observed 
to start at a low concentration of 0.45 ng/L DHT, showing the high sensitivity of the assay. The 
responses observed at 0 h and 24 h, are similar to those seen in the progesterone screen and 
probably do not represent androgenic activity, but cross reactivity of progesterone with the 
androgen receptor, a condition reported in the literature. Reported in vivo experiment shows 
that progesterone can interact with other steroidal nuclear receptors especially the androgen 
receptor. Reported control for the observed cross reactivity is to run the screen on a test 
sample solely spiked with a given androgen. This is however, not possible in the present study 











































implication therefore is, P4 will always be present in test tanks until it is degraded below the 
minimum concentration needed to activate the androgen receptor. No activity was recorded 
in the control tanks. 
No similar or close response was seen in the samples for other time point as P4 degraded. 
These results show that as P4 degraded, resultant androgenic TPs concentration were below 
0.03 µg/L, the minimum concentration of androgenic compounds needed to activate the 
androgen receptor. If 20% of progesterone were to degrade into an androgen over 48 hours, 
this would be equivalent to 200 μg/L of that androgen in the present study considering that 
tanks were spiked at relatively high concentration of P4 (1,000 μg/L). Such concentration 
would have been high enough to cause an observable response in the 48 hours samples. But 
this was not the case. Samples used for the present assay were in aqueous phase compared 
to the conventional use of concentrated samples. As noted earlier, samples were not 
concentrated up because of the uncertainty involved if a given SPE method is applied in the 
recovery of TPs whose chemical identity and properties are unknown. The use of these 
aqueous solutions is relevant considering that any androgen occurring in the environment as 
a result of progesterone degradation will exist in a similar phase. Thus, it is reasonable to 
conclude in the light of the present results that though P4 degrades to androgen as shown by 
chemical analysis, the concentrations in the environment are unlikely to represent any 




Figure 4.26: Androgen screen response curve. Response seen at 0 h (15 minutes after 
spiking) and 24 h probably does not represent androgenic activity, but cross-reactivity of P4 
with the androgen receptor. High concentration of P4 is reported in the literature to activate 
the androgen receptor. 
 
4.3.5 Repeatability of P4 Degradation across multiple sites 
Following the second degradation study that confirmed the reproducibility of progesterone 
degradation in the Maple Cross location, a third study was undertaken. As noted in section 
3.3.2, this third study was designed to observe and compare P4 degradation across multiple 
sites. Sampling time and conditions were kept the same to minimize temporal variability in 
conditions and allow for effective comparison of results. 
The conditions within the control and degradation tanks for all sites were stable for the entire 
study period. Temperature was stable from 22 to 240C and pH at 8.1 to 8.8 (Table 4.11).  



































High Wycombe degradation tanks. However, DO dropped at 24 hours to 7.1 and 7.8 in the 
other sites and remained below 8.0 mg/L for the remaining study period. There were no 





Table 4.11: Physical-chemical conditions in degradation tanks across sites 
Sample Degradation Tanks (DT) (Spiked) Control Tanks (CT) (Non-Spiked) 
  High Wycombe Chesham Blackbirds High Wycombe Chesham Blackbirds 
























A 8.2 8.4 23.4 8.1 8.8 24.1 8.1 8.5 24.0 8.2 9.7 23.6 8.1 8.7 23.7 8.0 8.5 24.2 
0 8.1 8.5 23.0 8.0 8.7 24.7 8.0 8.4 23.6 8.2 8.7 23.3 8.1 8.8 23.4 8.0 8.5 24.0 
4 8.1 8.4 23.1 8.1 8.8 24.8 8.1 8.5 23.4 8.2 8.8 23.4 8.1 8.7 23.5 8.1 8.6 24.0 
8 8.2 8.4 22.5 8.1 8.8 23.3 8.1 8.5 23.2 8.3 8.7 22.7 8.3 8.8 22.9 8.2 8.6 23.0 
12 8.3 8.3 22.0 8.2 8.8 22.6 8.1 8.6 22.5 8.3 8.5 22.6 8.3 8.8 22.5 8.2 8.6 23.0 
24 8.3 8.3 22.6 7.1 8.4 23.4 7.9 8.3 23.2 8.3 8.4 23.2 8.3 8.7 23.0 8.2 8.5 23.4 
48 8.4 8.4 21.6 7.5 8.1 22.8 8.1 8.3 22.4 8.4 8.1 22.4 8.4 8.8 22.4 8.3 8.6 22.7 
72 8.3 8.4 21.9 7.6 8.2 22.7 8.1 8.3 22.5 8.5 8.3 22.3 8.5 8.8 22.3 8.3 8.7 22.8 
*A: Starting conditions in tanks prior to spiking     
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Overall, spiked progesterone concentrations (1,000 µg/L nominal) degraded rapidly such that 
concentrations at the Chesham and Blackbirds sites were below instrument limit of 
quantification (0.96 µg/L) (Fig 4.27) after 48 hours of degradation.  As noted in section 4.3.4, 
the sensitivity of the analytical method (LOD) was determined at each run by calculating the 
signal-to-noise-ratio of the progesterone peak recorded in the lowest calibration standard. 
However, approximately 100 µg/L of the spiked P4 concentration was left after 72 hours of 
degradation in the High Wycombe site, representing 90% breakdown of the nominal 
progesterone concentration. Measured starting concentrations were below (Fig 4.27) nominal 
concentration (1,000 µg/L) in all sites in this study relative to the previous studies. This 
observation may be because volume of P4 used for spiking in the third study or solvent 
volumes measured when preparing calibration standard, were not exactly right. However, the 
degradation trend was the same for all studies. The High Wycombe location was the only 
location in all the degradation studies that had residuals of P4 detected after 72 hours of 
degradation. This observation can be attributed to two possible factors, namely; variation in 
microbial community in the High Wycombe site relative to the other sites or that existing similar 
microbial population in this site were less metabolically active relative to the Maple Cross, 
Chesham and Blackbirds sites. Progesterone was degraded below analytical method limit of 





Figure 4.27: Comparison of P4 rate of degradation across degradation sites. Like the first and 
second studies, P4 nominal concentration (1000 µg/L) decreased with increasing incubation 
time, with concentration falling below 0.96 µg/L (methods LOQ) in 48th hour at all sites except 
in High Wycombe where remnant (approx. 100 µg/L) of P4 were detected at 72nd Hour of 
degradation (Instrument LOD (0.32 µg/L)). 
 
Low Resolution Detection of Putative Transformation Products 
Like the first and second studies, peaks corresponding to monitored suspected masses, were 
detected as progesterone concentration decreases. Masses detected and their corresponding 
transformation products codes are illustrated with m/z 313 (TP-ALG-1) (Fig. 4.28) and 287 
(TP-ALG-4) (Fig. 4.29). Detected transformation products were similar to those reported in the 

























Maple Cross (1st Study)








Figure 4.28: Overlaid chromatogram (top) and mass spectra (bottom) showing detected peak 





Figure 4.29: Overlaid chromatogram (top) and mass spectra (bottom) showing detected peak 
corresponding to m/z 287 across sites under low resolution. Mass spectra for peaks 
highlighted in chromatogram for all sites were like the ones presented here. 
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High Resolution Detection of Putative Transformation Products 
High resolution mass spectrometry confirmed the presence of three of the products (TP-ALG-
1, TP-ALG-4 and TP-ALG-5) detected in unit resolution and one of the ones predicted by the 
biodegradation database, m/z 329 (TP-BBD-1). TP-BBD-1 was found at m/z 329.2115 which 
corresponded to a mass of 328.2038 (0.72 ppm error) and proposed molecular formula 
C21H28O3. Product TP-ALG-4 was present in samples from all study sites including Maple 
Cross (Table 4.12). While this product was degraded after 48 h in samples from Maple Cross, 
Chesham and Blackbirds, it was still seen at 72 hours in samples from the High Wycombe 
site. Product TP-ALG-5 was also detected at 72 h in the High Wycombe site and not in the 
others. Product TP-BBD-1 was detected only in the High Wycombe, Chesham and Blackbirds 
sites and not in Maple Cross.  This product was also seen at the 72 h in the High Wycombe 
samples relative to the other sites. TP-BDD-1 corresponded to a molecular mass of 328.2038 
(monoisotopic mass was 324.2038), a 2.32 ppm error and a proposed molecular formula of 
C21H28O3, which matches with the database predicted formula for this product. Two of the 
products, TP-ALG-1 and TP-ALG-4 were present in the initial degradation study. 
Table 4.12: Summary of High Resolution Data for Detected TPs at all Sites 
TPs Locations 
 Maple Lodge High 
Wycombe 
Chesham Blackbirds 
 1st Study 2nd Study    
TP-ALG-1 + + + + + 
TP-ALG-2  +    
TP-ALG-3      
TP-ALG-4 + + + + + 
TP-ALG-5  + +   
TP-ALG-6      
TP-BBD-1   + + + 
TP-BBD-2           
*+: Present in samples from that site 
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4.4 The Half-life (t1/2) and Kinetic Rate Constant of Progesterone 
Degradation Across Sites 
The interest in half-life and kinetic rate constant was to further understand the empirical 
variation in degradation rate seen in Figure 4.27 and to compare results of the present study 
with those reported in the literature. Such comparison is aimed at putting the results obtained 
in perspective and of establishing the reliability of degradation approach adopted in this study. 
A review of literature shows that no study till date had investigated P4 degradation in surface 
waters. Thus, a comparison of kinetic rate and half-life reported for batch experiment with the 
present study result, will fill a gap in knowledge.  
The degradation of P4 followed the first-order reaction model (Figure 4.30a and b).  Half-life 
and kinetic rate constant were calculated using the relation presented in equations 3 and 4 
(section 3.3.2). The kinetic parameters including the kinetic rate constant (k) and the half-life 
(t1/2) are given in Table 4.13. Degradation rate was faster in the Chesham (0.1024 h) and 
Blackbirds (0.1025 h) locations relative to the other two (Maple Cross and High Wycombe). 
This is also reflected in their similar half-life of 6.77 h and 6.76 h respectively. This observation 
may be due to similarity in microbial community and metabolic rate in the two locations. The 
second study at the Maple Cross was had a higher degradation rate (0.1106 h) relative to the 
first (0.0459 h) even though sampling was done at the same location and at the same season. 
Perhaps, the microbial community were more diverse or if they were the same as the first, 
they are more active than before. Progesterone degraded least (0.0236 h) in the High 






Figure: 4.30a: Comparison of progesterone degradation kinetic rate constant and half-life 
across different sites. Plots to the left represent first order degradation curve and the one to 
the right, rate constant plot. Progesterone degradation rate and half-life were similar for the 
Chesham and Blackbirds sites. Degradation rate was least in the High Wycombe and half-life 






Figure: 4.30b: Comparison of progesterone degradation kinetic rate constant and half-life 
across different sites. Plots to the left represent first order degradation curve and the one to 
the right, rate constant plot. Progesterone degradation rate and half-life were similar for the 
Chesham and Blackbirds sites. Degradation rate was least in the High Wycombe and half-life 
was longer (29.39 h). 
 
 
Table 4.13: Kinetic Parameters and Half-life of Progesterone Degradation 
Location Rate constant (k)(h) R2 Half-life (t1/2) (h) 
Maple Cross 1 0.0459 0.99 15.11 
Maple Cross 2 0.1106 0.95 6.27 
Chesham 0.1024 0.95 6.77 
Blackbirds 0.1025 0.95 6.76 
High Wycombe 0.0236 0.95 29.39 
*h: Hours; k: Kinetic rate constant, calculated using the first-order reaction kinetic model (C = C0*exp(-





















5.0 General Discussion 
5.1 Analytical Methods 
 
5.1.1 Analysis of Model Compounds and Suspected Transformation 
Products in Reed Bed 
As discussed in section 3.2 and 4.3.2, a relatively simple multi-residue analytical method 
involving an SPE extraction step, was developed and applied briefly to detect model 
compounds and suspected TPs in  influent and effluent from reed beds.  The determination of 
the presence or absence of TPs in samples, involved the extraction of the chromatogram for 
a given product in a sample and overlaying it with the corresponding extracted chromatogram 
in the control (blank: double deionised water). All peaks found in samples that were also 
present in the control, were excluded. Response had to occur only in the spiked sample for 
peaks to be considered as possible degradation products.  The quantitation of transformation 
products was not undertaken. Suspected TPs of P4 were the sole focus in reed bed sample 
analysis owing to progesterone rapid degradability relative to the other model compounds (see 
section 3.2.2). It was thought that, to validate developed SPE method in the recovery of 
degradation products, a compound that was known to readily degrade in the environment was 
ideal as its associated TPs were expected to be present in reed bed samples.  
Multi-residue methods involving SPE procedure are popular in analytical chemistry especially 
for parent compound, and involve the application of a single analytical method for the 
determination of a range of compounds in aqueous environmental samples. For example, 81 
pharmaceuticals covering several therapeutic classes were determined in surface water by 
the application of a multi-residue analytical method that was based on automated off-line SPE 
and followed by high performance liquid chromatography coupled to a quadrupole linear ion 
trap mass spectrometer (Gros et al., 2012). As noted in section 2.2.1, some workers have 
applied extraction procedures in the analysis of TPs in environmental matrices, but mostly in 
target screening were the identity of TPs are known and associated standards are available. 
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For example, a sample extraction step was used in the target analysis of metabolites of the 
analgesic dipyrone in effluent samples to avoid the assignment of erroneous identifications to 
detected TPs (Ibáñez et al. 2012). However, because most TPs are unknown, analytical 
standards are largely unavailable and the understanding of their binding properties to sorbent 
materials is limited, extraction procedures that have been applied by some researchers in 
transformation studies, are usually not complicated, but generic and robust involving mostly 
the use of Oasis HLB (Pico et al. 2015; Al-Odaini et al. 2010; Kasprzyk-Hordern et al. 2007; 
2009a, b).  See section 2.2.1.1 for reasons for the preferred use of Oasis HLB relative to other 
sorbents. A major drawback highlighted in the literature for the application of extraction 
methods to suspect and non-target screen, is the potential for loss of TPs due to breakthrough, 
because of the absence of analytical standards for most TPs and the lack of knowledge on 
their binding properties (Pico et al. 2015; Krauss et al. 2010; Kern et al. 2009).  
As noted in section 4.3.2, only one peak corresponding to the biodegradation database 
predicted ring cleaved product, TP-BBD-1, was detected. None of the commonly reported 
products relating to side-chain modification of the P4 structure, were detected (see Table 2.1). 
Because, literature recommended hydrophilic-lipophilic balance reversed-phase sorbents, 
Oasis HLB, was used in this study and suspected TPs were largely undetected, it is believed 
that suspected TPs monitored and commonly reported for P4, could have been present in 
samples, but lost due to breakthrough effect. The application of the concentration step (SPE) 
of unknown efficiency was thought to have added some uncertainty, as if the products were 
present, but not retained by cartridges. This may have resulted in a false negative outcome.  
A further sampling of reed beds was planned to compare results. However, because of limited 
access to the site, it was not possible to do further sampling of the reed beds. Thus, the present 
study moved on to spiking river water in the laboratory with high concentration of progesterone 
such that concentrations of transformation products formed can be detected in aqueous 
solution without the application of an SPE process whose efficiency for unknown TPs could 




5.1.2 Removal of Parent Compounds by the Reed Bed 
As discussed in section 4.2.1 of this work, a further aim of the sampling done at Barston STW 
was the measurement of the concentrations of four model parent compounds including 
progesterone, to briefly assess reed beds performance in removing these compounds. Reed 
beds have been reported to have varying removal efficiency for a range of pharmaceuticals 
depending on individual compound’s properties (e.g. Koc, Kow, hydrophobicity, planarity, 
lipophilicity, etc.), reed beds characteristics (type of reed beds and operational design 
including effluent (hydraulic) retention time), associated flora and extent of colonization, 
environmental factors and soil properties (Verlicchi & Zambello, 2014; Li et al. 2014).   
Concentration of individual compounds in influent was compared with their corresponding 
concentrations in effluent following influent polishing by the reed bed. Comparison of 
concentration pharmaceuticals in influent samples with their corresponding concentration in 
effluent is a common approach applied in measuring reed beds performance. For example, 
Verlicchi & Zambello, 2014 reported a removal efficiency of 88 and 99% for sulfamethoxazole 
and acetaminophen in horizontal subsurface flow and surface flow reed beds when the 
concentrations of the two pharmaceuticals in influent and effluent samples were compared. 
Diclofenac is reported to be among most readily removed pharmaceuticals by reed beds with 
over 70% removal efficiency in both surface and subsurface flow systems (Kucerak 2014; 
Verlicchi & Zambello, 2014; Li et al. 2014).  
In the present study, removal was highest for fluoxetine, followed by progesterone, diclofenac 
and propranolol. Removal of target compounds was generally above 65% for all model 
compounds. Observed 73% removal of DCF in reed beds is similar to those reported in the 
literature (Kucerak 2014; Verlicchi & Zambello, 2014; Li et al. 2014). Progesterone influent 
concentration of 7 ng/L was removed to 1 ng/L in effluent, representing 90% removal 
efficiency. This result was similar to that reported by Vymazal et al. (2015), in their study of 
steroids removal efficiency by horizontal subsurface flow system. Progesterone influent 
concentration of 20 ng/L in that study, was removed to below analytical method limit of 
quantification (LOQ=0.5 ng/L) in effluent. Removal efficiency similar to P4 was further reported 
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by Vymazal et al. (2015), for the other steroids, estrone, estriol, 17β-estradiol, 17α-
ethinylestradiol and testosterone.  Similar high removal efficiency was reported when the 
proportion of estrogenic and androgenic activities in influent and effluent samples treated with 
reed beds were compared. Cai et al. (2012), reported a 95% and 92% removal efficiency for 
estrogen and androgen respectively when dairy wastewater was treated with surface flow reed 
beds. Overall, reed beds appear to be an effective tertiary treatment option. 
At the time of sampling reed beds, reeds diversity could not be determined as reeds had not 
fully colonized the bed surface (very sparse reed distribution). Associated reed bed soil 
properties such as organic carbon content (critical for model compounds’ partitioning 
behaviour to soil) was not known and hydraulic retention time was zero as effluent sample 
(outlet of reed bed) was taking immediately after flooding with influent (spot sampling).  These 
are factors reported (Verlicchi & Zambello, 2014; Li et al. 2014) to influence organic 
compounds removal by reed beds. The plan was to determine these factors in subsequent 
visit to the site. However, because further access to site was not possible, the reed beds 
characteristics (factors mentioned above), could not be determined and subsequent 
modification of sampling protocol to compare results, could not be achieved. Furthermore, 
initial work in reed beds used P4d9 as a sole IS, with the intention that further work will use 
compound specific IS, which were not available at the time the first sampling was carried out. 
The sole use of one IS for compound quantification, was thought to lead to some bias, in that 
we were correcting for recovery using a compound with different characteristics and which 
may respond differently in different matrices. The use of compound specific IS may not always 
eliminate problems associated with ionisation efficiency in MS analysis (Gomez et al. 2004), 
let alone when they are dissimilar to the compound they quantify. Thus, the results presented 
for concentrations of model compounds in reed beds and their performance in removing model 




5.2 Progesterone Degradation 
5.2.1 Chemical Analysis and Biological Assays  
Results of progesterone degradation were the same in both chemical and yeast assays. 
Progesterone concentration and associated progestogenic activity decreased with increasing 
incubation time. Results of the present study are similar to chemical analysis results reported 
by Janna (2011), who monitored the degradation of a range of progestogens including P4. 
Janna (2011) reported a decrease from 410 ng/L nominal progesterone concentration to 6 
ng/L after 24 hours of incubation. Cwiertny et al. (2014) noted that there are situations were 
decrease in a parent compound’s concentration in a degradation system, is marked by 
corresponding increase in biological activity, showing the formation of bioactive TP(s). This 
report, informed the inclusion of biological screens in the present study design to determine if 
degradation of P4 was associated with increased progestogenic or androgenic activity and to 
what extent. The observed decrease in progestogenic activity in the present study was not 
marked by a corresponding increase in androgenic activity seeing that androgens were 
detected in chemical analysis. The responses observed at 0 h and 24 h, were similar to those 
seen in the progesterone screen and may not represent androgenic activity, but cross 
reactivity of progesterone with the androgen receptor, an effect previously reported in the 
literature (Runnalls et al., 2013). Runnalls et al. (2013) in vivo experiment on the relative 
potency of synthetic progestogens on the fathead minnow indicated that these compounds 
can interact with other steroidal nuclear receptors especially the androgen receptor. 
Recommended control in the literature (Runnalls et al. 2013) for the observed cross reactivity 
of progesterone in androgen screen, is to run the screen on a test sample solely spiked with 
a given androgen. This was however, not possible in the present study as the main intent is 
to observe spiked progesterone degrading into androgens. The implication therefore was, P4 
was always present in test tanks until it was degraded below the minimum concentration 




5.2.2 The Efficiency of the EAWAG Biodegradation Database Prediction 
As mentioned in section 4.3.1, in addition to literature reported TPs of P4 that were selected 
for monitoring under low resolution, the EAWAG Biodegradation Biocatalysis Database 
pathway prediction system was used to predict other potential products of progesterone 
transformation in the environment. The efficacy of the BBD in predicting real time metabolism 
of pharmaceuticals and other contaminants (including pesticides) has been reported by 
Prasse et al. (2011) and Helbling et al. (2010). 
In the present study, the database predicted five bacteria mediated products (TP-BBD) (Fig. 
4.11) resulting from the cleavage of the ‘B’ ring in the P4 C21 pregnane skeletal backbone 
through a two-step aerobic prediction system. The ring cleavage of P4 predicted by the BBD 
may hardly have occurred as only m/z 329.3 corresponding to one (TP-BBD-1) of the five BBD 
predicted masses was seen in all study sites. Biotransformation rule 0356 that facilitated the 
formation of TP-BBD-1 was reported to facilitate several steps in steroid metabolism including 
aromatization, spontaneous ring cleavage and oxidation (Philipp, 2011; Horinouchi et al., 
2005). However, it has a 50% likelihood of occurrence in an aerobic system. The assumption 
on the possible factors that may have accounted for this observation were:  
A. The aerobic condition of the degradation tank may not have favoured reactions that 
yield BBD-predicted transformation products. 
B. BBD-predicted transformation products are rapidly formed and degraded at a rate that 
the present study sampling regime is unable to detect 
C. The microbial community available in degradation tank may be less diverse/active and 
thus not include bacterial strains predicted by the database to carry out reactions that 
yield its predicted TPs. 
D. Cleaving of the P4 ring may require too high an input of metabolic energy; instead, 
degrading microorganisms favour the alternative carbon source available in side 
chains and that requires relatively less energy. 
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The low occurrence of the database predicted TPs observed is not specific to the present 
study alone. In the Prasse et al. (2011) study mentioned earlier, the database predicted 58 
possible products out of which just four were observed in their batch experiment. Furthermore, 
the database accessory pathway prediction system has been reported to predict irrelevant 
TPs  (low selectivity) that are unlikely to be seen in real environmental situations (Fenner et 
al., 2008). These performance issues were the reason for the development of the new tool 
(enviPath) designed as an improvement and replacement for the EAWAG BBD (Wicker et al. 
2016). 
Using this new tool (enviPath), the degradation of P4 was modelled. The structures and names 
of predicted TPs are presented in Figure 5.1. The molecular formulae and isotopic masses of 
the predicted TPs are presented in Table 5.1. The information on progesterone has been 
included in the Table 5.1 for easy reference. Side-chain modification of peripheral atoms 
relative to ring-cleavage predicted by the EAWAG BBD, was responsible for the formation of 
enviPath predicted TPs. Hydroxylation was the main pathway responsible for the formation of 
predicted TPs. Product TP-ALG-2 detected in the second study in the Maple Cross location 
(see Table 4.12) corresponds to enviPath predicted Pregnane-3,20-dione. It would be recalled 
that this product (TP-ALG-2) was detected following HRMS in the first study, but with lower 
degree of confidence as its intensity was low and molecular formula could not be generated. 
The peak corresponding to this product was however stronger in the second study at Maple 
Cross and molecular formula could be generated. The predicted molecular formula and 
isotopic mass by enviPath, corresponds to HRMS measured mass and formula for TP-ALG-2 
(compare Table 4.10 and Table 5.1). A review of literature on evidence of enviPath application 
with a view to comparing other workers report on its predictive power was not successful. 
Publications available either referred to the Eawag-Soil public database developed in 
enviPath, and containing all freely accessible regulatory data on pesticide degradation in 
laboratory soil simulation studies for pesticides registered in the EU (Latino et al. 2017), or 
applied EAWAG BBD and only passively mentioned enviPath as a new tool (Tratnyek et al. 





Figure 5.1: enviPath Predicted transformation products of progesterone. Side-change 





Table 34: enviPath Predicted Transformation Products of Progesterone 
Predicted TPs Name Molecule Formula Isotopic Mass (Da) 
P4 (Pregn-4-en-3,20-dione) C21H30O2 314.2246 
Pregnane-3,20-dione C21H32O2 316.2402 
11-Hydroxypregn-4-ene-3,20-dione C21H30O3 330.2195 
12-Hydroxypregn-4-ene-3,20-dione C21H30O3 330.2195 
15-Hydroxypregn-4-ene-3,20-dione C21H30O3 330.2195 
14-Hydroxypregn-4-ene-3,20-dione C21H30O3 330.2195 
21-Hydroxypregn-4-ene-3,20-dione C21H30O3 330.2195 
16-Hydroxypregn-4-ene-3,20-dione C21H30O3 330.2195 
7-Hydroxypregn-4-ene-3,20-dione C21H30O3 330.2195 
17-Hydroxypregn-4-ene-3,20-dione C21H30O3 330.2195 
6-Hydroxypregn-4-ene-3,20-dione C21H30O3 330.2195 
(5β)-5-Hydroxypregnane-3,20-dione C21H32O3 332.2351 
1-Hydroxypregn-4-ene-3,20-dione C21H30O3 330.2195 
9-Hydroxypregn-4-ene-3,20-dione C21H30O3 330.2195 
 
 
5.2.3 Degradation Pathways 
The reactions that resulted in detection of most m/z linked to the TPs observed in the 
degradation study were hydroxylation, hydrogenation, dehydrogenation, ketone and hydroxyl 
functional group interconversion and side-chain breakdown. Sometimes, individual pathways 
proceeded alone to form products. But most often, several pathways acted together to produce 
a given TP. Of these pathways, dehydrogenation and side–chain breakdown were the 
dominant pathways as determined empirically by a combination of their peak area and the 
prevalence of their TPs across study sites.  For example, the major transformation product of 
the first study was TP-ALG-1, as determined by comparison of products peak areas (Fig. 5.2).  
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It was not possible to calibrate the instrument on unknowns, so, peak area was used. A given 
compound’s peak area is affected by factors such as ionisation efficiency, such that a higher 
size area may not mean more of that compound is present than another. For the degradation 
products and their associated pathways, however, peak area provided an empirical 
assessment of their possible significance and their change with time. The metabolic reactions 
identified for P4 degradation have earlier been reported as the main transformation pathways 
for progesterone degradation by some strains of fungi, the cyanobacterium Microchaeta 
tenera and two freshwater microalgae, Scenedesmus obliquus and Chlorella pyrenoidosa 
(Polio et al., 1994; 1996, Safiarian et al., 2012 and Peng et al., 2014). Peng et al. (2014) study 
spiked with an initial P4 concentration of 503 µg/L and 250 mg/L by Safiarian et al. (2012).  
Accordingly, it is possible that P4 transformation observed in this study may have been carried 
out by a consortium of microorganisms using P4 as a carbon source and utilizing diverse 
reaction pathways. 
TP-ALG-1 was formed by a dehydrogenation reaction at C1 and C2 resulting in the formation 
of a double bond between these carbon atoms. This is a common bacterial and algal mediated 
transformation pathway in natural and engineered treatment systems. For example, 
boldenone was reported to be formed from testosterone by bacteria-mediated 
dehydrogenation at C1 and C2 of the parent molecule (Cwiertny et al., 2014; Yang et al., 
2011). Microbial (Nocardia sp.) mediated dehydrogenation of ring D of 17β-estradiol at C17 
was a contributory pathway in the formation of estrone (Yu et al. 2013; 2007). 
Dihydrotestosterone was reported to have also been formed from testosterone by 
dehydrogenation at C4 and C5 of the parent compound (Peng et al., 2014). TP-ALG-2 was 
formed by the hydrogenation reaction at C4 and C5 resulting in the loss of the double between 
those carbon atoms in the parent molecule. A similar pathway was reported for the formation 
of 4,5-dihydronorgestrel from algae-mediated hydrogenation of C4 and C5 of norgestrel by 





Figure 5.2: Chemical reactions that yielded the transformation products identified in this study. 
Based on peak areas, dehydrogenation was the most dominant reaction. 
 
Hydroxylation is another important pathway commonly reported in the literature for the 
biological transformation of pharmaceuticals. For example, degradation of 17β-estradiol into 
4-hydroxyl-17β estradiol by the aerobic bacteria Sphingomonas sp. was reported by Kurisu et 
al. (2010), to proceed by hydroxylation at C4. Similarly, hydroxylation of C2 in 17α-ethinyl 
estradiol by nitrifying bacteria was reported to result in the formation of 2-hydroxyl-17α-ethinyl 
estradiol (Yi & Harper, 2007). Also, the hydroxylation of C6 of 17α-ethinyl estradiol by the 
microalgae Ankistrodesmus braunii was reported to yield 6-hydroxyl-17α-ethinyl estradiol 
(Della Greca et al., 2008). Hydroxylation, reduction and the side-chain degradation, were also 
reported as the dominant pathway for P4 degradation by microalgae (Safiarian et al. 2012; 
Polio et al. 1994; 1996). In the present study, hydroxylation of the ketone group at C3 of P4 
was a contributory pathway in the biotransformation of progesterone to TP-ALG-3. Side-chain 
breakdown was an important pathway in the formation of TPs suspected to be androgens in 


























COCH3 at C17 of progesterone and subsequent hydroxylation at C17. This could be followed 
by dehydrogenation at C1 and C2 of P4 to form boldenone or oxygenation of C17 into ketone 
to form androstene (Peng et al., 2014). TP-ALG-5 was formed by similar side chain breakdown 
and subsequent hydroxylation of C17.  Dehydrogenation at C4 and C5 of P4 following side-
chain cleavage and hydroxylation at C17 resulted in the formation of one of the possible 
compounds depicted as TP-ALG-6 in this study, dihydrotestosterone. Hydroxylation would 
account for the formation of epi-androsterone (the other form of TP-ALG-6) from TP-ALG-4, 
assuming TP-ALG-4 was 4-androstene-3,17-dione as reported by Peng et al. (2014). 
 
5.2.4 Identification of the Transformation Products 
The identification of transformation products was achieved by applying a mass defect filter in 
HRMS. This was followed with fragmentation by collision induced dissociation of any feature 
recorded. The systematic approach followed in this study for the identification TPs have been 
reported previously. For example, Ruff et al. (2015) applied mass defect filtering and collision 
induced dissociation in the target and non-target analysis of polar compounds in a major river 
in central Europe. Guan et al.  (2006) applied collision induced dissociation in the elucidation 
of the fragmentation pathways of anabolic steroids, including boldenone, trenbolone and 
tetrahydrogestrinone.  Similarly, analysis of chromatograms for peaks of an exact mass that 
are derived from the known molecular formula of suspect TPs, comparison of their structure, 
retention behaviour and MSn fragmentation are common approaches used in the literature for 
the identification and confirmation of suspect TPs (Bletsou et al. 2015; Hug et al. 2014; 
Gómez-Ramos et al., 2011; Kern et al., 2009).  In all degradation studies, five features were 
found; m/z 313.2170 (TP-ALG-1), m/z 317.2466 (TP-ALG-2), m/z 287.1997 (TP-ALG-4), m/z 
289.2160 (TP-ALG-5) and m/z 329.2115 (TP-BBD-1). TP-ALG-2 that was detected with a 
lower degree of confidence in the first study because of the lack of a molecular formula and 
very low intensity was seen in the other studies with high confidence (Refer to Tables 4.6 and 
4.10 for HRMS data). Collision induced dissociation (CID) fragmentation of the detected 
features was however successful only for m/z 313.2170 and 287.1997 and not the others 
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because their concentrations were too low to work with. CID MSn fragmentation of the m/z 
corresponding to TP-ALG-1 and TP-ALG-4, showed similar fragment ions at m/z 121.0648 
and 121.0643 respectively (Table 4.7 and Fig. 4.17). Fragmentation of both TP-ALG-1 and 
TP-ALG-4 was believed to have occurred in the A-ring, most probably due to protonation of 
the ketone group attached to C3 (Fig. 5.3). Subsequent relocation of the positive charge either 
on carbon 1 or 5 due to resonance resulted in the dissociation of the bond between C9 and 
C10. CID experiments for m/z 287.1997 helped to identify this feature as boldenone since the 
two major fragments of 121.0643 and 135.1161 are likely to be produced via the fragmentation 




Figure 5.3: Proposed fragmentation scheme for the generation of the fragments ions of m/z 
313 (TP-ALG-1). Similar scheme was reported by Guan et al. (2006) for the generation of the 
major fragment (m/z 121 and 135) of boldenone (i: inductive cleavage; rH1,2: rearrangement 
of a hydrogen atom to an adjacent carbon with concurrent site arrangement of the charge). 
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The high-resolution data provided accurate masses for TP-ALG-1, TP-ALG-2, TP-ALG-4, TP-
ALG-5 and TP-BBD-1 as 312.2097, 316.2402, 286.1933, 288.2089 and 328.2038 
respectively. For TP-ALG-1 this matches the theoretical monoisotopic mass/formula for 1, 4-
pregnadiene-3, 20-dione, a reported derivative of P4 degradation. The accurate mass of 
286.1933 for TP-ALG-4, fits the theoretical monoisotopic mass/formula for androstenedione 
and boldenone, both reported derivatives of P4 (Peng et al., 2014). Also, the accurate masses 
of 216.2402 for TP-ALG-2 and 288.2089 for TP-ALG-5 matche the theoretical monoisotopic 
masses/formulae for 3,20-allpregnanedione and testosterone respectively. The CID 
fragmentation of TP-ALG-1 and TP-ALG-4 peaks shows that both TPs had the base peak m/z 
121.064 in common. This fragment has been previously reported as the major fragment 
resulting from collision-induced dissociation of a number of microbially synthesized 
monohydroxylated progesterones (2α-hydroxyP4, 7β-ydroxyP4 and 9α-hydroxyP4), 
compounds recognized for their pharmacologically active properties (Kang et al., 2004). 
 
5.2.5 Half-life of Progesterone Degradation 
The transformation of progesterone in all sites in the present study followed the first-order 
reaction model (Fig 4.30a, b). First order degradation kinetics like those observed in this study 
have been reported for the biotransformation of progesterone and norgestrel by two 
microalgae, Scenedesmus obliquus and Chlorella pyrenoidosa (Peng et al. 2014). Unlike the 
Peng et al. (2014) study where 95% of spiked P4 concentration (503 µg/L) was degraded in 
120 h (5 days), spiked P4 concentration in the present study (1,000 µg/L) was degraded below 
instrument detection limit (representative 100% degradation) in 72 h (3 days) for all locations 
except High Wycombe where 90% degradation occurred. A comparison of the progesterone 
degradation parameters recorded in this study with those reported by other workers are 
presented in Table 5.1. Degradation rate was more rapid in the present study than those 
reported for algae, thus, indicating that a more diverse microbial community may have been 
responsible for the breakdown of P4 observed. The data for norgestrel has been included in 
the table to compare the relative ease of biodegradation of the natural progesterone, relative 
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to the synthetic progestogen. According to Hu et al. (1998), the relative persistence of 
norgestrel is due to the presence of 17α-ethynyl group in the compound’s structure.  The 17α-
ethynyl group is resistant to microbial breakdown (Hu et al. 1998. 
Table 5.1: Comparison of degradation parameters reported for Progesterone 
Study Compound Degrader/System Parameters 
      Rate Constant (k)(h) Half-life (h) 
Present P4 River 0.046 15.1 
Present P4 River 0.111 6.27 
Present P4 River 0.102 6.77 
Present P4 River 0.103 6.76 
Present P4 River 0.024 29.4 
Peng et al. 2014 P4 S. obliquus 0.044 16.0 
Peng et al. 2014 P4 C. pyrenoidosa 0.018 39.0 
Lui et al. 2013 P4 Activated Sludge - 4.30 
Peng et al. 2014 Norgestrel S. obliquus 0.017 40.0 
Peng et al. 2014 Norgestrel C. pyrenoidosa 0.009 88.0 
*h=hours 
The term “biodegradation” as used in this study refers to the loss of the parent compound in 
surface water samples relative to a sterile double deionised water (control). It is not known if 
sorption of P4 or TPs in suspended solids happened as river water was not filtered prior to the 
study. Biodegradation and sorption are components of the natural attenuation process, during 
which parent compounds are lost from the aqueous phase. It is difficult at best and often nearly 
impossible to separate the influence of biodegradation from that of sorption. Therefore, the 
experiments were designed to simplify the complexities of natural systems and to focus only 
on water phase.  
 
5.3 Significance of the Results of the Present Study  
This study has highlighted the significance of the bioconversion of one class of steroid into 
another. The result presented will help the water industry appreciate the possibility that there 
179  
 
are diverse sources of steroids in surface waters as there are multiple transformation 
pathways in the water environment. That this is the case is highlighted by the Peng et al. 
(2014) study. Furthermore, this study indicates that in addition to the natural excretion from 
humans and animals, androgens present in the aquatic environment could be produced from 
the transformation of progesterone in surface water. A range of synthetic progestogens are 
used clinically, primarily in hormonal contraceptives. These synthetic progestogens differ 
appreciatively in structure from each other, and from P4.  For example, quite a few, such as 
the widely used levonorgestrel, is a C19 steroid, not a C21 steroid like P4. These significant 
differences in structure mean that it is impossible to know whether or not results presented 
here are applicable to the biodegradation of synthetic progestogens. Nevertheless, it may be 
likely that the main finding, that as a steroid hormone degrades, it can lead to the formation of 
other steroids with different biological activities, will be applicable to the degradation of other 
steroid hormones, both natural and synthetic. 
The yeast screen results demonstrated that P4 degradation in the environment is likely to 
result in a corresponding decrease in associated progestogenic activity. Though P4 degrades 
to androgen as shown by chemical analysis, the concentrations in the environment are unlikely 
to represent any immediate threat to aquatic resources, as results of the androgen screen did 
not show any androgenic activity when working at elevated (1,000 μg/L) concentrations. 
Knowledge of degradation half-lives and pathways of degradation of progesterone in surface 
waters will be useful in understanding the fate of this compound in the environment and will 
















6.0 General Conclusion 
 A number of compounds were initially identified for study on the basis of their high and 
regular use in the United Kingdom, constant detection in wastewater influent, effluent 
and surface water, reported toxicity effects on aquatic biota and inclusion in the EU 
priority chemical watchlist. 
 However, based on the degradation potential reported for identified compounds in the 
literature, progesterone was selected for laboratory based degradation study based on 
its rapid biodegradability relative to the other model compounds. 
 Degradation products and pathways for progesterone, were identified from the 
literature and from predictions by the EAWAG Biodegradation Biocatalysis Database 
(BBD). The biodegradation database predicted products (abbreviated as TP-BBD) 
resulting from the cleavage of the ‘B’ ring in the progesterone C21 pregnane skeletal 
backbone through a two-step aerobic prediction system. The literature search, 
however, identified algal products (TP-ALG) that did not show ring cleavage. Reported 
algal TPs resulted from reaction pathways such as hydroxylation, oxidation, 
hydrogenation, dehydrogenation and breakdown of side chains. 
 It was apparent that the BBD accompanied pathway predicting system gave different 
products and pathways to those reported in the literature. The BBD predicted ring 
cleavage may follow anaerobic degradation pathways. 
 Using the new tool, enviPath, predicted TPs were observed to be different from those 
predicted by the EAWAG BBD. Instead of ring cleavage predicted by the latter, 
peripheral rings modification mainly by hydroxylation was predicted by the former 
(enviPath). 
 Reed beds at a wastewater treatment works were identified as a suitable system for 
studying the degradation and removal of selected compounds.  
 An analytical methodology was set up using HPLC and initially low resolution tandem 
mass spectrometry (LC-MS/MS). Methods were applied and data obtained from reed 
beds at Barston wastewater treatment works. 
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 The developed method could detect the selected compounds at environmentally 
relevant concentrations. Influent concentrations (ng/L) in reed beds were 8.6±2.1 
(Progesterone), 87.7±19.6 (Fluoxetine), 335±73.7 (Propranolol) and 5,704±4,700 
(Diclofenac). Effluent concentrations (ng/L) were 1.2±0.2 (Progesterone), 3.5±1.6 
(Fluoxetine), 112±10.5 (Propranolol) and 3,570±2,924 (Diclofenac). Limits of detection 
(LODs) were 0.27 µg/L (Progesterone), 0.22 µg/L (Fluoxetine), 0.25 µg/L and 1.0 µg/L 
(Diclofenac). It was apparent, however, that using low resolution mass spectrometry 
alone would limit identification of transformation products. 
 Removal of target compounds was generally above 65% for all model compounds 
except DCF that was 37%. 
 Further access to reed bed site was not possible to determine certain reed beds 
removal dependent characteristics and implement needed modification to sampling 
protocol. Thus, results presented for concentrations of model compounds in reed beds 
and their performance in removing model compounds, will require further study to 
verify their reliability. 
 Following the assessment of reed beds samples for degradation products, low 
concentration was thought to lead to uncertainty in determining the presence or 
absence of TPs. It was apparent that environmental concentrations of model 
compounds in the real environment would prove challenging for detection and 
identification of transformation products. 
 Specific putative degradation products were identified in the laboratory studies; 1,4-
Pregnadiene-3,20-dione (TP-ALG-1), 3,20-Allopregnanedione (TP-ALG-2), boldenone 
(TP-ALG-4), testosterone (TP-ALG-5) and 1‐acetyl‐4‐[2‐(5‐hydroxy‐2‐
methylphenyl)ethyl]‐7a‐methyl‐octahydro‐1H‐inden‐5‐one (TP-BBD-1) (Tables 4.4 
and 4.9). 
 The reactions that resulted in detection of TPs observed in the degradation study were 
hydroxylation, hydrogenation, dehydrogenation, ketone and hydroxyl functional group 
interconversion and side-chain breakdown. Of these pathways, dehydrogenation and 
side–chain breakdown were estimated to be the dominant pathways 
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 Sometimes, individual pathways proceeded alone to form products. But most often, 
several pathways acted together to produce a given TP. 
 It was apparent that some degradation products were biologically active. However, 
there was no evidence of activity in either progesterone or androgen assays resulting 
from their formation from a 1,000 μg/L initial progesterone concentration. Thus, it would 
seem unlikely that the degradation products of progesterone pose a risk in the 
environment through pathways monitored in this work. 
 The degradation of progesterone was complete in three of the four sites studied after 
48 hours. Progesterone degradation half-life was approximately 7 hours in all sites 
except High Wycombe (29 hours) where some residual progesterone (100 μg/L) was 
present after 72 hours. The study therefore indicates that degradation of progesterone 
is relatively rapid in surface waters, following similar pathways as those identified. 
 
6.1 Recommendation for Future Work 
 Carry out multiple sampling of reed beds with modified sampling protocol to allow for 
literature recommended HRT coupled with monitoring of reed bed dependent 
compound removal characteristics. 
 Purchase and use each model compound specific internal standard and compare 
removal results. 
 Model progesterone degradation using a range of predictive models and compare 
results. 
 Use a range of more sensitive analytical instruments (e.g. Fourier Transform Ion 
Cyclotron Resonance (FT-ICR) and Orbitrap) and data processing software to 
compare results and reach more definite conclusion on identity of TPs. 
 Carry out degradation study in the summer and microbial profiling of sampling sites to 
compare results with those of the present study (winter) and link observed degradation 
rate with microbial diversity and metabolic activity. 
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 Design study such that any degradation due to hydrolysis or volatilization is determined 
to account for degradation based sole on biological breakdown. This was not done in 
the present study owing to literature reports (Peng et al. 2014; Liu et al. 2013) that 
degradation due to hydrolysis and volatilization was negligible for progesterone. 
 Determine insitu physiochemical conditions (e.g. temperature) of surface waters at the 
time of sampling and compare such with observed conditions in the laboratory. This 
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